

Approved



Haiti

Country Operational Plan

FY 2018



Budget Summary Reports

Summary of Planned Funding by Agency and Funding Source

Agency	Funding Source			Funding Source Total	Applied Pipeline	Total All Funding Sources and Applied Pipeline Amount
	GAP	GHP-State	GHP-USAID			
State		425,000		425,000	0	425,000
USAID		51,200,968		51,200,968	614,157	51,815,125
HHS/CDC	987,500	47,759,875		48,747,375	0	48,747,375
Total	987,500	99,385,843	0	100,373,343	614,157	100,987,500

Summary of Planned Funding by Budget Code and Agency

Budget Code	Agency				Total
	State	HHS/CDC	State/SGAC	USAID	
CIRC	0	0		0	0
HBHC	42,500	6,224,830	0	2,481,203	8,748,533
HKID	21,063	3,541,964		7,374,409	10,937,436
HLAB	0	1,380,098		1,832,837	3,212,935
HMBL	0	0		0	0
HMIN	0	0		0	0
HTXD	0	2,190		14,888,669	14,890,859
HTXS	169,627	11,605,976		8,257,552	20,033,155
HVAB	0	42,500		715,427	757,927
HVCT	0	6,878,870		3,945,976	10,824,846
HVMS	21,063	3,949,986		1,846,751	5,817,800
HVOP	0	757,279		1,114,287	1,871,566
HVSI	21,437	2,415,850		817,156	3,254,443
HVTB	63,188	3,361,678		1,834,888	5,259,754
IDUP	0	0		0	0

Approved



MTCT	187	3,087,403		1,896,001	4,983,591
OHSS	0	861,571		1,811,034	2,672,605
PDCS	561	1,722,209		970,402	2,693,172
PDTX	85,374	2,914,971		1,414,376	4,414,721
	425,000	48,747,375	0	51,200,968	100,373,343



Technical Areas

Technical Area Summary

Technical Area: Care

Budget Code	Budget Code Planned Amount
HBHC	7,880,741
HKID	10,531,176
HVTB	4,986,403
PDCS	2,293,495
Total Technical Area Planned Funding:	25,691,815

Technical Area: Governance and Systems

Budget Code	Budget Code Planned Amount
HLAB	3,075,981
HVSI	3,015,624
OHSS	2,436,265
Total Technical Area Planned Funding:	8,527,870

Technical Area: Prevention

Budget Code	Budget Code Planned Amount
CIRC	0
HMBL	0
HMIN	0
HVAB	757,927
HVCT	10,633,025
HVOP	1,717,279
IDUP	0
MTCT	4,822,654
Total Technical Area Planned Funding:	17,930,885

Approved



Technical Area: Treatment

Budget Code	Budget Code Planned Amount
HTXD	14,810,509
HTXS	18,588,361
PDTX	3,863,060
Total Technical Area Planned Funding:	37,261,930



Technical Area Summary Indicators and Targets

Indicator Number	Label	2019
PMTCT_STAT_DSD	PMTCT_STAT_DSD Number and percentage of pregnant women with known status (includes women who were tested for HIV and received their results) (DSD)	100 %
	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	213,127
	Number of new ANC and L&D clients	213,127
	By Age (Denominator): <15-19	8,524
	By Age (Denominator): 20-24	19,179
	By Age (Denominator): 50+	29,837
	By Number of known positives: 15-19	81
	By Number of known positives: 20-24	186
	By Number of known positives: 50+	288
	By Number of new positives: 15-19	85
	By Number of new positives: 20-24	194
	By Number of new positives: 50+	299
	By Number of new negative: 15-19	8,353
	By Number of new negative: 20-24	18,795
	By Number of new negative: 50+	29,188
	By Age (Numerator): 15-19	8,524
	By Age (Numerator): 20-24	19,179
	By Age (Numerator): 50+	29,837
PMTCT_STAT_D_DSD_Age_Sex		38,918



	25-29, Female	
	PMTCT_STAT_D_DSD_Age_Sex 30-34, Female	38,904
	PMTCT_STAT_D_DSD_Age_Sex 35-39, Female	38,890
	PMTCT_STAT_D_DSD_Age_Sex 40-49, Female	38,875
	PMTCT_STAT_N_DSD_Age_Sex_ KnownNewResult 25-29, Female, Known at Entry Positive	379
	PMTCT_STAT_N_DSD_Age_Sex_ KnownNewResult 25-29, Female, Newly Identified Negative	38,121
	PMTCT_STAT_N_DSD_Age_Sex_ KnownNewResult 25-29, Female, Newly Identified Positive	402
	PMTCT_STAT_N_DSD_Age_Sex_ KnownNewResult 30-34, Female, Known at Entry Positive	379
	PMTCT_STAT_N_DSD_Age_Sex_ KnownNewResult 30-34, Female, Newly Identified Negative	38,120
	PMTCT_STAT_N_DSD_Age_Sex_ KnownNewResult 30-34, Female, Newly Identified Positive	398
	PMTCT_STAT_N_DSD_Age_Sex_ KnownNewResult 35-39, Female, Known at Entry Positive	379
	PMTCT_STAT_N_DSD_Age_Sex_ KnownNewResult 35-39, Female, Newly Identified Negative	38,121
	PMTCT_STAT_N_DSD_Age_Sex_ KnownNewResult 35-39, Female, Newly Identified Positive	401
	PMTCT_STAT_N_DSD_Age_Sex_	379



	KnownNewResult 40-49, Female, Known at Entry Positive	
	PMTCT_STAT_N_DSD_Age_Sex_ KnownNewResult 40-49, Female, Newly Identified Negative	38,121
	PMTCT_STAT_N_DSD_Age_Sex_ KnownNewResult 40-49, Female, Newly Identified Positive	398
	PMTCT_STAT_N_DSD_Age_Sex 25-29, Female	38,918
	PMTCT_STAT_N_DSD_Age_Sex 30-34, Female	38,904
	PMTCT_STAT_N_DSD_Age_Sex 35-39, Female	38,890
	PMTCT_STAT_N_DSD_Age_Sex 40-49, Female	38,875
PMTCT_ART_DSD	PMTCT_ART_DSD Percentage of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy	2 %
	Number of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy	4,135
	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	213,127
	New on ART	2,098
	Already on ART at beginning of current pregnancy	2,037
PrEP_NEW_DSD	PrEP_NEW_DSD Number of individuals who have received	n/a



	antiretroviral pre-exposure prophylaxis (PrEP) to prevent HIV infection in the reporting period.	
	Number of individuals who have been newly enrolled on oral antiretroviral pre-exposure prophylaxis (PrEP) in the reporting period to prevent HIV infection	1,000
	Male 15-19	23
	Male 20-24	90
	Male 50+	19
	Female 15-19	22
	Female 20-24	88
	Female 50+	20
	FSW	487
	MSM	488
	PrEP_NEW_N_DSD_Age_Sex_v2 25-29, Female	131
	PrEP_NEW_N_DSD_Age_Sex_v2 25-29, Male	143
	PrEP_NEW_N_DSD_Age_Sex_v2 30-34, Female	117
	PrEP_NEW_N_DSD_Age_Sex_v2 30-34, Male	113
	PrEP_NEW_N_DSD_Age_Sex_v2 35-39, Female	71
	PrEP_NEW_N_DSD_Age_Sex_v2 35-39, Male	74
	PrEP_NEW_N_DSD_Age_Sex_v2 40-49, Female	48
	PrEP_NEW_N_DSD_Age_Sex_v2 40-49, Male	41
	PrEP_NEW_N_DSD_KeyPopAbr Other Key Populations	25



PP_PREV_DSD	PP_PREV_DSD Percentage of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period (DSD)	n/a
	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	35,900
	Age/sex: 10-14 Male	45
	Age/sex: 15-19 Male	3,978
	Age/sex: 20-24 Male	9,265
	Age/sex: 50+ Male	1,089
	Age/sex: 15-19 Female	362
	Age/sex: 20-24 Female	1,199
	Age/sex: 50+ Female	75
	PP_PREV_N_DSD_Age_Sex_v2 25-29, Female	578
	PP_PREV_N_DSD_Age_Sex_v2 25-29, Male	4,396
	PP_PREV_N_DSD_Age_Sex_v2 30-34, Female	578
	PP_PREV_N_DSD_Age_Sex_v2 30-34, Male	4,394
	PP_PREV_N_DSD_Age_Sex_v2 35-39, Female	578
	PP_PREV_N_DSD_Age_Sex_v2 35-39, Male	4,394
	PP_PREV_N_DSD_Age_Sex_v2 40-49, Female	577
	PP_PREV_N_DSD_Age_Sex_v2 40-49, Male	4,392



KP_PREV_DSD	KP_PREV_DSD Percentage of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required (DSD)	n/a
	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	84,318
	By key population type: Men who have sex with men who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	20,200
	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	54,050
	By key population type: People in prisons and enclosed settings (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	10,068



TB_STAT_DSD	TB_STAT_DSD Percentage of registered new and relapsed TB cases with documented HIV status.	100 %
	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	11,676
	Total number of registered new and relapsed TB cases, during the reporting period.	11,676
	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	231
	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	4,092
	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	346
	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	7,007
	Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	231



	Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	4,092
	Aggregated Age/Sex: Female <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	346
	Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	7,007
HTS_SELF_DSD	HTS_SELF_N_DSD	15,000
	HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 15-19, Female, Directly-Assisted	536
	HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 15-19, Female, Unassisted	536
	HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 15-19, Male, Directly-Assisted	536
	HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 15-19, Male, Unassisted	536
	HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 20-24, Female, Directly-Assisted	536
	HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 20-24, Female, Unassisted	536
	HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 20-24, Male, Directly-Assisted	536
	HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 20-24, Male, Unassisted	536



HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 25-29, Female, Directly-Assisted	536
HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 25-29, Female, Unassisted	536
HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 25-29, Male, Directly-Assisted	536
HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 25-29, Male, Unassisted	536
HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 30-34, Female, Directly-Assisted	536
HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 30-34, Female, Unassisted	536
HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 30-34, Male, Directly-Assisted	536
HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 30-34, Male, Unassisted	536
HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 35-39, Female, Directly-Assisted	536
HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 35-39, Female, Unassisted	536
HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 35-39, Male, Directly-Assisted	536
HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 35-39, Male, Unassisted	536
HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 40-49, Female,	536



	Directly-Assisted	
	HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 40-49, Female, Unassisted	536
	HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 40-49, Male, Directly-Assisted	536
	HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 40-49, Male, Unassisted	536
	HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 50+, Female, Directly-Assisted	536
	HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 50+, Female, Unassisted	536
	HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 50+, Male, Directly-Assisted	533
	HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 50+, Male, Unassisted	533
	HTS_SELF_N_DSD_HIVSelfTest Directly-Assisted	7,500
	HTS_SELF_N_DSD_HIVSelfTest Unassisted	7,500
	HTS_SELF_N_DSD_HIVSelfTestU ser Unassisted - Other	2,441
	HTS_SELF_N_DSD_HIVSelfTestU ser Unassisted - Self	2,441
	HTS_SELF_N_DSD_HIVSelfTestU ser Unassisted - Sex Partner	2,618
	HTS_SELF_N_DSD_KeyPop_HIV SelfTest FSW, Directly-Assisted	2,625
	HTS_SELF_N_DSD_KeyPop_HIV SelfTest FSW, Unassisted	2,625
	HTS_SELF_N_DSD_KeyPop_HIV	874



	SelfTest MSM, Directly-Assisted	
	HTS_SELF_N_DSD_KeyPop_HIV SelfTest MSM, Unassisted	874
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	816,526
	Service Delivery Point (Facility) Inpatient: 10-14, Female, Negative	1,130
	Service Delivery Point (Facility) Inpatient: 10-14, Male, Negative	1,477
	Service Delivery Point (Facility) Inpatient: 10-14, Male, Positive	62
	Service Delivery Point (Facility) Inpatient: 15-19, Female, Negative	518
	Service Delivery Point (Facility) Inpatient: 15-19, Female, Positive	6
	Service Delivery Point (Facility) Inpatient: 15-19, Male, Negative	191
	Service Delivery Point (Facility) Inpatient: 15-19, Male, Positive	1
	Service Delivery Point (Facility) Inpatient: 20-24, Female, Negative	1,654
	Service Delivery Point (Facility) Inpatient: 20-24, Female, Positive	25
	Service Delivery Point (Facility) Inpatient: 20-24, Male, Negative	607
	Service Delivery Point (Facility) Inpatient: 20-24, Male, Positive	5
	Service Delivery Point (Facility) Inpatient: 50+, Female, Negative	2,000
	Service Delivery Point (Facility) Inpatient: 50+, Female, Positive	43
	Service Delivery Point (Facility)	1,815



	Inpatient: 50+, Male, Negative	
	Service Delivery Point (Facility)	34
	Inpatient: 50+, Male, Positive	
	Service Delivery Point (Facility)	350
	Inpatient: <1, Negative	
	Service Delivery Point (Facility)	10
	Inpatient: <1, Positive	
	Service Delivery Point (Facility)	3,979
	Inpatient: 1-9, Negative	
	Service Delivery Point (Facility)	211
	Inpatient: 1-9, Positive	
	Service Delivery Point (Community)	
	Mobile Testing: 15-19, Female, Negative	131
	Service Delivery Point (Community)	
	Mobile Testing: 15-19, Female, Positive	1
	Service Delivery Point (Community)	
	Mobile Testing: 15-19, Male, Negative	71
	Service Delivery Point (Community)	
	Mobile Testing: 15-19, Male, Positive	1
	Service Delivery Point (Community)	
	Mobile Testing: 20-24, Female, Negative	496
	Service Delivery Point (Community)	
	Mobile Testing: 20-24, Female, Positive	13
	Service Delivery Point (Community)	
	Mobile Testing: 20-24, Male, Negative	210
	Service Delivery Point (Community)	
	Mobile Testing: 20-24, Male, Positive	5



	Service Delivery Point (Community) Mobile Testing: 50+, Female, Negative	789
	Service Delivery Point (Community) Mobile Testing: 50+, Female, Positive	23
	Service Delivery Point (Community) Mobile Testing: 50+, Male, Negative	597
	Service Delivery Point (Community) Mobile Testing: 50+, Male, Positive	16
	Service Delivery Point (Facility) Other PITC: 15-19, Female, Negative	1,306
	Service Delivery Point (Facility) Other PITC: 15-19, Female, Positive	23
	Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative	561
	Service Delivery Point (Facility) Other PITC: 15-19, Male, Positive	7
	Service Delivery Point (Facility) Other PITC: 20-24, Female, Negative	4,273
	Service Delivery Point (Facility) Other PITC: 20-24, Female, Positive	101
	Service Delivery Point (Facility) Other PITC: 20-24, Male, Negative	1,610
	Service Delivery Point (Facility) Other PITC: 20-24, Male, Positive	36
	Service Delivery Point (Facility) Other PITC: 50+, Female, Negative	7,001
	Service Delivery Point (Facility) Other PITC: 50+, Female, Positive	150



Service Delivery Point (Facility) Other PITC: 50+, Male, Negative	5,740
Service Delivery Point (Facility) Other PITC: 50+, Male, Positive	123
Service Delivery Point (Facility) Pediatric : <5 Negative	29,245
Service Delivery Point (Facility) Pediatric : <5 Positive	294
Service Delivery Point (Facility) TB: 10-14, Male, Negative	476
Service Delivery Point (Facility) TB: 10-14, Male, Positive	54
Service Delivery Point (Facility) TB: 15-19, Female, Negative	154
Service Delivery Point (Facility) TB: 15-19, Female, Positive	10
Service Delivery Point (Facility) TB: 15-19, Male, Negative	83
Service Delivery Point (Facility) TB: 15-19, Male, Positive	4
Service Delivery Point (Facility) TB: 20-24, Female, Negative	576
Service Delivery Point (Facility) TB: 20-24, Female, Positive	68
Service Delivery Point (Facility) TB: 20-24, Male, Negative	266
Service Delivery Point (Facility) TB: 20-24, Male, Positive	26
Service Delivery Point (Facility) TB: 50+, Female, Negative	898
Service Delivery Point (Facility) TB: 50+, Female, Positive	135
Service Delivery Point (Facility) TB: 50+, Male, Negative	708



	Service Delivery Point (Facility) TB: 50+, Male, Positive	86
	Service Delivery Point (Facility) Index: 10-14, Female, Negative	3,368
	Service Delivery Point (Facility) Index: 10-14, Female, Positive	79
	Service Delivery Point (Facility) Index: 10-14, Male, Negative	4,078
	Service Delivery Point (Facility) Index: 10-14, Male, Positive	65
	Service Delivery Point (Facility) Index: 15-19, Female, Negative	616
	Service Delivery Point (Facility) Index: 15-19, Female, Positive	94
	Service Delivery Point (Facility) Index: 15-19, Male, Negative	332
	Service Delivery Point (Facility) Index: 15-19, Male, Positive	48
	Service Delivery Point (Facility) Index: 20-24, Female, Negative	2,201
	Service Delivery Point (Facility) Index: 20-24, Female, Positive	392
	Service Delivery Point (Facility) Index: 20-24, Male, Negative	960
	Service Delivery Point (Facility) Index: 20-24, Male, Positive	160
	Service Delivery Point (Facility) Index: 50+, Female, Negative	3,630
	Service Delivery Point (Facility) Index: 50+, Female, Positive	644
	Service Delivery Point (Facility) Index: 50+, Male, Negative	2,950
	Service Delivery Point (Facility) Index: 50+, Male, Positive	519



	Service Delivery Point (Facility) Index: <1, Negative	970
	Service Delivery Point (Facility) Index: <1, Positive	10
	Service Delivery Point (Facility) Index: 1-9, Negative	11,039
	Service Delivery Point (Facility) Index: 1-9, Positive	219
	By Key Population: FSW, Negative	44,729
	By Key Population: FSW, Positive	2,534
	By Key Population: MSM, Negative	14,924
	By Key Population: MSM, Positive	843
	By Key Population: People in prisons and other enclosed settings, Negative	31,583
	By Key Population: People in prisons and other enclosed settings, Positive	1,171
	Service Delivery Point (Community) Index Mod: 15-19, Female, Negative	159
	Service Delivery Point (Community) Index Mod: 15-19, Female, Positive	28
	Service Delivery Point (Community) Index Mod: 15-19, Male, Negative	87
	Service Delivery Point (Community) Index Mod: 15-19, Male, Positive	15
	Service Delivery Point (Community) Index Mod: 20-24, Female, Negative	612
	Service Delivery Point (Community) Index Mod: 20-24, Female, Positive	108
	Service Delivery Point (Community) Index Mod: 20-24, Male, Negative	249



	Service Delivery Point (Community) Index Mod: 20-24, Male, Positive	43
	Service Delivery Point (Community) Index Mod: 50+, Female, Negative	1,005
	Service Delivery Point (Community) Index Mod: 50+, Female, Positive	177
	Service Delivery Point (Community) Index Mod: 50+, Male, Negative	736
	Service Delivery Point (Community) Index Mod: 50+, Male, Positive	129
	Service Delivery Point (Facility) ANC: 15-19, Negative	8,342
	Service Delivery Point (Facility) ANC: 15-19, Positive	85
	Service Delivery Point (Facility) ANC: 20-24, Negative	18,772
	Service Delivery Point (Facility) ANC: 20-24, Positive	194
	Service Delivery Point (Facility) ANC: 50+, Negative	29,152
	Service Delivery Point (Facility) ANC: 50+, Positive	299
	Service Delivery Point (Facility) VCT: 15-19, Female, Negative	6,232
	Service Delivery Point (Facility) VCT: 15-19, Female, Positive	148
	Service Delivery Point (Facility) VCT: 15-19, Male, Negative	3,510
	Service Delivery Point (Facility) VCT: 15-19, Male, Positive	70
	Service Delivery Point (Facility) VCT: 20-24, Female, Negative	22,150
	Service Delivery Point (Facility) VCT: 20-24, Female, Positive	547



	Service Delivery Point (Facility) VCT: 20-24, Male, Negative	9,335
	Service Delivery Point (Facility) VCT: 20-24, Male, Positive	235
	Service Delivery Point (Facility) VCT: 50+, Female, Negative	38,703
	Service Delivery Point (Facility) VCT: 50+, Female, Positive	916
	Service Delivery Point (Facility) VCT: 50+, Male, Negative	31,906
	Service Delivery Point (Facility) VCT: 50+, Male, Positive	743
	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Female, Negative	4,067
	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Female, Positive	720
	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Male, Negative	2,173
	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Male, Positive	383
	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Female, Negative	4,067
	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Female, Positive	720
	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Male, Negative	2,173
	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Male, Positive	383
	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Female, Negative	4,067
	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Female, Positive	720
	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Male, Negative	2,173



HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Male, Positive	383
HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Female, Negative	4,052
HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Female, Positive	711
HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Male, Negative	2,193
HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Male, Positive	394
HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Female, Negative	2,478
HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Female, Positive	47
HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Male, Negative	1,357
HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Male, Positive	24
HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Female, Negative	2,478
HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Female, Positive	47
HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Male, Negative	1,357
HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Male, Positive	24
HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Female, Negative	2,478
HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Female, Positive	47
HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Male, Negative	1,357
HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Male, Positive	24



HTS_TST_N_DSD_Inpat_Age_Sex _Result 40-49, Female, Negative	2,477
HTS_TST_N_DSD_Inpat_Age_Sex _Result 40-49, Female, Positive	80
HTS_TST_N_DSD_Inpat_Age_Sex _Result 40-49, Male, Negative	1,360
HTS_TST_N_DSD_Inpat_Age_Sex _Result 40-49, Male, Positive	52
HTS_TST_N_DSD_MbMod_Age_ Sex_Result 25-29, Female, Negative	942
HTS_TST_N_DSD_MbMod_Age_ Sex_Result 25-29, Female, Positive	24
HTS_TST_N_DSD_MbMod_Age_ Sex_Result 25-29, Male, Negative	478
HTS_TST_N_DSD_MbMod_Age_ Sex_Result 25-29, Male, Positive	13
HTS_TST_N_DSD_MbMod_Age_ Sex_Result 30-34, Female, Negative	942
HTS_TST_N_DSD_MbMod_Age_ Sex_Result 30-34, Female, Positive	25
HTS_TST_N_DSD_MbMod_Age_ Sex_Result 30-34, Male, Negative	478
HTS_TST_N_DSD_MbMod_Age_ Sex_Result 30-34, Male, Positive	13
HTS_TST_N_DSD_MbMod_Age_ Sex_Result 35-39, Female, Negative	942
HTS_TST_N_DSD_MbMod_Age_ Sex_Result 35-39, Female, Positive	24



HTS_TST_N_DSD_MbMod_Age_Sex_Result 35-39, Male, Negative	478
HTS_TST_N_DSD_MbMod_Age_Sex_Result 35-39, Male, Positive	13
HTS_TST_N_DSD_MbMod_Age_Sex_Result 40-49, Female, Negative	942
HTS_TST_N_DSD_MbMod_Age_Sex_Result 40-49, Female, Positive	24
HTS_TST_N_DSD_MbMod_Age_Sex_Result 40-49, Male, Negative	478
HTS_TST_N_DSD_MbMod_Age_Sex_Result 40-49, Male, Positive	13
HTS_TST_N_DSD_MN_Age_Sex_Result <5, Unknown Sex, Negative	3,744
HTS_TST_N_DSD_MN_Age_Sex_Result <5, Unknown Sex, Positive	72
HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Female, Negative	1,168
HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Female, Positive	206
HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Male, Negative	583
HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Male, Positive	103
HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Female, Negative	1,168
HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Female, Positive	206



HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Male, Negative	583
HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Male, Positive	103
HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Female, Negative	1,168
HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Female, Positive	206
HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Male, Negative	583
HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Male, Positive	103
HTS_TST_N_DSD_NdxMod_Age_Sex_Result 40-49, Female, Negative	1,168
HTS_TST_N_DSD_NdxMod_Age_Sex_Result 40-49, Female, Positive	206
HTS_TST_N_DSD_NdxMod_Age_Sex_Result 40-49, Male, Negative	583
HTS_TST_N_DSD_NdxMod_Age_Sex_Result 40-49, Male, Positive	103
HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Female, Negative	6,874
HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Female, Positive	161
HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Male, Negative	3,836
HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Male, Positive	81



HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Female, Negative	6,874
HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Female, Positive	161
HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Male, Negative	3,836
HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Male, Positive	81
HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Female, Negative	6,874
HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Female, Positive	161
HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Male, Negative	3,836
HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Male, Positive	81
HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Female, Negative	6,871
HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Female, Positive	175
HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Male, Negative	3,854
HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Male, Positive	119
HTS_TST_N_DSD_PMTCT_Age_Sex_Result 25-29, Female, Negative	38,072
HTS_TST_N_DSD_PMTCT_Age_Sex_Result 25-29, Female,	403



	Positive	
	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 30-34, Female, Negative	38,071
	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 30-34, Female, Positive	398
	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 35-39, Female, Negative	38,072
	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 35-39, Female, Positive	401
	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 40-49, Female, Negative	38,072
	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 40-49, Female, Positive	399
	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Female, Negative	1,044
	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Female, Positive	127
	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Male, Negative	550
	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Male, Positive	62
	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Female, Negative	1,044
	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Female, Positive	127
	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Male, Negative	550
	HTS_TST_N_DSD_TBC_Age_Sex	62



	_Result 30-34, Male, Positive	
	HTS_TST_N_DSD_TBC_Age_Sex _Result 35-39, Female, Negative	1,044
	HTS_TST_N_DSD_TBC_Age_Sex _Result 35-39, Female, Positive	127
	HTS_TST_N_DSD_TBC_Age_Sex _Result 35-39, Male, Negative	550
	HTS_TST_N_DSD_TBC_Age_Sex _Result 35-39, Male, Positive	62
	HTS_TST_N_DSD_TBC_Age_Sex _Result 40-49, Female, Negative	1,039
	HTS_TST_N_DSD_TBC_Age_Sex _Result 40-49, Female, Positive	143
	HTS_TST_N_DSD_TBC_Age_Sex _Result 40-49, Male, Negative	589
	HTS_TST_N_DSD_TBC_Age_Sex _Result 40-49, Male, Positive	109
	HTS_TST_N_DSD_VCT_Age_Sex _Result 25-29, Female, Negative	43,250
	HTS_TST_N_DSD_VCT_Age_Sex _Result 25-29, Female, Positive	1,038
	HTS_TST_N_DSD_VCT_Age_Sex _Result 25-29, Male, Negative	22,906
	HTS_TST_N_DSD_VCT_Age_Sex _Result 25-29, Male, Positive	555
	HTS_TST_N_DSD_VCT_Age_Sex _Result 30-34, Female, Negative	43,250
	HTS_TST_N_DSD_VCT_Age_Sex _Result 30-34, Female, Positive	1,038
	HTS_TST_N_DSD_VCT_Age_Sex _Result 30-34, Male, Negative	22,906
	HTS_TST_N_DSD_VCT_Age_Sex _Result 30-34, Male, Positive	555
	HTS_TST_N_DSD_VCT_Age_Sex	43,250



	_Result 35-39, Female, Negative	
	HTS_TST_N_DSD_VCT_Age_Sex _Result 35-39, Female, Positive	1,038
	HTS_TST_N_DSD_VCT_Age_Sex _Result 35-39, Male, Negative	22,906
	HTS_TST_N_DSD_VCT_Age_Sex _Result 35-39, Male, Positive	555
	HTS_TST_N_DSD_VCT_Age_Sex _Result 40-49, Female, Negative	43,260
	HTS_TST_N_DSD_VCT_Age_Sex _Result 40-49, Female, Positive	1,066
	HTS_TST_N_DSD_VCT_Age_Sex _Result 40-49, Male, Negative	22,895
	HTS_TST_N_DSD_VCT_Age_Sex _Result 40-49, Male, Positive	562
GEND_GBV_DSD	Number of people receiving post-GBV care	1,526
	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	898
	By type of service: Sexual Violence (Post-Rape Care)	628
	By PEP service provision (related to sexual violence services provided)	628
	<10, Female, Physical and/or Emotional Violence	7
	<10, Female, Sexual Violence (Post-Rape Care)	53
	<10, Male, Physical and/or Emotional Violence	7
	<10, Male, Sexual Violence (Post-Rape Care)	1
	10-14, Female, Physical and/or	37



	Emotional Violence	
	10-14, Female, Sexual Violence (Post-Rape Care)	144
	10-14, Male, Physical and/or Emotional Violence	15
	10-14, Male, Sexual Violence (Post-Rape Care)	2
	15-19, Female, Physical and/or Emotional Violence	123
	15-19, Female, Sexual Violence (Post-Rape Care)	160
	15-19, Male, Physical and/or Emotional Violence	55
	15-19, Male, Sexual Violence (Post-Rape Care)	6
	20-24, Female, Physical and/or Emotional Violence	301
	20-24, Female, Sexual Violence (Post-Rape Care)	150
	20-24, Male, Physical and/or Emotional Violence	148
	20-24, Male, Sexual Violence (Post-Rape Care)	5
	50+, Female, Physical and/or Emotional Violence	14
	50+, Female, Sexual Violence (Post-Rape Care)	6
	50+, Male, Physical and/or Emotional Violence	14
	50+, Male, Sexual Violence (Post-Rape Care)	1
	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 25-29, Female, Physical and/or Emotional Violence	28



GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 25-29, Female, Sexual Violence (Post-Rape Care)	32
GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 25-29, Male, Physical and/or Emotional Violence	20
GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 25-29, Male, Sexual Violence (Post-Rape Care)	5
GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 30-34, Female, Physical and/or Emotional Violence	27
GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 30-34, Female, Sexual Violence (Post-Rape Care)	20
GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 30-34, Male, Physical and/or Emotional Violence	18
GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 30-34, Male, Sexual Violence (Post-Rape Care)	4
GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 35-39, Female, Physical and/or Emotional Violence	27
GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 35-39, Female, Sexual Violence (Post-Rape Care)	19
GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 35-39, Male, Physical and/or Emotional Violence	17
GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 35-39, Male, Sexual Violence (Post-Rape Care)	2
GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 40-49, Female,	24



	Physical and/or Emotional Violence	
	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 40-49, Female, Sexual Violence (Post-Rape Care)	16
	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 40-49, Male, Physical and/or Emotional Violence	16
	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 40-49, Male, Sexual Violence (Post-Rape Care)	2
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	98,320
	Age/Sex: 10-14 Male	9,793
	Age/Sex: 15-17 Male	6,673
	By: Age/sex: Male 18-24	5,901
	By: Age/sex: Male 25+	9,828
	Age/Sex: 10-14 Female	9,997
	Age/Sex: 15-17 Female	7,029
	By: Age/sex: 18-24 Female	6,437
	By: Age/sex: 25+ Female	17,162
	Sum of Age/Sex disaggregates	33,492
	Age/Sex: <1	3,843
	Age/Sex: 1-9	21,657
	Program Completion: Active	95,370
	Program Completion: Graduation	2,950
OVC_HIVSTAT_DSD	OVC_HIVSTAT_DSD Number of orphans and vulnerable children (<18 years old) whose HIV status is known or unknown by the OVC implementing partner.	60 %
	Number of orphans and vulnerable children (<18 years old) whose HIV	58,992



	status is known or unknown by the OVC implementing partner.	
	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	98,320
TB_ART_DSD	TB_ART_DSD Percentage of HIV-positive new and relapsed registered TB cases on ART during TB treatment	n/a
	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	1,973
	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	36
	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	696
	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	57



	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	1,184
TB_PREV_DSD	TB_PREV_DSD TB_PREV_DSD	90 %
	The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period	21,106
	The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting period).	23,448
	By Age/Sex (Denominator): <15, Female	706
	By Age/Sex (Denominator): <15, Male	466
	By Age/Sex (Denominator): 15+, Female	14,072
	By Age/Sex (Denominator): 15+, Male	8,204
	By Age/Sex (Numerator): <15, Female	630
	By Age/Sex (Numerator): <15, Male	419



	Male	
	By Age/Sex (Numerator): 15+, Female	12,670
	By Age/Sex (Numerator): 15+, Male	7,387
	TB_PREV_D_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, New, Positive	23,448
	TB_PREV_N_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, New, Positive	21,106
TX_TB_DSD	TX_TB_DSD The proportion of ART patients who were screened who are receiving TB treatment	0 %
	Number of ART patients who were screened for TB at least once during the reporting period	133,195
	Denominator: By Aggregated Age/Sex: <15, Female	3,994
	Denominator: By Aggregated Age/Sex: <15, Male	2,666
	Denominator: By Aggregated Age/Sex:15+, Female	79,740
	Denominator: By Aggregated Age/Sex:15+, Male	46,694
	Denominator: Number of ART patients who had a specimen sent for bacteriologic diagnosis of active TB disease	5,316
	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Other (No Xpert)	178
	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Smear Only	3,012



	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Gene Xpert MTB / R if Assay	2,126
	TX_TB_D_DSD_TBScreen_NewEx istingART_HIV Life-long ART, Already, TB Screen - Negative, Positive	103,223
	TX_TB_D_DSD_TBScreen_NewEx istingART_HIV Life-long ART, Already, TB Screen - Positive, Positive	4,304
	TX_TB_D_DSD_TBScreen_NewEx istingART_HIV Life-long ART, New, TB Screen - Negative, Positive	24,320
	TX_TB_D_DSD_TBScreen_NewEx istingART_HIV Life-long ART, New, TB Screen - Positive, Positive	1,015
PMTCT_EID_DSD	PMTCT_EID_DSD Percent of infants born to HIV-positive women that receive a virological HIV test within 12 months of birth (DSD)	n/a
	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	4,151
	By infants who received a virologic test within 2 months of birth	3,322
	By infants who received their first virologic HIV test between 2 and 12 months of age	829
	Sum of Infant Age disaggregates	4,151
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	132,888
	Age/Sex: 15-19 Male	1,217
	Age/Sex: 15-19 Female	2,149



	Age/Sex: <1	340
	Age/Sex: <1-9	3,913
	Age/Sex: 10-14 Male	1,166
	Age/Sex: 10-14 Female	1,417
	Age/Sex: 20-24 Male	3,517
	Age/Sex: 50+ Male	10,143
	Age/Sex: 20-24 Female	7,811
	Age/Sex: 50+ Female	12,647
	TX_CURR_N_DSD_Age_Sex_HIV Status 25-29, Female, Positive	14,415
	TX_CURR_N_DSD_Age_Sex_HIV Status 25-29, Male, Positive	7,752
	TX_CURR_N_DSD_Age_Sex_HIV Status 30-34, Female, Positive	14,415
	TX_CURR_N_DSD_Age_Sex_HIV Status 30-34, Male, Positive	7,752
	TX_CURR_N_DSD_Age_Sex_HIV Status 35-39, Female, Positive	14,415
	TX_CURR_N_DSD_Age_Sex_HIV Status 35-39, Male, Positive	7,752
	TX_CURR_N_DSD_Age_Sex_HIV Status 40-49, Female, Positive	14,365
	TX_CURR_N_DSD_Age_Sex_HIV Status 40-49, Male, Positive	7,702
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	25,364
	By Age/Sex: <1	60
	By Age/Sex: 1-9	779
	By Age/Sex: 10-14 Male	228
	By Age/Sex: 15-19 Male	212
	By Age/Sex: 20-24 Male	678
	By Age/Sex: 50+ Male	2,343



	By Age/Sex: 10-14 Female	269
	By Age/Sex: 15-19 Female	437
	By Age/Sex: 20-24 Female	1,417
	By Age/Sex: 50+ Female	2,250
	Pregnancy status	1,985
	Breastfeeding status	301
	FSW	2,310
	MSM	1,038
	People in prisons and other enclosed settings	1,280
	TX_NEW_N_DSD_Age_Sex_HIVS tatus 25-29, Female, Positive	2,666
	TX_NEW_N_DSD_Age_Sex_HIVS tatus 25-29, Male, Positive	1,512
	TX_NEW_N_DSD_Age_Sex_HIVS tatus 30-34, Female, Positive	2,664
	TX_NEW_N_DSD_Age_Sex_HIVS tatus 30-34, Male, Positive	1,508
	TX_NEW_N_DSD_Age_Sex_HIVS tatus 35-39, Female, Positive	2,663
	TX_NEW_N_DSD_Age_Sex_HIVS tatus 35-39, Male, Positive	1,508
	TX_NEW_N_DSD_Age_Sex_HIVS tatus 40-49, Female, Positive	2,662
	TX_NEW_N_DSD_Age_Sex_HIVS tatus 40-49, Male, Positive	1,508
TX_PVLS_DSD	TX_PVLS_DSD Percentage of ART patients with a viral load result documented in the medical record and/or laboratory information systems (LIS) within the past 12 months with a suppressed viral load (<1000 copies/ml)	0 %
	Number of adult and pediatric ART	120,482



	patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	
	Denominator: Indication: Routine	108,414
	Denominator: Indication: Targeted	12,068
	Denominator: Aggregate Age/Sex by Indication: <15 Male Targeted	245
	Denominator: Aggregate Age/Sex by Indication: 15+ Male Targeted	4,229
	Denominator: Aggregate Age/Sex by Indication: <15 Female Targeted	368
	Denominator: Aggregate Age/Sex by Indication: 15+ Female Targeted	7,226
	Denominator: Aggregate Age/Sex by Indication: <15 Male Routine	2,152
	Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine	38,014
	Denominator: Aggregate Age/Sex by Indication: <15 Female Routine	3,248
	Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine	65,000
TX_RET_DSD	TX_RET_DSD Percent of adults and children known to be alive and on treatment 12 months after initiation of antiretroviral therapy	100 %
	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	25,426
	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to	25,426



	follow-up	
	Numerator by Status: Pregnant	2,546
	Numerator by Status: Breastfeeding	304
	Denominator by Status: Pregnant	2,540
	Denominator by Status: Breastfeeding	303
	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	504
	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	8,913
	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	772
	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	15,237
	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	504



	<p>Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)</p>	<p>8,913</p>
	<p>Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)</p>	<p>772</p>
	<p>Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)</p>	<p>15,237</p>



Partners and Implementing Mechanisms

Partner List

Mech ID	Partner Name	Organization Type	Agency	Funding Source	Planned Funding
10639	Global Health Supply Chain Program	Private Contractor	U.S. Agency for International Development	GHP-State	25,631,533
12608	Ministre de la Sante Publique et Population, Haiti	Host Country Government Agency	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention		
12692	Ministre de la Sante Publique et Population, Haiti	Host Country Government Agency	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	16,006,875
12708	POZ	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention		
13569	University of Miami School of Medicine	University	U.S. Department of Health and Human Services/Centers		



			for Disease Control and Prevention		
13620	Groupe Haitien d'Etude du Sarcome de Kaposi et des Infections Opportunistes	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention		
13744	Groupe Haitien d'Etude du Sarcome de Kaposi et des Infections Opportunistes	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention		
14624	University of Maryland	University	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention		
14627	Catholic Medical Mission Board	FBO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention		
14706	Foundation for Reproductive Health and Family Education	NGO	U.S. Department of Health and Human Services/Centers for Disease		



			Control and Prevention		
14710	University of Washington	University	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention		
14761	Health Through Walls	NGO	U.S. Agency for International Development	GHP-State	1,250,000
16801	Caris Foundation	NGO	U.S. Agency for International Development		
16856	University of Washington	University	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	2,490,500
17691	Ministre de la Sante Publique et Population, Haiti	Host Country Government Agency	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention		
18018	FHI 360	NGO	U.S. Agency for International Development	GHP-State	2,700,000
18047	National Alliance of State and Territorial AIDS Directors	NGO	U.S. Department of Health and Human Services/Centers	GHP-State	1,500,000



			for Disease Control and Prevention		
18050	Center for Development and Health	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	1,000,000
18086	Measure Evaluation	NGO	U.S. Agency for International Development	GHP-State	300,000
18266	Groupe Haitien d'Etude du Sarcome de Kaposi et des Infections Opportunistes	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	3,000,000
18267	Partners in Health	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	6,500,000
18268	Catholic Medical Mission Board	FBO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	5,200,000
18269	Groupe Haitien d'Etude du	NGO	U.S. Department of Health and	GHP-State	4,600,000



	Sarcome de Kaposi et des Infections Opportunistes		Human Services/Centers for Disease Control and Prevention		
18270	Foundation for Reproductive Health and Family Education	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	1,700,000
18425	Right To Care, South Africa	NGO	U.S. Agency for International Development	GHP-State	2,200,000
18623	Catholic Relief Services	FBO	U.S. Agency for International Development	GHP-State	1,994,831
18625	DAI	Private Contractor	U.S. Agency for International Development	GHP-State	1,000,000
18631	Caris Foundation	NGO	U.S. Agency for International Development	GHP-State	5,433,710
70101	TBD	TBD	Redacted	Redacted	Redacted
70102	TBD	TBD	Redacted	Redacted	Redacted
70104	Global Health Supply Chain Program	Private Contractor	U.S. Agency for International Development		
70105	Global Health Supply Chain Program	Private Contractor	U.S. Agency for International Development	GHP-State	1,455,051
70506	TBD	TBD	Redacted	Redacted	Redacted



Implementing Mechanism(s)

Implementing Mechanism Details

Mechanism ID: 10639	Mechanism Name: Global Health Supply Chain Program
Funding Agency: USAID	Procurement Type: Contract
Prime Partner Name: Global Health Supply Chain Program	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 25,631,533	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 25,631,533	
Funding Source	Funding Amount
GHP-State	25,631,533

Cross-Cutting Budget Attribution(s)

Condom programming	134,082
Water	522,000

Budget Code Information

Mechanism ID: 10639 Mechanism Name: Global Health Supply Chain Program Prime Partner Name: Global Health Supply Chain Program		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	698,092



Strategic Area	Budget Code	Planned Amount
Care	HKID	798,301
Strategic Area	Budget Code	Planned Amount
Care	HVTB	122,541
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	1,805,981
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	173,612
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	739,265
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	704,688
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	187,491
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	14,810,509
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	5,209,404
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	381,649

Implementing Mechanism Indicator Information

(No data provided.)



Implementing Mechanism Details

Mechanism ID: 12608	Mechanism Name: Blood Safety
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Ministre de la Sante Publique et Population, Haiti	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:
Total All Funding Sources: 0	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 12608		
Mechanism Name: Blood Safety		
Prime Partner Name: Ministre de la Sante Publique et Population, Haiti		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0



Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount



Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 12692	Mechanism Name: MSPP/UGP (National AIDS Strategic Plan)
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Ministre de la Sante Publique et Population, Haiti	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: Yes	Managing Agency: HHS/CDC

Total All Funding Sources: 16,006,875	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 16,006,875	
Funding Source	Funding Amount
GHP-State	16,006,875

Cross-Cutting Budget Attribution(s)



Key Populations: MSM and TG	200,000
Focus Area:	Training of health workers and community outreach workers
Focus Area:	Implementation of core HIV prevention interventions for MSM/TG that are consistent with the current PEPFAR technical guidance
Focus Area:	Collection and use of strategic information
Focus Area:	Monitoring and evaluation of MSM/TG programs
Key Populations: FSW	200,000
Focus Area:	Collection and use of strategic information on SWs and clients
Focus Area:	Conducting epidemiologic, social science, and operational research among SWs, their partners, and clients
Focus Area:	Implementation of core HIV prevention interventions for SWs consistent with PEPFAR guidance on sexual prevention
Focus Area:	Training of health workers and community outreach workers
Focus Area:	Monitoring and evaluation of SW programs
Gender: GBV	300,000
Focus Area:	GBV Prevention
Sub Area:	Capacity building
Human Resources for Health	87,500
Adolescent Girls and Young Women (AGYW)	140,426

Budget Code Information

Mechanism ID: 12692		
Mechanism Name: MSPP/UGP (National AIDS Strategic Plan)		
Prime Partner Name: Ministre de la Sante Publique et Population, Haiti		
Strategic Area	Budget Code	Planned Amount



Care	HBHC	1,275,788
Strategic Area	Budget Code	Planned Amount
Care	HKID	1,896,688
Strategic Area	Budget Code	Planned Amount
Care	HVTB	1,201,996
Strategic Area	Budget Code	Planned Amount
Care	PDCS	310,194
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	1,150,000
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	676,512
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	760,000
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	3,085,625



Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	950,465
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	4,145,284
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	554,323

Implementing Mechanism Indicator Information

Indicator Number	Label	2019
PMTCT_ART_DSD	Number of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy	866
PMTCT_ART_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	49,885
PMTCT_ART_DSD	New on ART	408
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	458
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	49,885



PMTCT_STAT_DSD	Number of new ANC and L&D clients	49,885
PMTCT_STAT_DSD	By Age (Denominator): <15-19	1,997
PMTCT_STAT_DSD	By Age (Denominator): 20-24	4,490
PMTCT_STAT_DSD	By Age (Denominator): 50+	6,986
PMTCT_STAT_DSD	By Number of known positives: 15-19	20
PMTCT_STAT_DSD	By Number of known positives: 20-24	45
PMTCT_STAT_DSD	By Number of known positives: 50+	70
PMTCT_STAT_DSD	By Number of new positives: 15-19	18
PMTCT_STAT_DSD	By Number of new positives: 20-24	38
PMTCT_STAT_DSD	By Number of new positives: 50+	55
PMTCT_STAT_DSD	By Number of new negative: 15-19	1,960
PMTCT_STAT_DSD	By Number of new negative: 20-24	4,409
PMTCT_STAT_DSD	By Number of new negative: 50+	6,834
PMTCT_STAT_DSD	By Age (Numerator): 15-19	1,997
PMTCT_STAT_DSD	By Age (Numerator): 20-24	4,490
PMTCT_STAT_DSD	By Age (Numerator): 50+	6,986
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 25-29, Female	9,110
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 30-34, Female	9,104
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 35-39, Female	9,100
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 40-49, Female	9,098
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 25-29, Female, Known at Entry Positive	88
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 25-29, Female, Newly Identified Negative	8,943
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 25-29, Female, Newly Identified Positive	79
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 30-34, Female, Known at Entry Positive	91
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 30-34, Female, Newly Identified Negative	8,943
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 30-34, Female, Newly Identified Positive	74
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult	91



	35-39, Female, Known at Entry Positive	
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 35-39, Female, Newly Identified Negative	8,943
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 35-39, Female, Newly Identified Positive	77
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 40-49, Female, Known at Entry Positive	84
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 40-49, Female, Newly Identified Negative	8,943
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 40-49, Female, Newly Identified Positive	73
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 25-29, Female	9,110
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 30-34, Female	9,104
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 35-39, Female	9,100
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 40-49, Female	9,098
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	183,648
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Female, Negative	140
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Male, Negative	260
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Male, Positive	10
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Female, Negative	42
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Male, Negative	28
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Female, Negative	158
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Female, Positive	2
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Male, Negative	80



HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Female, Negative	273
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Female, Positive	5
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Male, Negative	207
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Male, Positive	3
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: <1, Negative	59
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 1-9, Negative	643
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 1-9, Positive	35
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Female, Negative	174
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Female, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative	111
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Male, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Female, Negative	611
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Female, Positive	14
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Male, Negative	240
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Male, Positive	4
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Female, Negative	1,660
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Female, Positive	38
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Male, Negative	1,192
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Male, Positive	26



	Positive	
HTC_TST_DSD	Service Delivery Point (Facility) Pediatric : <5 Negative	4,876
HTC_TST_DSD	Service Delivery Point (Facility) Pediatric : <5 Positive	49
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Male, Negative	52
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Male, Positive	5
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Female, Negative	16
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Male, Negative	8
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Female, Negative	45
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Female, Positive	5
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Male, Negative	17
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Female, Negative	128
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Female, Positive	22
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Male, Negative	106
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Male, Positive	11
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Female, Negative	552
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Female, Positive	16
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Male, Negative	711
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Male, Positive	11
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Female, Negative	122



HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Female, Positive	20
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Male, Negative	80
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Male, Positive	12
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Female, Negative	436
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Female, Positive	79
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Male, Negative	194
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Male, Positive	31
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Female, Negative	956
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Female, Positive	169
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Male, Negative	749
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Male, Positive	134
HTC_TST_DSD	Service Delivery Point (Facility) Index: <1, Negative	158
HTC_TST_DSD	Service Delivery Point (Facility) Index: 1-9, Negative	1,765
HTC_TST_DSD	Service Delivery Point (Facility) Index: 1-9, Positive	37
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 15-19, Negative	1,962
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 15-19, Positive	18
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 20-24, Negative	4,414
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 20-24, Positive	38
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 50+, Negative	6,841
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 50+, Positive	55
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Female, Negative	1,364



HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Female, Positive	34
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Male, Negative	887
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Male, Positive	19
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Female, Negative	4,683
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Female, Positive	119
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Male, Negative	2,000
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Male, Positive	53
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Female, Negative	10,713
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Female, Positive	254
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Male, Negative	8,648
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Male, Positive	199
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Female, Negative	975
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Female, Positive	171
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Male, Negative	504
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Male, Positive	88
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Female, Negative	975
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Female, Positive	171



HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Male, Negative	504
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Male, Positive	88
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Female, Negative	975
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Female, Positive	171
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Male, Negative	504
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Male, Positive	88
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Female, Negative	970
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Female, Positive	175
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Male, Negative	502
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Male, Positive	93
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Female, Negative	308
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Female, Positive	6
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Male, Negative	170
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Male, Positive	2
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Female, Negative	308
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Female, Positive	6
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Male, Negative	170



HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Male, Positive	2
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Female, Negative	308
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Female, Positive	6
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Male, Negative	170
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Male, Positive	2
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Female, Negative	315
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Female, Positive	12
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Male, Negative	171
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Male, Positive	11
HTC_TST_DSD	HTS_TST_N_DSD_MN_Age_Sex_Result <5, Unknown Sex, Negative	612
HTC_TST_DSD	HTS_TST_N_DSD_MN_Age_Sex_Result <5, Unknown Sex, Positive	11
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Female, Negative	1,528
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Female, Positive	38
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Male, Negative	784
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Male, Positive	15
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Female, Negative	1,528
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Female, Positive	38

HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Male, Negative	784
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Male, Positive	15
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Female, Negative	1,528
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Female, Positive	38
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Male, Negative	784
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Male, Positive	15
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Female, Negative	1,535
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Female, Positive	28
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Male, Negative	781
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Male, Positive	29
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 25-29, Female, Negative	8,952
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 25-29, Female, Positive	80
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 30-34, Female, Negative	8,952
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 30-34, Female, Positive	75
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 35-39, Female, Negative	8,952
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 35-39, Female, Positive	78
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 40-49, Female, Negative	8,952



HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 40-49, Female, Positive	74
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Female, Negative	116
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Female, Positive	12
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Male, Negative	60
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Male, Positive	6
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Female, Negative	116
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Female, Positive	12
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Male, Negative	60
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Male, Positive	6
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Female, Negative	116
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Female, Positive	12
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Male, Negative	60
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Male, Positive	6
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Female, Negative	123
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Female, Positive	23
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Male, Negative	67
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Male, Positive	15



HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Female, Negative	10,967
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Female, Positive	263
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Male, Negative	5,589
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Male, Positive	136
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Female, Negative	10,967
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Female, Positive	263
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Male, Negative	5,589
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Male, Positive	136
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Female, Negative	10,967
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Female, Positive	263
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Male, Negative	5,589
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Male, Positive	136
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Female, Negative	10,969
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Female, Positive	263
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Male, Negative	5,583
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Male, Positive	133
TB_STAT_DSD	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	1,291



TB_STAT_DSD	Total number of registered new and relapsed TB cases, during the reporting period.	1,291
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	25
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	454
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	39
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	773
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	25
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	454
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	39
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	773
GEND_GBV_DSD	Number of people receiving post-GBV care	394
GEND_GBV_DSD	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	1
GEND_GBV_DSD	By type of service: Sexual Violence (Post-Rape Care)	393
GEND_GBV_DSD	By PEP service provision (related to sexual violence services provided)	393
GEND_GBV_DSD	<10, Female, Sexual Violence (Post-Rape Care)	32
GEND_GBV_DSD	<10, Male, Sexual Violence (Post-Rape Care)	1



GEND_GBV_DSD	10-14, Female, Sexual Violence (Post-Rape Care)	91
GEND_GBV_DSD	10-14, Male, Sexual Violence (Post-Rape Care)	1
GEND_GBV_DSD	15-19, Female, Sexual Violence (Post-Rape Care)	104
GEND_GBV_DSD	15-19, Male, Sexual Violence (Post-Rape Care)	2
GEND_GBV_DSD	20-24, Female, Physical and/or Emotional Violence	1
GEND_GBV_DSD	20-24, Female, Sexual Violence (Post-Rape Care)	94
GEND_GBV_DSD	20-24, Male, Sexual Violence (Post-Rape Care)	2
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 25-29, Female, Sexual Violence (Post-Rape Care)	19
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 25-29, Male, Sexual Violence (Post-Rape Care)	4
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 30-34, Female, Sexual Violence (Post-Rape Care)	14
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 30-34, Male, Sexual Violence (Post-Rape Care)	3
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 35-39, Female, Sexual Violence (Post-Rape Care)	13
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 35-39, Male, Sexual Violence (Post-Rape Care)	1
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 40-49, Female, Sexual Violence (Post-Rape Care)	11
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 40-49, Male, Sexual Violence (Post-Rape Care)	1
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	15,733
OVC_SERV_DSD	Age/Sex: 10-14 Male	1,575
OVC_SERV_DSD	Age/Sex: 15-17 Male	1,253
OVC_SERV_DSD	By: Age/sex: Male 18-24	1,160
OVC_SERV_DSD	By: Age/sex: Male 25+	1,574
OVC_SERV_DSD	Age/Sex: 10-14 Female	1,592
OVC_SERV_DSD	Age/Sex: 15-17 Female	1,290
OVC_SERV_DSD	By: Age/sex: 18-24 Female	1,218



OVC_SERV_DSD	By: Age/sex: 25+ Female	2,332
OVC_SERV_DSD	Sum of Age/Sex disaggregates	5,710
OVC_SERV_DSD	Age/Sex: <1	554
OVC_SERV_DSD	Age/Sex: 1-9	3,185
OVC_SERV_DSD	Program Completion: Active	15,268
OVC_SERV_DSD	Program Completion: Graduation	465
OVC_HIVSTAT_DSD	Number of orphans and vulnerable children (<18 years old) whose HIV status is known or unknown by the OVC implementing partner.	7,411
OVC_HIVSTAT_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	15,733
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	93
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	35
TB_ART_DSD	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	1
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	57
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	860
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	689
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	171
PMTCT_EID_DSD	Sum of Infant Age disaggregates	860



TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	29,360
TX_CURR_DSD	Age/Sex: 15-19 Male	265
TX_CURR_DSD	Age/Sex: 15-19 Female	404
TX_CURR_DSD	Sum of age/sex disaggregates	669
TX_CURR_DSD	Age/Sex: <1	72
TX_CURR_DSD	Age/Sex: <1-9	834
TX_CURR_DSD	Age/Sex: 10-14 Male	260
TX_CURR_DSD	Age/Sex: 10-14 Female	317
TX_CURR_DSD	Age/Sex: 20-24 Male	673
TX_CURR_DSD	Age/Sex: 50+ Male	2,457
TX_CURR_DSD	Age/Sex: 20-24 Female	1,448
TX_CURR_DSD	Age/Sex: 50+ Female	3,166
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 25-29, Female, Positive	3,197
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 25-29, Male, Positive	1,669
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 30-34, Female, Positive	3,197
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 30-34, Male, Positive	1,669
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 35-39, Female, Positive	3,197
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 35-39, Male, Positive	1,669
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 40-49, Female, Positive	3,197
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 40-49, Male, Positive	1,669
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	5,260
TX_NEW_DSD	By Age/Sex: <1	10
TX_NEW_DSD	By Age/Sex: 1-9	140



TX_NEW_DSD	By Age/Sex: 10-14 Male	42
TX_NEW_DSD	By Age/Sex: 15-19 Male	47
TX_NEW_DSD	By Age/Sex: 20-24 Male	120
TX_NEW_DSD	By Age/Sex: 50+ Male	459
TX_NEW_DSD	By Age/Sex: 10-14 Female	54
TX_NEW_DSD	By Age/Sex: 15-19 Female	73
TX_NEW_DSD	By Age/Sex: 20-24 Female	256
TX_NEW_DSD	By Age/Sex: 50+ Female	554
TX_NEW_DSD	Sum of Age/Sex disaggregates	1,605
TX_NEW_DSD	Pregnancy status	398
TX_NEW_DSD	Breastfeeding status	62
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 25-29, Female, Positive	575
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 25-29, Male, Positive	302
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 30-34, Female, Positive	575
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 30-34, Male, Positive	302
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 35-39, Female, Positive	574
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 35-39, Male, Positive	302
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 40-49, Female, Positive	573
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 40-49, Male, Positive	302
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	26,890
TX_PVLS_DSD	Denominator: Indication: Routine	24,191
TX_PVLS_DSD	Denominator: Indication: Targeted	2,699
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15	55



	Male Targeted	
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Male Targeted	947
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Female Targeted	87
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Female Targeted	1,610
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Male Routine	474
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine	8,535
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Female Routine	723
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine	14,459
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	5,158
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	5,158
TX_RET_DSD	Numerator by Status: Pregnant	518
TX_RET_DSD	Numerator by Status: Breastfeeding	62
TX_RET_DSD	Denominator by Status: Pregnant	512
TX_RET_DSD	Denominator by Status: Breastfeeding	61
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	100
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,821
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	158

TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	3,079
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	100
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,821
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	158
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	3,079
HTS_SELF_DSD	HTS_SELF_N_DSD	1,850
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Female, Directly-Assisted	66
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Female, Unassisted	66
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Male, Directly-Assisted	66
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Male, Unassisted	66
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Female, Directly-Assisted	66
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Male, Unassisted	66



	Female, Unassisted	
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Male, Directly-Assisted	66
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Male, Unassisted	66
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Female, Directly-Assisted	66
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Female, Unassisted	66
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Male, Directly-Assisted	66
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Male, Unassisted	66
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Female, Directly-Assisted	66
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Female, Unassisted	66
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Male, Directly-Assisted	66
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Male, Unassisted	66
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Female, Directly-Assisted	66
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Female, Unassisted	66
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Male, Directly-Assisted	66
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Male, Unassisted	66
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Female, Directly-Assisted	66
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Female, Unassisted	66
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Male, Directly-Assisted	66
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Male, Unassisted	66



	Male, Directly-Assisted	
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Male, Unassisted	66
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Female, Directly-Assisted	66
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Female, Unassisted	66
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Male, Directly-Assisted	67
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Male, Unassisted	67
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTest Directly-Assisted	925
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTest Unassisted	925
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTestUser Unassisted - Other	296
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTestUser Unassisted - Self	296
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTestUser Unassisted - Sex Partner	333
TB_PREV_DSD	The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period	4,230
TB_PREV_DSD	The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting period).	4,701
TB_PREV_DSD	By Age/Sex (Denominator): <15, Female	141
TB_PREV_DSD	By Age/Sex (Denominator): <15, Male	93
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Female	2,819
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Male	1,648



TB_PREV_DSD	By Age/Sex (Numerator): <15, Female	125
TB_PREV_DSD	By Age/Sex (Numerator): <15, Male	85
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Female	2,538
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Male	1,482
TB_PREV_DSD	TB_PREV_D_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, New, Positive	4,701
TB_PREV_DSD	TB_PREV_N_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, New, Positive	4,230
TX_TB_DSD	Number of ART patients who were screened for TB at least once during the reporting period	29,362
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Female	876
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Male	591
TX_TB_DSD	Denominator: By Aggregated Age/Sex:15+, Female	17,539
TX_TB_DSD	Denominator: By Aggregated Age/Sex:15+, Male	10,355
TX_TB_DSD	Denominator: Number of ART patients who had a specimen sent for bacteriologic diagnosis of active TB disease	1,162
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Other (No Xpert)	40
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Smear Only	658
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Gene Xpert MTB / R if Assay	464
TX_TB_DSD	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, Already, TB Screen - Negative, Positive	22,568
TX_TB_DSD	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, Already, TB Screen - Positive, Positive	942
TX_TB_DSD	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, New, TB Screen - Negative, Positive	5,317
TX_TB_DSD	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, New, TB Screen - Positive, Positive	224

Implementing Mechanism Details

Mechanism ID: 12708	Mechanism Name: POZ
----------------------------	----------------------------



Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: POZ	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 0	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 12708 Mechanism Name: POZ Prime Partner Name: POZ		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount



Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0



Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 13569	Mechanism Name: University of Miami
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: University of Miami School of Medicine	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:
Total All Funding Sources: 0	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount

Cross-Cutting Budget Attribution(s)

(No data provided.)



Budget Code Information

Mechanism ID: 13569 Mechanism Name: University of Miami Prime Partner Name: University of Miami School of Medicine		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0



Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 13620	Mechanism Name: GHESKIO 0545
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Groupe Haitien d'Etude du Sarcome de Kaposi et des Infections Opportunistes	
Agreement Start Date: Redacted	Agreement End Date: Redacted



TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:
Total All Funding Sources: 0	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	13620	
Mechanism Name:	GHESKIO 0545	
Prime Partner Name:	Groupe Haitien d'Etude du Sarcome de Kaposi et des Infections Opportunistes	
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount



Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0



Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 13744	Mechanism Name: GHESKIO 541
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Groupe Haitien d'Etude du Sarcome de Kaposi et des Infections Opportunistes	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:
Total All Funding Sources: 0	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 13744



Mechanism Name: GHESKIO 541 Prime Partner Name: Groupe Haitien d'Etude du Sarcome de Kaposi et des Infections Opportunistes		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount



Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 14624	Mechanism Name: University of Maryland
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: University of Maryland	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	



G2G: No	Managing Agency:
Total All Funding Sources: 0	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	14624	
Mechanism Name:	University of Maryland	
Prime Partner Name:	University of Maryland	
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount



Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0



Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 14627	Mechanism Name: Catholic Medical Mission Board
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Catholic Medical Mission Board	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 0	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	14627
Mechanism Name:	Catholic Medical Mission Board
Prime Partner Name:	Catholic Medical Mission Board



Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount



Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 14706	Mechanism Name: FOSREF
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Foundation for Reproductive Health and Family Education	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 0	Total Mechanism Pipeline: N/A
-------------------------------------	--------------------------------------



Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 14706		
Mechanism Name: FOSREF		
Prime Partner Name: Foundation for Reproductive Health and Family Education		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount



Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0



Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 14710	Mechanism Name: ITECH 549
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: University of Washington	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:
Total All Funding Sources: 0	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 14710		
Mechanism Name: ITECH 549		
Prime Partner Name: University of Washington		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0



Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 14761	Mechanism Name: HTW (Health Through Walls)
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Health Through Walls	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 1,250,000	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 1,250,000	
Funding Source	Funding Amount
GHP-State	1,250,000

Cross-Cutting Budget Attribution(s)

Gender: GBV	19,500
Focus Area:	GBV Prevention
Sub Area:	Implementation
Sub Area:	Capacity building
Condom programming	40,000
Motor Vehicles: Purchased	100,000
Water	20,000

Budget Code Information



Mechanism ID: 14761		
Mechanism Name: HTW (Health Through Walls)		
Prime Partner Name: Health Through Walls		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	750,000
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount



Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	150,000
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	200,000
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	150,000
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2019
KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	10,068
KP_PREV_DSD	By key population type: People in prisons and enclosed settings (Numerator: Number of key populations reached with individual and/or small group level HIV	10,068



	preventive interventions that are based on evidence and/or meet the minimum standards required)	
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	33,165
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Female, Negative	46
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Female, Negative	16
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Male, Negative	11
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Female, Negative	64
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Female, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Male, Negative	37
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Male, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Female, Negative	81
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Female, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Male, Negative	56
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Male, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Female, Negative	39
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Female, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative	26
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19,	1



	Male, Positive	
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Female, Negative	165
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Female, Positive	4
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Male, Negative	79
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Male, Positive	2
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Female, Negative	271
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Female, Positive	6
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Male, Negative	192
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Male, Positive	4
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Male, Negative	16
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Male, Positive	2
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Female, Negative	5
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Female, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Male, Negative	3
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Female, Negative	22
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Female, Positive	3
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Male, Negative	13
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Male, Positive	2



	Positive	
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Female, Negative	26
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Female, Positive	3
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Male, Negative	18
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Male, Positive	2
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Female, Negative	39
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Female, Positive	6
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Male, Negative	22
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Male, Positive	3
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Female, Negative	148
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Female, Positive	26
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Male, Negative	76
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Male, Positive	13
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Female, Negative	250
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Female, Positive	44
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Male, Negative	187
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Male, Positive	34
HTC_TST_DSD	By Key Population: People in prisons and other enclosed settings, Negative	31,583



HTC_TST_DSD	By Key Population: People in prisons and other enclosed settings, Positive	1,171
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Female, Negative	416
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Female, Positive	10
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Male, Negative	238
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Male, Positive	4
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Female, Negative	1,516
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Female, Positive	41
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Male, Negative	752
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Male, Positive	20
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Female, Negative	2,728
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Female, Positive	67
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Male, Negative	2,069
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Male, Positive	52
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Female, Negative	281
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Female, Positive	51
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Male, Negative	146
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Male, Positive	25



HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Female, Negative	281
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Female, Positive	51
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Male, Negative	146
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Male, Positive	25
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Female, Negative	281
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Female, Positive	51
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Male, Negative	146
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Male, Positive	25
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Female, Negative	279
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Female, Positive	46
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Male, Negative	150
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Male, Positive	28
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Female, Negative	106
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Female, Positive	2
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Male, Negative	58
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Male, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Female, Negative	106

HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Female, Positive	2
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Male, Negative	58
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Male, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Female, Negative	106
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Female, Positive	2
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Male, Negative	58
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Male, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Female, Negative	105
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Female, Positive	4
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Male, Negative	55
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Male, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Female, Negative	313
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Female, Positive	6
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Male, Negative	157
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Male, Positive	4
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Female, Negative	313
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Female, Positive	6



HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Male, Negative	157
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Male, Positive	4
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Female, Negative	313
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Female, Positive	6
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Male, Negative	157
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Male, Positive	4
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Female, Negative	313
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Female, Positive	15
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Male, Negative	165
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Male, Positive	4
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Female, Negative	36
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Female, Positive	5
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Male, Negative	19
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Male, Positive	2
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Female, Negative	36
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Female, Positive	5
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Male, Negative	19



HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Male, Positive	2
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Female, Negative	36
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Female, Positive	5
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Male, Negative	19
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Male, Positive	2
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Female, Negative	35
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Female, Positive	3
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Male, Negative	20
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Male, Positive	4
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Female, Negative	2,941
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Female, Positive	73
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Male, Negative	1,524
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Male, Positive	40
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Female, Negative	2,941
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Female, Positive	73
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Male, Negative	1,524
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Male, Positive	40



HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Female, Negative	2,941
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Female, Positive	73
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Male, Negative	1,524
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Male, Positive	40
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Female, Negative	2,941
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Female, Positive	82
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Male, Negative	1,524
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Male, Positive	39
TB_STAT_DSD	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	394
TB_STAT_DSD	Total number of registered new and relapsed TB cases, during the reporting period.	394
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	8
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	138
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	12
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	236
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases,	8



	during the reporting period)	
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	138
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	12
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	236
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	25
TB_ART_DSD	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	1
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	8
TB_ART_DSD	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	1
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	15
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	2,804
TX_CURR_DSD	Age/Sex: 15-19 Male	30
TX_CURR_DSD	Age/Sex: 15-19 Female	45
TX_CURR_DSD	Sum of age/sex disaggregates	75
TX_CURR_DSD	Age/Sex: 20-24 Male	98



TX_CURR_DSD	Age/Sex: 50+ Male	197
TX_CURR_DSD	Age/Sex: 20-24 Female	184
TX_CURR_DSD	Age/Sex: 50+ Female	266
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 25-29, Female, Positive	323
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 25-29, Male, Positive	173
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 30-34, Female, Positive	323
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 30-34, Male, Positive	173
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 35-39, Female, Positive	323
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 35-39, Male, Positive	173
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 40-49, Female, Positive	323
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 40-49, Male, Positive	173
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	1,287
TX_NEW_DSD	By Age/Sex: 15-19 Male	12
TX_NEW_DSD	By Age/Sex: 20-24 Male	41
TX_NEW_DSD	By Age/Sex: 50+ Male	98
TX_NEW_DSD	By Age/Sex: 15-19 Female	20
TX_NEW_DSD	By Age/Sex: 20-24 Female	80
TX_NEW_DSD	By Age/Sex: 50+ Female	132
TX_NEW_DSD	Sum of Age/Sex disaggregates	383
TX_NEW_DSD	Breastfeeding status	16
TX_NEW_DSD	People in prisons and other enclosed settings	1,280
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 25-29, Female, Positive	148
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 25-29, Male,	78



	Positive	
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 30-34, Female, Positive	148
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 30-34, Male, Positive	78
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 35-39, Female, Positive	148
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 35-39, Male, Positive	78
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 40-49, Female, Positive	148
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 40-49, Male, Positive	78
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	2,166
TX_PVLS_DSD	Denominator: Indication: Routine	1,948
TX_PVLS_DSD	Denominator: Indication: Targeted	218
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Male Targeted	4
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Male Targeted	77
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Female Targeted	6
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Female Targeted	131
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Male Routine	38
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine	681
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Female Routine	58
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine	1,171



TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	1,289
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	1,289
TX_RET_DSD	Numerator by Status: Pregnant	129
TX_RET_DSD	Numerator by Status: Breastfeeding	16
TX_RET_DSD	Denominator by Status: Pregnant	129
TX_RET_DSD	Denominator by Status: Breastfeeding	16
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	25
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	449
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	42
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	773
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	25
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	449
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period,	42



	including those who have died, those who have stopped ART, and those lost to follow-up)	
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	773
HTS_SELF_DSD	HTS_SELF_N_DSD	912
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Female, Directly-Assisted	33
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Female, Unassisted	33
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Male, Directly-Assisted	33
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Male, Unassisted	33
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Female, Directly-Assisted	33
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Female, Unassisted	33
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Male, Directly-Assisted	33
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Male, Unassisted	33
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Female, Directly-Assisted	33
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Female, Unassisted	33
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Male, Directly-Assisted	33
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Male, Unassisted	33
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Female, Directly-Assisted	33



HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Female, Unassisted	33
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Male, Directly-Assisted	33
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Male, Unassisted	33
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Female, Directly-Assisted	33
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Female, Unassisted	33
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Male, Directly-Assisted	33
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Male, Unassisted	33
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Female, Directly-Assisted	33
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Female, Unassisted	33
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Male, Directly-Assisted	33
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Male, Unassisted	33
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Female, Directly-Assisted	33
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Female, Unassisted	33
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Male, Directly-Assisted	33
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Male, Unassisted	33
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTest Directly-Assisted	456
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTest Unassisted	456
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTestUser Unassisted - Other	149



HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTestUser Unassisted - Self	149
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTestUser Unassisted - Sex Partner	158
HTS_SELF_DSD	HTS_SELF_N_DSD_KeyPop_HIVSelfTest FSW, Directly-Assisted	341
HTS_SELF_DSD	HTS_SELF_N_DSD_KeyPop_HIVSelfTest FSW, Unassisted	341
HTS_SELF_DSD	HTS_SELF_N_DSD_KeyPop_HIVSelfTest MSM, Directly-Assisted	115
HTS_SELF_DSD	HTS_SELF_N_DSD_KeyPop_HIVSelfTest MSM, Unassisted	115
TB_PREV_DSD	The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period	1,129
TB_PREV_DSD	The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting period).	1,255
TB_PREV_DSD	By Age/Sex (Denominator): <15, Female	39
TB_PREV_DSD	By Age/Sex (Denominator): <15, Male	24
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Female	753
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Male	439
TB_PREV_DSD	By Age/Sex (Numerator): <15, Female	33
TB_PREV_DSD	By Age/Sex (Numerator): <15, Male	23
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Female	680
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Male	393
TB_PREV_DSD	TB_PREV_D_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, New, Positive	1,255
TB_PREV_DSD	TB_PREV_N_DSD_TherapyType_NewExArt_HIV IPT,	1,129



	Life-long ART, New, Positive	
TX_TB_DSD	Number of ART patients who were screened for TB at least once during the reporting period	2,811
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Female	86
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Male	54
TX_TB_DSD	Denominator: By Aggregated Age/Sex:15+, Female	1,688
TX_TB_DSD	Denominator: By Aggregated Age/Sex:15+, Male	983
TX_TB_DSD	Denominator: Number of ART patients who had a specimen sent for bacteriologic diagnosis of active TB disease	113
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Other (No Xpert)	3
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Smear Only	65
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Gene Xpert MTB / R if Assay	45
TX_TB_DSD	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, Already, TB Screen - Negative, Positive	2,185
TX_TB_DSD	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, Already, TB Screen - Positive, Positive	93
TX_TB_DSD	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, New, TB Screen - Negative, Positive	510
TX_TB_DSD	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, New, TB Screen - Positive, Positive	21

Implementing Mechanism Details

Mechanism ID: 16801	Mechanism Name: BEST (Byen en ak Sante Timoun)
Funding Agency: USAID	Procurement Type: Contract
Prime Partner Name: Caris Foundation	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Approved



Total All Funding Sources: 0	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 16801		
Mechanism Name: BEST (Byen en ak Sante Timoun)		
Prime Partner Name: Caris Foundation		
Strategic Area	Budget Code	Planned Amount
Care	HKID	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 16856	Mechanism Name: ITECH 1331
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: University of Washington	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:



Total All Funding Sources: 2,490,500	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 2,490,500	
Funding Source	Funding Amount
GHP-State	2,490,500

Cross-Cutting Budget Attribution(s)

Motor Vehicles: Purchased	149,200
---------------------------	---------

Budget Code Information

Mechanism ID: 16856		
Mechanism Name: ITECH 1331		
Prime Partner Name: University of Washington		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	117,301
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	58,650
Strategic Area	Budget Code	Planned Amount
Care	PDCS	58,650
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount



Governance and Systems	HVSI	1,112,500
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	58,649
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	100,000
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	105,000
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	469,200



Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	410,550

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 17691	Mechanism Name: MSPP Research
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Ministre de la Sante Publique et Population, Haiti	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:
Total All Funding Sources: 0	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	17691	
Mechanism Name:	MSPP Research	
Prime Partner Name:	Ministre de la Sante Publique et Population, Haiti	
Strategic Area	Budget Code	Planned Amount



Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0



Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 18018	Mechanism Name: Linkages
Funding Agency: USAID	Procurement Type: Contract
Prime Partner Name: FHI 360	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:
Total All Funding Sources: 2,700,000	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	



Total All Funding Sources and Applied Pipeline Amount: 2,700,000	
Funding Source	Funding Amount
GHP-State	2,700,000

Cross-Cutting Budget Attribution(s)

Key Populations: MSM and TG	1,200,000
Focus Area:	Training of health workers and community outreach workers
Focus Area:	Implementation of core HIV prevention interventions for MSM/TG that are consistent with the current PEPFAR technical guidance
Focus Area:	Collection and use of strategic information
Focus Area:	Monitoring and evaluation of MSM/TG programs
Key Populations: FSW	1,800,000
Focus Area:	Implementation of core HIV prevention interventions for SWs consistent with PEPFAR guidance on sexual prevention
Focus Area:	Training of health workers and community outreach workers
Focus Area:	Collection and use of strategic information on SWs and clients
Focus Area:	Monitoring and evaluation of SW programs
Gender: GBV	70,500
Focus Area:	Post GBV Care
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Focus Area:	GBV Prevention
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Human Resources for Health	300,000



Budget Code Information

Mechanism ID: 18018		
Mechanism Name: Linkages		
Prime Partner Name: FHI 360		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	502,500
Strategic Area	Budget Code	Planned Amount
Care	PDCS	55,000
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	415,000
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	760,000
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	190,000
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	722,500
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	55,000

Implementing Mechanism Indicator Information

Indicator Number	Label	2019
-------------------------	--------------	-------------



PrEP_NEW_DSD	Number of individuals who have been newly enrolled on oral antiretroviral pre-exposure prophylaxis (PrEP) in the reporting period to prevent HIV infection	650
PrEP_NEW_DSD	Male 15-19	15
PrEP_NEW_DSD	Male 20-24	59
PrEP_NEW_DSD	Male 50+	13
PrEP_NEW_DSD	Female 15-19	13
PrEP_NEW_DSD	Female 20-24	56
PrEP_NEW_DSD	Female 50+	13
PrEP_NEW_DSD	FSW	315
PrEP_NEW_DSD	MSM	335
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 25-29, Female	82
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 25-29, Male	93
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 30-34, Female	74
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 30-34, Male	75
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 35-39, Female	46
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 35-39, Male	53
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 40-49, Female	31
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 40-49, Male	27
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	19,500
PP_PREV_DSD	Age/sex: 15-19 Male	2,893
PP_PREV_DSD	Age/sex: 20-24 Male	4,662
PP_PREV_DSD	Age/sex: 50+ Male	490
PP_PREV_DSD	Age/sex: 15-19 Female	362
PP_PREV_DSD	Age/sex: 20-24 Female	1,199
PP_PREV_DSD	Age/sex: 50+ Female	75
PP_PREV_DSD	Sum of Age/Sex disaggregates	9,681
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 25-29, Female	578
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 25-29, Male	1,879
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 30-34, Female	578



PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 30-34, Male	1,877
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 35-39, Female	578
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 35-39, Male	1,877
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 40-49, Female	577
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 40-49, Male	1,875
KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	41,500
KP_PREV_DSD	By key population type: Men who have sex with men who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	13,400
KP_PREV_DSD	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	28,100
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	38,826
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Female, Negative	34
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Female, Negative	11
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Male, Negative	6
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Female, Negative	36
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Male, Negative	17
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Female, Negative	65



HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Female, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Male, Negative	57
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Male, Positive	1
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Female, Negative	131
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Female, Positive	1
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Male, Negative	71
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Male, Positive	1
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Female, Negative	496
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Female, Positive	13
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Male, Negative	210
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Male, Positive	5
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 50+, Female, Negative	789
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 50+, Female, Positive	23
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 50+, Male, Negative	597
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 50+, Male, Positive	16
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Female, Negative	13
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative	7



HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Female, Negative	49
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Male, Negative	22
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Female, Negative	91
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Male, Negative	66
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Female, Negative	20
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Female, Positive	2
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Male, Negative	14
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Male, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Female, Negative	68
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Female, Positive	13
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Male, Negative	34
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Male, Positive	6
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Female, Negative	145
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Female, Positive	27
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Male, Negative	116
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Male, Positive	20
HTC_TST_DSD	By Key Population: FSW, Negative	27,143
HTC_TST_DSD	By Key Population: FSW, Positive	1,933



HTC_TST_DSD	By Key Population: MSM, Negative	9,061
HTC_TST_DSD	By Key Population: MSM, Positive	643
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Female, Negative	159
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Female, Positive	28
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Male, Negative	87
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Male, Positive	15
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Female, Negative	612
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Female, Positive	108
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Male, Negative	249
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Male, Positive	43
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+, Female, Negative	1,005
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+, Female, Positive	177
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+, Male, Negative	736
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+, Male, Positive	129
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Female, Negative	227
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Female, Positive	3
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Male, Negative	160
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Male, Positive	2

HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Female, Negative	763
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Female, Positive	18
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Male, Negative	368
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Male, Positive	8
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Female, Negative	1,774
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Female, Positive	39
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Male, Negative	1,454
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Male, Positive	32
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Female, Negative	147
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Female, Positive	26
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Male, Negative	81
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Male, Positive	15
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Female, Negative	147
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Female, Positive	26
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Male, Negative	81
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Male, Positive	15
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Female, Negative	147



HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Female, Positive	26
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Male, Negative	81
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Male, Positive	15
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Female, Negative	147
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Female, Positive	26
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Male, Negative	84
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Male, Positive	15
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Female, Negative	78
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Female, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Male, Negative	43
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Female, Negative	78
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Female, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Male, Negative	43
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Female, Negative	78
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Female, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Male, Negative	43
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Female, Negative	79



HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Female, Positive	3
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Male, Negative	42
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Male, Positive	3
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 25-29, Female, Negative	942
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 25-29, Female, Positive	24
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 25-29, Male, Negative	478
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 25-29, Male, Positive	13
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 30-34, Female, Negative	942
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 30-34, Female, Positive	25
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 30-34, Male, Negative	478
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 30-34, Male, Positive	13
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 35-39, Female, Negative	942
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 35-39, Female, Positive	24
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 35-39, Male, Negative	478
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 35-39, Male, Positive	13
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 40-49, Female, Negative	942
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 40-49, Female, Positive	24



HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 40-49, Male, Negative	478
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 40-49, Male, Positive	13
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Female, Negative	1,168
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Female, Positive	206
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Male, Negative	583
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Male, Positive	103
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Female, Negative	1,168
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Female, Positive	206
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Male, Negative	583
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Male, Positive	103
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Female, Negative	1,168
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Female, Positive	206
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Male, Negative	583
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Male, Positive	103
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 40-49, Female, Negative	1,168
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 40-49, Female, Positive	206
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 40-49, Male, Negative	583

HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 40-49, Male, Positive	103
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Female, Negative	96
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Female, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Male, Negative	50
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Female, Negative	96
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Female, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Male, Negative	50
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Female, Negative	96
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Female, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Male, Negative	50
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Female, Negative	99
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Female, Positive	7
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Male, Negative	49
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Male, Positive	5
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Female, Negative	1,740
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Female, Positive	41
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Male, Negative	972



HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Male, Positive	22
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Female, Negative	1,740
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Female, Positive	41
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Male, Negative	972
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Male, Positive	22
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Female, Negative	1,740
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Female, Positive	41
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Male, Negative	972
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Male, Positive	22
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Female, Negative	1,734
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Female, Positive	37
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Male, Negative	972
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Male, Positive	25
GEND_GBV_DSD	Number of people receiving post-GBV care	1
GEND_GBV_DSD	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	1
GEND_GBV_DSD	20-24, Male, Physical and/or Emotional Violence	1
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	3,882
TX_CURR_DSD	Age/Sex: 15-19 Male	38
TX_CURR_DSD	Age/Sex: 15-19 Female	61



TX_CURR_DSD	Sum of age/sex disaggregates	99
TX_CURR_DSD	Age/Sex: 20-24 Male	106
TX_CURR_DSD	Age/Sex: 50+ Male	303
TX_CURR_DSD	Age/Sex: 20-24 Female	233
TX_CURR_DSD	Age/Sex: 50+ Female	401
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 25-29, Female, Positive	450
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 25-29, Male, Positive	235
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 30-34, Female, Positive	450
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 30-34, Male, Positive	235
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 35-39, Female, Positive	450
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 35-39, Male, Positive	235
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 40-49, Female, Positive	450
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 40-49, Male, Positive	235
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	1,886
TX_NEW_DSD	By Age/Sex: 15-19 Male	18
TX_NEW_DSD	By Age/Sex: 20-24 Male	47
TX_NEW_DSD	By Age/Sex: 50+ Male	148
TX_NEW_DSD	By Age/Sex: 15-19 Female	30
TX_NEW_DSD	By Age/Sex: 20-24 Female	110
TX_NEW_DSD	By Age/Sex: 50+ Female	197
TX_NEW_DSD	Sum of Age/Sex disaggregates	550
TX_NEW_DSD	Breastfeeding status	23
TX_NEW_DSD	FSW	1,381
TX_NEW_DSD	MSM	460



TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 25-29, Female, Positive	222
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 25-29, Male, Positive	112
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 30-34, Female, Positive	222
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 30-34, Male, Positive	112
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 35-39, Female, Positive	222
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 35-39, Male, Positive	112
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 40-49, Female, Positive	222
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 40-49, Male, Positive	112
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	2,168
TX_PVLS_DSD	Denominator: Indication: Routine	1,951
TX_PVLS_DSD	Denominator: Indication: Targeted	217
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Male Targeted	3
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Male Targeted	76
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Female Targeted	7
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Female Targeted	131
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Male Routine	39
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine	682
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15	59



	Female Routine	
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine	1,171
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	1,283
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	1,283
TX_RET_DSD	Numerator by Status: Pregnant	128
TX_RET_DSD	Numerator by Status: Breastfeeding	17
TX_RET_DSD	Denominator by Status: Pregnant	128
TX_RET_DSD	Denominator by Status: Breastfeeding	17
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	25
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	449
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	38
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	771
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	25
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	449



TX_RET_DSD	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	38
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	771
HTS_SELF_DSD	HTS_SELF_N_DSD	6,086
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Female, Directly-Assisted	217
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Female, Unassisted	217
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Male, Directly-Assisted	217
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Male, Unassisted	217
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Female, Directly-Assisted	217
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Female, Unassisted	217
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Male, Directly-Assisted	217
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Male, Unassisted	217
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Female, Directly-Assisted	217
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Female, Unassisted	217
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Male, Directly-Assisted	217
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Male, Unassisted	217



	Male, Unassisted	
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Female, Directly-Assisted	217
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Female, Unassisted	217
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Male, Directly-Assisted	217
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Male, Unassisted	217
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Female, Directly-Assisted	217
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Female, Unassisted	217
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Male, Directly-Assisted	217
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Male, Unassisted	217
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Female, Directly-Assisted	217
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Female, Unassisted	217
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Male, Directly-Assisted	217
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Male, Unassisted	217
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Female, Directly-Assisted	217
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Female, Unassisted	217
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Male, Directly-Assisted	217
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Male, Unassisted	217
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTest Directly-Assisted	3,043

HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTest Unassisted	3,043
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTestUser Unassisted - Other	1,009
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTestUser Unassisted - Self	1,009
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTestUser Unassisted - Sex Partner	1,025
HTS_SELF_DSD	HTS_SELF_N_DSD_KeyPop_HIVSelfTest FSW, Directly-Assisted	2,284
HTS_SELF_DSD	HTS_SELF_N_DSD_KeyPop_HIVSelfTest FSW, Unassisted	2,284
HTS_SELF_DSD	HTS_SELF_N_DSD_KeyPop_HIVSelfTest MSM, Directly-Assisted	759
HTS_SELF_DSD	HTS_SELF_N_DSD_KeyPop_HIVSelfTest MSM, Unassisted	759
TB_PREV_DSD	The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period	1,116
TB_PREV_DSD	The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting period).	1,242
TB_PREV_DSD	By Age/Sex (Denominator): <15, Female	37
TB_PREV_DSD	By Age/Sex (Denominator): <15, Male	24
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Female	746
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Male	435
TB_PREV_DSD	By Age/Sex (Numerator): <15, Female	34
TB_PREV_DSD	By Age/Sex (Numerator): <15, Male	23
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Female	670
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Male	389



TB_PREV_DSD	TB_PREV_D_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, New, Positive	1,242
TB_PREV_DSD	TB_PREV_N_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, New, Positive	1,116
TX_TB_DSD	Number of ART patients who were screened for TB at least once during the reporting period	3,161
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Female	94
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Male	63
TX_TB_DSD	Denominator: By Aggregated Age/Sex:15+, Female	1,897
TX_TB_DSD	Denominator: By Aggregated Age/Sex:15+, Male	1,107
TX_TB_DSD	Denominator: Number of ART patients who had a specimen sent for bacteriologic diagnosis of active TB disease	125
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Other (No Xpert)	1
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Smear Only	72
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Gene Xpert MTB / R if Assay	52
TX_TB_DSD	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, Already, TB Screen - Negative, Positive	2,455
TX_TB_DSD	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, Already, TB Screen - Positive, Positive	101
TX_TB_DSD	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, New, TB Screen - Negative, Positive	580
TX_TB_DSD	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, New, TB Screen - Positive, Positive	23

Implementing Mechanism Details

Mechanism ID: 18047	Mechanism Name: NASTAD 1525
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: National Alliance of State and Territorial AIDS Directors	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No



Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:
Total All Funding Sources: 1,500,000	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 1,500,000	
Funding Source	Funding Amount
GHP-State	1,500,000

Cross-Cutting Budget Attribution(s)

Gender: GBV	20,000
Focus Area:	GBV Prevention
Sub Area:	Capacity building
Focus Area:	Post GBV Care
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Monitoring and Evaluation

Budget Code Information

Mechanism ID: 18047		
Mechanism Name: NASTAD 1525		
Prime Partner Name: National Alliance of State and Territorial AIDS Directors		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	248,000
Strategic Area	Budget Code	Planned Amount
Care	HKID	0



Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	31,000
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	423,000
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	87,000
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	31,000
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	100,000
Strategic Area	Budget Code	Planned Amount



Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	270,000
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	279,000
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	31,000

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 18050	Mechanism Name: CDS 1528
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Center for Development and Health	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:
Total All Funding Sources: 1,000,000	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 1,000,000	
Funding Source	Funding Amount
GHP-State	1,000,000



Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 18050		
Mechanism Name: CDS 1528		
Prime Partner Name: Center for Development and Health		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	166,031
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	43,506
Strategic Area	Budget Code	Planned Amount
Care	PDCS	14,610
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0



Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	180,202
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	90,000
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	426,426
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	79,225

Implementing Mechanism Indicator Information



Indicator Number	Label	2019
PMTCT_ART_DSD	Number of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy	128
PMTCT_ART_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	6,880
PMTCT_ART_DSD	New on ART	78
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	50
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	6,880
PMTCT_STAT_DSD	Number of new ANC and L&D clients	6,880
PMTCT_STAT_DSD	By Age (Denominator): <15-19	276
PMTCT_STAT_DSD	By Age (Denominator): 20-24	620
PMTCT_STAT_DSD	By Age (Denominator): 50+	964
PMTCT_STAT_DSD	By Number of known positives: 15-19	2
PMTCT_STAT_DSD	By Number of known positives: 20-24	5
PMTCT_STAT_DSD	By Number of known positives: 50+	7
PMTCT_STAT_DSD	By Number of new positives: 15-19	2
PMTCT_STAT_DSD	By Number of new positives: 20-24	8
PMTCT_STAT_DSD	By Number of new positives: 50+	12
PMTCT_STAT_DSD	By Number of new negative: 15-19	270
PMTCT_STAT_DSD	By Number of new negative: 20-24	606
PMTCT_STAT_DSD	By Number of new negative: 50+	943
PMTCT_STAT_DSD	By Age (Numerator): 15-19	276
PMTCT_STAT_DSD	By Age (Numerator): 20-24	620
PMTCT_STAT_DSD	By Age (Numerator): 50+	964
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 25-29, Female	1,255
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 30-34, Female	1,255
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 35-39, Female	1,255
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 40-49, Female	1,255
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult	9



	25-29, Female, Known at Entry Positive	
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 25-29, Female, Newly Identified Negative	1,231
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 25-29, Female, Newly Identified Positive	15
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 30-34, Female, Known at Entry Positive	9
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 30-34, Female, Newly Identified Negative	1,231
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 30-34, Female, Newly Identified Positive	15
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 35-39, Female, Known at Entry Positive	10
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 35-39, Female, Newly Identified Negative	1,231
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 35-39, Female, Newly Identified Positive	16
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 40-49, Female, Known at Entry Positive	9
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 40-49, Female, Newly Identified Negative	1,231
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 40-49, Female, Newly Identified Positive	15
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 25-29, Female	1,255
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 30-34, Female	1,255
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 35-39, Female	1,255
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 40-49, Female	1,255
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	25,928
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Female, Negative	409
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Male, Negative	26



HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Male, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Female, Negative	178
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Female, Positive	4
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Male, Negative	44
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Male, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Female, Negative	533
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Female, Positive	10
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Male, Negative	94
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Male, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Female, Negative	737
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Female, Positive	13
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Male, Negative	754
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Male, Positive	13
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: <1, Negative	9
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 1-9, Negative	130
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 1-9, Positive	7
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Female, Negative	20
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative	7
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24,	68



	Female, Negative	
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Female, Positive	2
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Male, Negative	25
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Male, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Female, Negative	88
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Female, Positive	2
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Male, Negative	76
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Male, Positive	2
HTC_TST_DSD	Service Delivery Point (Facility) Pediatric : <5 Negative	774
HTC_TST_DSD	Service Delivery Point (Facility) Pediatric : <5 Positive	8
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Male, Negative	8
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Male, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Female, Negative	3
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Female, Negative	9
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Female, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Male, Negative	2
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Female, Negative	16
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Female, Positive	4
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Male,	12



	Negative	
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Male, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Female, Negative	59
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Female, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Male, Negative	69
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Male, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Female, Negative	24
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Female, Positive	3
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Male, Negative	9
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Male, Positive	2
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Female, Negative	79
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Female, Positive	13
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Male, Negative	26
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Male, Positive	4
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Female, Negative	106
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Female, Positive	19
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Male, Negative	96
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Male, Positive	16



HTC_TST_DSD	Service Delivery Point (Facility) Index: <1, Negative	24
HTC_TST_DSD	Service Delivery Point (Facility) Index: 1-9, Negative	348
HTC_TST_DSD	Service Delivery Point (Facility) Index: 1-9, Positive	7
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 15-19, Negative	270
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 15-19, Positive	2
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 20-24, Negative	606
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 20-24, Positive	8
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 50+, Negative	943
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 50+, Positive	12
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Female, Negative	114
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Female, Positive	3
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Male, Negative	53
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Male, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Female, Negative	412
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Female, Positive	13
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Male, Negative	176
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Male, Positive	5
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Female, Negative	542
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Female, Positive	16
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Male, Negative	445
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Male, Positive	14



HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Female, Negative	138
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Female, Positive	25
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Male, Negative	72
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Male, Positive	13
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Female, Negative	138
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Female, Positive	25
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Male, Negative	72
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Male, Positive	13
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Female, Negative	138
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Female, Positive	25
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Male, Negative	72
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Male, Positive	13
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Female, Negative	143
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Female, Positive	24
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Male, Negative	73
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Male, Positive	11
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Female, Negative	937



HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Female, Positive	17
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Male, Negative	486
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Male, Positive	9
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Female, Negative	937
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Female, Positive	17
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Male, Negative	486
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Male, Positive	9
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Female, Negative	937
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Female, Positive	17
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Male, Negative	486
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Male, Positive	9
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Female, Negative	942
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Female, Positive	19
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Male, Negative	486
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Male, Positive	9
HTC_TST_DSD	HTS_TST_N_DSD_MN_Age_Sex_Result <5, Unknown Sex, Negative	103
HTC_TST_DSD	HTS_TST_N_DSD_MN_Age_Sex_Result <5, Unknown Sex, Positive	3



HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Female, Negative	117
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Female, Positive	3
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Male, Negative	61
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Male, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Female, Negative	117
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Female, Positive	3
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Male, Negative	61
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Male, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Female, Negative	117
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Female, Positive	3
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Male, Negative	61
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Male, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Female, Negative	115
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Female, Positive	4
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Male, Negative	61
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Male, Positive	3
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 25-29, Female, Negative	1,231



HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 25-29, Female, Positive	15
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 30-34, Female, Negative	1,231
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 30-34, Female, Positive	15
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 35-39, Female, Negative	1,231
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 35-39, Female, Positive	16
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 40-49, Female, Negative	1,231
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 40-49, Female, Positive	15
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Female, Negative	18
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Female, Positive	2
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Male, Negative	9
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Male, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Female, Negative	18
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Female, Positive	2
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Male, Negative	9
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Male, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Female, Negative	18
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Female, Positive	2



HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Male, Negative	9
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Male, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Female, Negative	18
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Female, Positive	3
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Male, Negative	7
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Male, Positive	2
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Female, Negative	728
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Female, Positive	23
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Male, Negative	375
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Male, Positive	12
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Female, Negative	728
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Female, Positive	23
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Male, Negative	375
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Male, Positive	12
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Female, Negative	728
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Female, Positive	23
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Male, Negative	375



HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Male, Positive	12
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Female, Negative	732
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Female, Positive	20
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Male, Negative	378
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Male, Positive	11
TB_STAT_DSD	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	191
TB_STAT_DSD	Total number of registered new and relapsed TB cases, during the reporting period.	191
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	3
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	66
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	6
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	116
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	3
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	66
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	6



TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	116
GEND_GBV_DSD	Number of people receiving post-GBV care	9
GEND_GBV_DSD	By type of service: Sexual Violence (Post-Rape Care)	9
GEND_GBV_DSD	By PEP service provision (related to sexual violence services provided)	9
GEND_GBV_DSD	<10, Female, Sexual Violence (Post-Rape Care)	1
GEND_GBV_DSD	10-14, Female, Sexual Violence (Post-Rape Care)	4
GEND_GBV_DSD	15-19, Female, Sexual Violence (Post-Rape Care)	1
GEND_GBV_DSD	20-24, Female, Sexual Violence (Post-Rape Care)	3
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	42
TB_ART_DSD	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	1
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	14
TB_ART_DSD	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	2
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	25
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	128
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	102



PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	26
PMTCT_EID_DSD	Sum of Infant Age disaggregates	128
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	2,912
TX_CURR_DSD	Age/Sex: 15-19 Male	20
TX_CURR_DSD	Age/Sex: 15-19 Female	56
TX_CURR_DSD	Sum of age/sex disaggregates	76
TX_CURR_DSD	Age/Sex: <1	8
TX_CURR_DSD	Age/Sex: <1-9	102
TX_CURR_DSD	Age/Sex: 10-14 Male	18
TX_CURR_DSD	Age/Sex: 10-14 Female	22
TX_CURR_DSD	Age/Sex: 20-24 Male	55
TX_CURR_DSD	Age/Sex: 50+ Male	227
TX_CURR_DSD	Age/Sex: 20-24 Female	183
TX_CURR_DSD	Age/Sex: 50+ Female	249
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 25-29, Female, Positive	325
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 25-29, Male, Positive	168
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 30-34, Female, Positive	325
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 30-34, Male, Positive	168
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 35-39, Female, Positive	325
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 35-39, Male, Positive	168
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 40-49, Female, Positive	325
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 40-49, Male, Positive	168
TX_NEW_DSD	Number of adults and children newly enrolled on	776



	antiretroviral therapy (ART)	
TX_NEW_DSD	By Age/Sex: <1	1
TX_NEW_DSD	By Age/Sex: 1-9	23
TX_NEW_DSD	By Age/Sex: 10-14 Male	4
TX_NEW_DSD	By Age/Sex: 15-19 Male	5
TX_NEW_DSD	By Age/Sex: 20-24 Male	17
TX_NEW_DSD	By Age/Sex: 50+ Male	60
TX_NEW_DSD	By Age/Sex: 10-14 Female	4
TX_NEW_DSD	By Age/Sex: 15-19 Female	15
TX_NEW_DSD	By Age/Sex: 20-24 Female	49
TX_NEW_DSD	By Age/Sex: 50+ Female	66
TX_NEW_DSD	Sum of Age/Sex disaggregates	220
TX_NEW_DSD	Pregnancy status	79
TX_NEW_DSD	Breastfeeding status	9
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 25-29, Female, Positive	88
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 25-29, Male, Positive	45
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 30-34, Female, Positive	88
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 30-34, Male, Positive	45
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 35-39, Female, Positive	88
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 35-39, Male, Positive	45
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 40-49, Female, Positive	88
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 40-49, Male, Positive	45
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	2,524



TX_PVLS_DSD	Denominator: Indication: Routine	2,271
TX_PVLS_DSD	Denominator: Indication: Targeted	253
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Male Targeted	6
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Male Targeted	88
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Female Targeted	7
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Female Targeted	152
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Male Routine	45
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine	795
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Female Routine	69
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine	1,362
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	777
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	777
TX_RET_DSD	Numerator by Status: Pregnant	78
TX_RET_DSD	Numerator by Status: Breastfeeding	9
TX_RET_DSD	Denominator by Status: Pregnant	78
TX_RET_DSD	Denominator by Status: Breastfeeding	9
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	15
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	273



TX_RET_DSD	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	23
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	466
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	15
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	273
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	23
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	466
HTS_SELF_DSD	HTS_SELF_N_DSD	196
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Female, Directly-Assisted	7
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Female, Unassisted	7
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Male, Directly-Assisted	7
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Male, Unassisted	7



HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Female, Directly-Assisted	7
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Female, Unassisted	7
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Male, Directly-Assisted	7
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Male, Unassisted	7
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Female, Directly-Assisted	7
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Female, Unassisted	7
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Male, Directly-Assisted	7
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Male, Unassisted	7
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Female, Directly-Assisted	7
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Female, Unassisted	7
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Male, Directly-Assisted	7
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Male, Unassisted	7
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Female, Directly-Assisted	7
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Female, Unassisted	7
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Male, Directly-Assisted	7
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Male, Unassisted	7
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Female, Directly-Assisted	7



HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Female, Unassisted	7
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Male, Directly-Assisted	7
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Male, Unassisted	7
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Female, Directly-Assisted	7
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Female, Unassisted	7
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Male, Directly-Assisted	7
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Male, Unassisted	7
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTest Directly-Assisted	98
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTest Unassisted	98
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTestUser Unassisted - Other	31
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTestUser Unassisted - Self	31
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTestUser Unassisted - Sex Partner	36
TB_PREV_DSD	The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period	660
TB_PREV_DSD	The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting period).	733
TB_PREV_DSD	By Age/Sex (Denominator): <15, Female	22



TB_PREV_DSD	By Age/Sex (Denominator): <15, Male	15
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Female	440
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Male	256
TB_PREV_DSD	By Age/Sex (Numerator): <15, Female	20
TB_PREV_DSD	By Age/Sex (Numerator): <15, Male	12
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Female	397
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Male	231
TB_PREV_DSD	TB_PREV_D_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, New, Positive	733
TB_PREV_DSD	TB_PREV_N_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, New, Positive	660
TX_TB_DSD	Number of ART patients who were screened for TB at least once during the reporting period	2,912
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Female	88
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Male	58
TX_TB_DSD	Denominator: By Aggregated Age/Sex:15+, Female	1,748
TX_TB_DSD	Denominator: By Aggregated Age/Sex:15+, Male	1,018
TX_TB_DSD	Denominator: Number of ART patients who had a specimen sent for bacteriologic diagnosis of active TB disease	117
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Other (No Xpert)	4
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Smear Only	66
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Gene Xpert MTB / R if Assay	47
TX_TB_DSD	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, Already, TB Screen - Negative, Positive	2,261
TX_TB_DSD	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, Already, TB Screen - Positive, Positive	94
TX_TB_DSD	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, New, TB Screen - Negative, Positive	533
TX_TB_DSD	TX_TB_D_DSD_TBScreen_NewExistingART_HIV	22



	Life-long ART, New, TB Screen - Positive, Positive	
--	--	--

Implementing Mechanism Details

Mechanism ID: 18086	Mechanism Name: MEASURE Evaluation Phase IV	
Funding Agency: USAID	Procurement Type: Cooperative Agreement	
Prime Partner Name: Measure Evaluation		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: No	
Global Fund / Multilateral Engagement: N/A		
G2G: No	Managing Agency:	

Total All Funding Sources: 300,000	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 300,000	
Funding Source	Funding Amount
GHP-State	300,000

Cross-Cutting Budget Attribution(s)

Gender: GBV	45,000
Focus Area:	GBV Prevention
Sub Area:	Collection and Use of Gender-related Strategic Information

Budget Code Information

Mechanism ID:	18086	
Mechanism Name:	MEASURE Evaluation Phase IV	
Prime Partner Name:	Measure Evaluation	
Strategic Area	Budget Code	Planned Amount



Care	HKID	300,000
------	------	---------

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 18266	Mechanism Name: GHESKIO 1924
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Groupe Haitien d'Etude du Sarcome de Kaposi et des Infections Opportunistes	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 3,000,000	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 3,000,000	
Funding Source	Funding Amount
GHP-State	3,000,000

Cross-Cutting Budget Attribution(s)

Key Populations: FSW	100,000
Focus Area:	Implementation of core HIV prevention interventions for SWs consistent with PEPFAR guidance on sexual prevention
Focus Area:	Training of health workers and community outreach workers
Focus Area:	Conducting epidemiologic, social science, and operational research among SWs, their partners, and clients
Gender: GBV	150,000



Focus Area:	GBV Prevention
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Operation Research
Sub Area:	Capacity building
Focus Area:	Post GBV Care
Sub Area:	Collection and Use of Gender-related Strategic Information
Gender: Gender Equality	20,000
Focus Area:	Changing harmful gender norms and promoting positive gender norms
Sub Area:	Capacity building
Sub Area:	Operation Research
Key Populations: MSM and TG	100,000
Focus Area:	Monitoring and evaluation of MSM/TG programs
Focus Area:	Training of health workers and community outreach workers
Focus Area:	Implementation of core HIV prevention interventions for MSM/TG that are consistent with the current PEPFAR technical guidance
Adolescent Girls and Young Women (AGYW)	100,000

Budget Code Information

Mechanism ID:	18266	
Mechanism Name:	GHESKIO 1924	
Prime Partner Name:	Groupe Haitien d'Etude du Sarcome de Kaposi et des Infections Opportunistes	
Strategic Area	Budget Code	Planned Amount
Care	HBHC	318,668



Strategic Area	Budget Code	Planned Amount
Care	HKID	469,797
Strategic Area	Budget Code	Planned Amount
Care	HVTB	209,111
Strategic Area	Budget Code	Planned Amount
Care	PDCS	209,111
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	120,000
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	80,000
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	42,500
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	562,778
Strategic Area	Budget Code	Planned Amount



Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	146,591
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	632,333
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	209,111

Implementing Mechanism Indicator Information

Indicator Number	Label	2019
PMTCT_ART_DSD	Number of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy	372
PMTCT_ART_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	4,356
PMTCT_ART_DSD	New on ART	68
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	304
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	4,356
PMTCT_STAT_DSD	Number of new ANC and L&D clients	4,356
PMTCT_STAT_DSD	By Age (Denominator): <15-19	174



PMTCT_STAT_DSD	By Age (Denominator): 20-24	392
PMTCT_STAT_DSD	By Age (Denominator): 50+	610
PMTCT_STAT_DSD	By Number of known positives: 15-19	12
PMTCT_STAT_DSD	By Number of known positives: 20-24	26
PMTCT_STAT_DSD	By Number of known positives: 50+	41
PMTCT_STAT_DSD	By Number of new positives: 15-19	4
PMTCT_STAT_DSD	By Number of new positives: 20-24	8
PMTCT_STAT_DSD	By Number of new positives: 50+	13
PMTCT_STAT_DSD	By Number of new negative: 15-19	158
PMTCT_STAT_DSD	By Number of new negative: 20-24	356
PMTCT_STAT_DSD	By Number of new negative: 50+	554
PMTCT_STAT_DSD	By Age (Numerator): 15-19	174
PMTCT_STAT_DSD	By Age (Numerator): 20-24	392
PMTCT_STAT_DSD	By Age (Numerator): 50+	610
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 25-29, Female	795
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 30-34, Female	795
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 35-39, Female	795
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 40-49, Female	795
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 25-29, Female, Known at Entry Positive	54
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 25-29, Female, Newly Identified Negative	724
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 25-29, Female, Newly Identified Positive	18
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 30-34, Female, Known at Entry Positive	54
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 30-34, Female, Newly Identified Negative	724
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 30-34, Female, Newly Identified Positive	17
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 35-39, Female, Known at Entry Positive	55
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult	724



	35-39, Female, Newly Identified Negative	
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 35-39, Female, Newly Identified Positive	18
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 40-49, Female, Known at Entry Positive	54
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 40-49, Female, Newly Identified Negative	724
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 40-49, Female, Newly Identified Positive	17
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 25-29, Female	795
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 30-34, Female	795
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 35-39, Female	795
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 40-49, Female	795
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	38,795
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Female, Negative	71
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Male, Negative	104
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Male, Positive	5
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Female, Negative	23
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Male, Negative	16
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Female, Negative	99
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Female, Positive	3
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Male, Negative	57
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Male, Positive	1



HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Female, Negative	117
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Female, Positive	3
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Male, Negative	83
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Male, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: <1, Negative	24
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: <1, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 1-9, Negative	264
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 1-9, Positive	14
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Female, Negative	46
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Female, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative	31
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Male, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Female, Negative	195
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Female, Positive	5
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Male, Negative	113
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Male, Positive	4
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Female, Negative	233
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Female, Positive	7
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Male, Negative	164



HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Male, Positive	5
HTC_TST_DSD	Service Delivery Point (Facility) Pediatric : <5 Negative	2,013
HTC_TST_DSD	Service Delivery Point (Facility) Pediatric : <5 Positive	20
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Male, Negative	89
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Male, Positive	12
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Female, Negative	28
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Female, Positive	4
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Male, Negative	19
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Male, Positive	2
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Female, Negative	120
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Female, Positive	15
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Male, Negative	70
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Male, Positive	9
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Female, Negative	142
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Female, Positive	16
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Male, Negative	101
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Male, Positive	13
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Female, Negative	235
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Female, Positive	6



	Positive	
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Male, Negative	280
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Male, Positive	5
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Female, Negative	42
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Female, Positive	8
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Male, Negative	29
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Male, Positive	5
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Female, Negative	175
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Female, Positive	31
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Male, Negative	102
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Male, Positive	18
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Female, Negative	208
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Female, Positive	37
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Male, Negative	147
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Male, Positive	26
HTC_TST_DSD	Service Delivery Point (Facility) Index: <1, Negative	65
HTC_TST_DSD	Service Delivery Point (Facility) Index: <1, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) Index: 1-9, Negative	711
HTC_TST_DSD	Service Delivery Point (Facility) Index: 1-9, Positive	15
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 15-19, Negative	158



HTC_TST_DSD	Service Delivery Point (Facility) ANC: 15-19, Positive	4
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 20-24, Negative	356
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 20-24, Positive	8
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 50+, Negative	554
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 50+, Positive	13
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Female, Negative	348
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Female, Positive	10
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Male, Negative	238
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Male, Positive	7
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Female, Negative	1,481
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Female, Positive	44
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Male, Negative	861
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Male, Positive	26
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Female, Negative	1,763
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Female, Positive	53
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Male, Negative	1,246
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Male, Positive	38
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Female, Negative	286
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Female, Positive	51
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29,	155



	Male, Negative	
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Male, Positive	27
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Female, Negative	286
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Female, Positive	51
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Male, Negative	155
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Male, Positive	27
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Female, Negative	286
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Female, Positive	51
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Male, Negative	155
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Male, Positive	27
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Female, Negative	288
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Female, Positive	49
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Male, Negative	152
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Male, Positive	28
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Female, Negative	162
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Female, Positive	4
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Male, Negative	87
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Male, Positive	1



	Male, Positive	
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Female, Negative	162
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Female, Positive	4
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Male, Negative	87
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Male, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Female, Negative	162
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Female, Positive	4
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Male, Negative	87
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Male, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Female, Negative	160
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Female, Positive	2
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Male, Negative	87
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Male, Positive	5
HTC_TST_DSD	HTS_TST_N_DSD_MN_Age_Sex_Result <5, Unknown Sex, Negative	249
HTC_TST_DSD	HTS_TST_N_DSD_MN_Age_Sex_Result <5, Unknown Sex, Positive	5
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Female, Negative	320
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Female, Positive	9
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29,	172



	Male, Negative	
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Male, Positive	5
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Female, Negative	320
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Female, Positive	9
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Male, Negative	172
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Male, Positive	5
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Female, Negative	320
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Female, Positive	9
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Male, Negative	172
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Male, Positive	5
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Female, Negative	320
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Female, Positive	11
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Male, Negative	174
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Male, Positive	6
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 25-29, Female, Negative	724
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 25-29, Female, Positive	18
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 30-34, Female, Negative	724
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 30-34, Male, Positive	17



	Female, Positive	
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 35-39, Female, Negative	724
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 35-39, Female, Positive	18
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 40-49, Female, Negative	724
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 40-49, Female, Positive	17
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Female, Negative	197
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Female, Positive	25
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Male, Negative	106
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Male, Positive	13
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Female, Negative	197
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Female, Positive	25
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Male, Negative	106
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Male, Positive	13
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Female, Negative	197
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Female, Positive	25
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Male, Negative	106
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Male, Positive	13
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49,	196



	Female, Negative	
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Female, Positive	25
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Male, Negative	106
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Male, Positive	15
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Female, Negative	2,425
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Female, Positive	73
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Male, Negative	1,306
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Male, Positive	39
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Female, Negative	2,425
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Female, Positive	73
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Male, Negative	1,306
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Male, Positive	39
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Female, Negative	2,425
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Female, Positive	73
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Male, Negative	1,306
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Male, Positive	39
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Female, Negative	2,423
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Male, Negative	73



	Female, Positive	
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Male, Negative	1,308
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Male, Positive	40
TB_STAT_DSD	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	2,172
TB_STAT_DSD	Total number of registered new and relapsed TB cases, during the reporting period.	2,172
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	43
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	760
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	66
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	1,303
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	43
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	760
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	66
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	1,303
GEND_GBV_DSD	Number of people receiving post-GBV care	54



GEND_GBV_DSD	By type of service: Sexual Violence (Post-Rape Care)	54
GEND_GBV_DSD	By PEP service provision (related to sexual violence services provided)	54
GEND_GBV_DSD	<10, Female, Sexual Violence (Post-Rape Care)	7
GEND_GBV_DSD	10-14, Female, Sexual Violence (Post-Rape Care)	12
GEND_GBV_DSD	15-19, Female, Sexual Violence (Post-Rape Care)	11
GEND_GBV_DSD	20-24, Female, Sexual Violence (Post-Rape Care)	14
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 25-29, Female, Sexual Violence (Post-Rape Care)	4
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 30-34, Female, Sexual Violence (Post-Rape Care)	2
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 35-39, Female, Sexual Violence (Post-Rape Care)	2
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 40-49, Female, Sexual Violence (Post-Rape Care)	2
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	528
OVC_SERV_DSD	Age/Sex: 10-14 Male	47
OVC_SERV_DSD	Age/Sex: 15-17 Male	47
OVC_SERV_DSD	By: Age/sex: Male 18-24	48
OVC_SERV_DSD	By: Age/sex: Male 25+	48
OVC_SERV_DSD	Age/Sex: 10-14 Female	47
OVC_SERV_DSD	Age/Sex: 15-17 Female	47
OVC_SERV_DSD	By: Age/sex: 18-24 Female	47
OVC_SERV_DSD	By: Age/sex: 25+ Female	47
OVC_SERV_DSD	Sum of Age/Sex disaggregates	188
OVC_SERV_DSD	Age/Sex: <1	25
OVC_SERV_DSD	Age/Sex: 1-9	125
OVC_SERV_DSD	Program Completion: Active	500
OVC_SERV_DSD	Program Completion: Graduation	28
OVC_HIVSTAT_DSD	Number of orphans and vulnerable children (<18 years old) whose HIV status is known or unknown by the	3,578



	OVC implementing partner.	
OVC_HIVSTAT_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	528
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	355
TB_ART_DSD	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	7
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	125
TB_ART_DSD	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	10
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	213
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	371
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	297
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	74
PMTCT_EID_DSD	Sum of Infant Age disaggregates	371
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	16,558
TX_CURR_DSD	Age/Sex: 15-19 Male	184
TX_CURR_DSD	Age/Sex: 15-19 Female	269



TX_CURR_DSD	Sum of age/sex disaggregates	453
TX_CURR_DSD	Age/Sex: <1	26
TX_CURR_DSD	Age/Sex: <1-9	296
TX_CURR_DSD	Age/Sex: 10-14 Male	95
TX_CURR_DSD	Age/Sex: 10-14 Female	115
TX_CURR_DSD	Age/Sex: 20-24 Male	666
TX_CURR_DSD	Age/Sex: 50+ Male	964
TX_CURR_DSD	Age/Sex: 20-24 Female	1,144
TX_CURR_DSD	Age/Sex: 50+ Female	1,363
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 25-29, Female, Positive	1,874
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 25-29, Male, Positive	1,010
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 30-34, Female, Positive	1,874
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 30-34, Male, Positive	1,010
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 35-39, Female, Positive	1,874
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 35-39, Male, Positive	1,010
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 40-49, Female, Positive	1,824
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 40-49, Male, Positive	960
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	1,536
TX_NEW_DSD	By Age/Sex: <1	5
TX_NEW_DSD	By Age/Sex: 1-9	61
TX_NEW_DSD	By Age/Sex: 10-14 Male	18
TX_NEW_DSD	By Age/Sex: 15-19 Male	9
TX_NEW_DSD	By Age/Sex: 20-24 Male	69
TX_NEW_DSD	By Age/Sex: 50+ Male	289



TX_NEW_DSD	By Age/Sex: 10-14 Female	20
TX_NEW_DSD	By Age/Sex: 15-19 Female	36
TX_NEW_DSD	By Age/Sex: 20-24 Female	54
TX_NEW_DSD	By Age/Sex: 50+ Female	55
TX_NEW_DSD	Sum of Age/Sex disaggregates	550
TX_NEW_DSD	Pregnancy status	68
TX_NEW_DSD	Breastfeeding status	22
TX_NEW_DSD	FSW	214
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 25-29, Female, Positive	120
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 25-29, Male, Positive	110
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 30-34, Female, Positive	120
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 30-34, Male, Positive	110
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 35-39, Female, Positive	120
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 35-39, Male, Positive	110
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 40-49, Female, Positive	120
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 40-49, Male, Positive	110
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	15,960
TX_PVLS_DSD	Denominator: Indication: Routine	14,362
TX_PVLS_DSD	Denominator: Indication: Targeted	1,598
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Male Targeted	33
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Male Targeted	559



TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Female Targeted	48
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Female Targeted	958
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Male Routine	287
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine	5,027
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Female Routine	430
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine	8,618
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	1,972
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	1,972
TX_RET_DSD	Numerator by Status: Pregnant	197
TX_RET_DSD	Numerator by Status: Breastfeeding	24
TX_RET_DSD	Denominator by Status: Pregnant	197
TX_RET_DSD	Denominator by Status: Breastfeeding	24
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	39
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	690
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	60
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,183



TX_RET_DSD	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	39
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	690
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	60
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,183
HTS_SELF_DSD	HTS_SELF_N_DSD	1,064
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Female, Directly-Assisted	38
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Female, Unassisted	38
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Male, Directly-Assisted	38
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Male, Unassisted	38
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Female, Directly-Assisted	38
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Female, Unassisted	38
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Male, Directly-Assisted	38



HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Male, Unassisted	38
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Female, Directly-Assisted	38
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Female, Unassisted	38
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Male, Directly-Assisted	38
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Male, Unassisted	38
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Female, Directly-Assisted	38
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Female, Unassisted	38
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Male, Directly-Assisted	38
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Male, Unassisted	38
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Female, Directly-Assisted	38
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Female, Unassisted	38
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Male, Directly-Assisted	38
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Male, Unassisted	38
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Female, Directly-Assisted	38
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Female, Unassisted	38
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Male, Directly-Assisted	38
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Male, Unassisted	38



HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Female, Directly-Assisted	38
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Female, Unassisted	38
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Male, Directly-Assisted	38
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Male, Unassisted	38
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTest Directly-Assisted	532
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTest Unassisted	532
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTestUser Unassisted - Other	176
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTestUser Unassisted - Self	176
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTestUser Unassisted - Sex Partner	180
TB_PREV_DSD	The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period	1,545
TB_PREV_DSD	The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting period).	1,716
TB_PREV_DSD	By Age/Sex (Denominator): <15, Female	51
TB_PREV_DSD	By Age/Sex (Denominator): <15, Male	34
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Female	1,030
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Male	601
TB_PREV_DSD	By Age/Sex (Numerator): <15, Female	46
TB_PREV_DSD	By Age/Sex (Numerator): <15, Male	31
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Female	927



TB_PREV_DSD	By Age/Sex (Numerator): 15+, Male	541
TB_PREV_DSD	TB_PREV_D_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, New, Positive	1,716
TB_PREV_DSD	TB_PREV_N_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, New, Positive	1,545
TX_TB_DSD	Number of ART patients who were screened for TB at least once during the reporting period	17,046
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Female	512
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Male	341
TX_TB_DSD	Denominator: By Aggregated Age/Sex:15+, Female	10,228
TX_TB_DSD	Denominator: By Aggregated Age/Sex:15+, Male	5,965
TX_TB_DSD	Denominator: Number of ART patients who had a specimen sent for bacteriologic diagnosis of active TB disease	682
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Other (No Xpert)	23
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Smear Only	387
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Gene Xpert MTB / R if Assay	272
TX_TB_DSD	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, Already, TB Screen - Negative, Positive	13,241
TX_TB_DSD	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, Already, TB Screen - Positive, Positive	552
TX_TB_DSD	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, New, TB Screen - Negative, Positive	3,123
TX_TB_DSD	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, New, TB Screen - Positive, Positive	130

Implementing Mechanism Details

Mechanism ID: 18267	Mechanism Name: PIH 1926
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Partners in Health	
Agreement Start Date: Redacted	Agreement End Date: Redacted

Approved



TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:
Total All Funding Sources: 6,500,000	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 6,500,000	
Funding Source	Funding Amount
GHP-State	6,500,000

Cross-Cutting Budget Attribution(s)

Gender: GBV	100,000
Focus Area:	GBV Prevention
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Sub Area:	Operation Research
Focus Area:	Post GBV Care
Sub Area:	Monitoring and Evaluation
Key Populations: FSW	200,000
Focus Area:	Implementation of core HIV prevention interventions for SWs consistent with PEPFAR guidance on sexual prevention
Focus Area:	Training of health workers and community outreach workers
Focus Area:	Monitoring and evaluation of SW programs
Key Populations: MSM and TG	200,000
Focus Area:	Training of health workers and community outreach workers
Focus Area:	Implementation of core HIV prevention interventions



	for MSM/TG that are consistent with the current PEPFAR technical guidance
Focus Area:	Conducting epidemiologic, social science, and operational research among MSM/TG and their sex partners
Adolescent Girls and Young Women (AGYW)	100,000

Budget Code Information

Mechanism ID: 18267 Mechanism Name: PIH 1926 Prime Partner Name: Partners in Health		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	1,209,658
Strategic Area	Budget Code	Planned Amount
Care	HKID	1,106,888
Strategic Area	Budget Code	Planned Amount
Care	HVTB	395,278
Strategic Area	Budget Code	Planned Amount
Care	PDCS	390,387
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	596,839
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	502,399
Strategic Area	Budget Code	Planned Amount



Treatment	HTXS	1,521,098
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	777,453

Implementing Mechanism Indicator Information

Indicator Number	Label	2019
PMTCT_ART_DSD	Number of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy	853
PMTCT_ART_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	35,903
PMTCT_ART_DSD	New on ART	414
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	439
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	35,903
PMTCT_STAT_DSD	Number of new ANC and L&D clients	35,903
PMTCT_STAT_DSD	By Age (Denominator): <15-19	1,437
PMTCT_STAT_DSD	By Age (Denominator): 20-24	3,230
PMTCT_STAT_DSD	By Age (Denominator): 50+	5,028
PMTCT_STAT_DSD	By Number of known positives: 15-19	19
PMTCT_STAT_DSD	By Number of known positives: 20-24	43
PMTCT_STAT_DSD	By Number of known positives: 50+	66
PMTCT_STAT_DSD	By Number of new positives: 15-19	18
PMTCT_STAT_DSD	By Number of new positives: 20-24	39
PMTCT_STAT_DSD	By Number of new positives: 50+	61
PMTCT_STAT_DSD	By Number of new negative: 15-19	1,401
PMTCT_STAT_DSD	By Number of new negative: 20-24	3,150
PMTCT_STAT_DSD	By Number of new negative: 50+	4,895



PMTCT_STAT_DSD	By Age (Numerator): 15-19	1,437
PMTCT_STAT_DSD	By Age (Numerator): 20-24	3,230
PMTCT_STAT_DSD	By Age (Numerator): 50+	5,028
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 25-29, Female	6,553
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 30-34, Female	6,553
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 35-39, Female	6,552
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 40-49, Female	6,550
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 25-29, Female, Known at Entry Positive	85
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 25-29, Female, Newly Identified Negative	6,387
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 25-29, Female, Newly Identified Positive	81
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 30-34, Female, Known at Entry Positive	82
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 30-34, Female, Newly Identified Negative	6,387
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 30-34, Female, Newly Identified Positive	82
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 35-39, Female, Known at Entry Positive	83
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 35-39, Female, Newly Identified Negative	6,387
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 35-39, Female, Newly Identified Positive	81
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 40-49, Female, Known at Entry Positive	85
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 40-49, Female, Newly Identified Negative	6,387
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 40-49, Female, Newly Identified Positive	80
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 25-29, Female	6,553
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 30-34, Female	6,553



PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 35-39, Female	6,552
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 40-49, Female	6,550
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	145,937
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Male, Negative	411
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Male, Positive	20
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: <1, Negative	112
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: <1, Positive	5
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 1-9, Negative	1,360
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 1-9, Positive	70
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Female, Negative	79
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Female, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative	33
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Female, Negative	294
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Female, Positive	6
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Male, Negative	75
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Male, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Female, Negative	461
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Female, Positive	9
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Male, Negative	390
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Male,	8



	Positive	
HTC_TST_DSD	Service Delivery Point (Facility) Pediatric : <5 Negative	9,265
HTC_TST_DSD	Service Delivery Point (Facility) Pediatric : <5 Positive	93
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Male, Negative	68
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Male, Positive	7
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Female, Negative	26
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Female, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Male, Negative	10
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Female, Negative	74
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Female, Positive	8
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Male, Negative	25
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Male, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Female, Negative	134
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Female, Positive	21
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Male, Negative	127
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Male, Positive	17
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Female, Negative	990
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Female, Positive	21
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Male, Negative	1,091



HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Male, Positive	21
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Female, Negative	102
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Female, Positive	15
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Male, Negative	43
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Male, Positive	7
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Female, Negative	330
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Female, Positive	57
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Male, Negative	93
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Male, Positive	16
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Female, Negative	574
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Female, Positive	100
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Male, Negative	528
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Male, Positive	91
HTC_TST_DSD	Service Delivery Point (Facility) Index: <1, Negative	300
HTC_TST_DSD	Service Delivery Point (Facility) Index: <1, Positive	5
HTC_TST_DSD	Service Delivery Point (Facility) Index: 1-9, Negative	3,615
HTC_TST_DSD	Service Delivery Point (Facility) Index: 1-9, Positive	74
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 15-19, Negative	1,388
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 15-19, Positive	18
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 20-24, Negative	3,122
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 20-24, Positive	39



HTC_TST_DSD	Service Delivery Point (Facility) ANC: 50+, Negative	4,852
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 50+, Positive	61
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Female, Negative	1,398
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Female, Positive	28
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Male, Negative	614
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Male, Positive	11
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Female, Negative	4,526
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Female, Positive	93
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Male, Negative	1,298
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Male, Positive	25
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Female, Negative	7,946
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Female, Positive	165
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Male, Negative	7,344
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Male, Positive	151
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Female, Negative	638
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Female, Positive	113
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Male, Negative	347
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Male, Positive	62



HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Female, Negative	638
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Female, Positive	113
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Male, Negative	347
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Male, Positive	62
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Female, Negative	638
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Female, Positive	113
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Male, Negative	347
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Male, Positive	62
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Female, Negative	634
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Female, Positive	111
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Male, Negative	352
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Male, Positive	60
HTC_TST_DSD	HTS_TST_N_DSD_MN_Age_Sex_Result <5, Unknown Sex, Negative	1,235
HTC_TST_DSD	HTS_TST_N_DSD_MN_Age_Sex_Result <5, Unknown Sex, Positive	25
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Female, Negative	519
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Female, Positive	10
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Male, Negative	269



HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Male, Positive	6
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Female, Negative	519
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Female, Positive	10
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Male, Negative	269
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Male, Positive	6
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Female, Negative	519
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Female, Positive	10
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Male, Negative	269
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Male, Positive	6
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Female, Negative	517
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Female, Positive	12
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Male, Negative	267
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Male, Positive	4
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 25-29, Female, Negative	6,329
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 25-29, Female, Positive	81
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 30-34, Female, Negative	6,329
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 30-34, Female, Positive	81



HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 35-39, Female, Negative	6,329
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 35-39, Female, Positive	80
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 40-49, Female, Negative	6,329
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 40-49, Female, Positive	80
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Female, Negative	146
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Female, Positive	18
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Male, Negative	80
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Male, Positive	9
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Female, Negative	146
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Female, Positive	18
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Male, Negative	80
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Male, Positive	9
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Female, Negative	146
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Female, Positive	18
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Male, Negative	80
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Male, Positive	9
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Female, Negative	143



HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Female, Positive	18
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Male, Negative	80
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Male, Positive	15
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Female, Negative	8,833
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Female, Positive	179
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Male, Negative	4,839
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Male, Positive	99
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Female, Negative	8,833
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Female, Positive	179
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Male, Negative	4,839
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Male, Positive	99
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Female, Negative	8,833
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Female, Positive	179
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Male, Negative	4,839
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Male, Positive	99
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Female, Negative	8,831
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Female, Positive	189



HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Male, Negative	4,841
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Male, Positive	100
TB_STAT_DSD	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	1,665
TB_STAT_DSD	Total number of registered new and relapsed TB cases, during the reporting period.	1,665
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	32
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	585
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	49
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	999
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	32
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	585
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	49
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	999
GEND_GBV_DSD	Number of people receiving post-GBV care	33
GEND_GBV_DSD	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	22



GEND_GBV_DSD	By type of service: Sexual Violence (Post-Rape Care)	11
GEND_GBV_DSD	By PEP service provision (related to sexual violence services provided)	11
GEND_GBV_DSD	<10, Female, Sexual Violence (Post-Rape Care)	2
GEND_GBV_DSD	10-14, Female, Physical and/or Emotional Violence	2
GEND_GBV_DSD	10-14, Female, Sexual Violence (Post-Rape Care)	2
GEND_GBV_DSD	15-19, Female, Physical and/or Emotional Violence	2
GEND_GBV_DSD	15-19, Female, Sexual Violence (Post-Rape Care)	5
GEND_GBV_DSD	15-19, Male, Physical and/or Emotional Violence	2
GEND_GBV_DSD	20-24, Female, Physical and/or Emotional Violence	4
GEND_GBV_DSD	20-24, Female, Sexual Violence (Post-Rape Care)	2
GEND_GBV_DSD	20-24, Male, Physical and/or Emotional Violence	2
GEND_GBV_DSD	50+, Female, Physical and/or Emotional Violence	2
GEND_GBV_DSD	50+, Male, Physical and/or Emotional Violence	2
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 25-29, Female, Physical and/or Emotional Violence	2
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 30-34, Female, Physical and/or Emotional Violence	2
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 35-39, Female, Physical and/or Emotional Violence	2
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	13,985
OVC_SERV_DSD	Age/Sex: 10-14 Male	1,403
OVC_SERV_DSD	Age/Sex: 15-17 Male	1,142
OVC_SERV_DSD	By: Age/sex: Male 18-24	1,078
OVC_SERV_DSD	By: Age/sex: Male 25+	1,402
OVC_SERV_DSD	Age/Sex: 10-14 Female	1,421
OVC_SERV_DSD	Age/Sex: 15-17 Female	1,172
OVC_SERV_DSD	By: Age/sex: 18-24 Female	1,124
OVC_SERV_DSD	By: Age/sex: 25+ Female	2,023
OVC_SERV_DSD	Sum of Age/Sex disaggregates	5,138
OVC_SERV_DSD	Age/Sex: <1	488



OVC_SERV_DSD	Age/Sex: 1-9	2,732
OVC_SERV_DSD	Program Completion: Active	13,572
OVC_SERV_DSD	Program Completion: Graduation	413
OVC_HIVSTAT_DSD	Number of orphans and vulnerable children (<18 years old) whose HIV status is known or unknown by the OVC implementing partner.	7,156
OVC_HIVSTAT_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	13,985
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	356
TB_ART_DSD	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	8
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	124
TB_ART_DSD	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	12
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	212
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	857
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	685
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	172
PMTCT_EID_DSD	Sum of Infant Age disaggregates	857



TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	20,625
TX_CURR_DSD	Age/Sex: 15-19 Male	150
TX_CURR_DSD	Age/Sex: 15-19 Female	345
TX_CURR_DSD	Sum of age/sex disaggregates	495
TX_CURR_DSD	Age/Sex: <1	86
TX_CURR_DSD	Age/Sex: <1-9	1,041
TX_CURR_DSD	Age/Sex: 10-14 Male	280
TX_CURR_DSD	Age/Sex: 10-14 Female	308
TX_CURR_DSD	Age/Sex: 20-24 Male	318
TX_CURR_DSD	Age/Sex: 50+ Male	1,784
TX_CURR_DSD	Age/Sex: 20-24 Female	1,098
TX_CURR_DSD	Age/Sex: 50+ Female	1,939
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 25-29, Female, Positive	2,145
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 25-29, Male, Positive	1,174
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 30-34, Female, Positive	2,145
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 30-34, Male, Positive	1,174
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 35-39, Female, Positive	2,145
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 35-39, Male, Positive	1,174
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 40-49, Female, Positive	2,145
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 40-49, Male, Positive	1,174
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	4,035
TX_NEW_DSD	By Age/Sex: <1	19
TX_NEW_DSD	By Age/Sex: 1-9	256



TX_NEW_DSD	By Age/Sex: 10-14 Male	66
TX_NEW_DSD	By Age/Sex: 15-19 Male	30
TX_NEW_DSD	By Age/Sex: 20-24 Male	61
TX_NEW_DSD	By Age/Sex: 50+ Male	343
TX_NEW_DSD	By Age/Sex: 10-14 Female	71
TX_NEW_DSD	By Age/Sex: 15-19 Female	66
TX_NEW_DSD	By Age/Sex: 20-24 Female	213
TX_NEW_DSD	By Age/Sex: 50+ Female	358
TX_NEW_DSD	Sum of Age/Sex disaggregates	1,208
TX_NEW_DSD	Pregnancy status	414
TX_NEW_DSD	Breastfeeding status	49
TX_NEW_DSD	FSW	321
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 25-29, Female, Positive	413
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 25-29, Male, Positive	225
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 30-34, Female, Positive	413
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 30-34, Male, Positive	225
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 35-39, Female, Positive	413
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 35-39, Male, Positive	225
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 40-49, Female, Positive	413
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 40-49, Male, Positive	225
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	19,039
TX_PVLS_DSD	Denominator: Indication: Routine	17,134
TX_PVLS_DSD	Denominator: Indication: Targeted	1,905



TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Male Targeted	37
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Male Targeted	668
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Female Targeted	57
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Female Targeted	1,143
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Male Routine	343
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine	5,997
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Female Routine	514
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine	10,280
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	4,277
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	4,277
TX_RET_DSD	Numerator by Status: Pregnant	428
TX_RET_DSD	Numerator by Status: Breastfeeding	52
TX_RET_DSD	Denominator by Status: Pregnant	428
TX_RET_DSD	Denominator by Status: Breastfeeding	52
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	85
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,496
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on	129



	treatment at 12 months after initiating ART)	
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	2,567
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	85
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,496
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	129
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	2,567
HTS_SELF_DSD	HTS_SELF_N_DSD	1,252
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Female, Directly-Assisted	45
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Female, Unassisted	45
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Male, Directly-Assisted	45
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Male, Unassisted	45
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Female, Directly-Assisted	45



HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Female, Unassisted	45
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Male, Directly-Assisted	45
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Male, Unassisted	45
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Female, Directly-Assisted	45
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Female, Unassisted	45
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Male, Directly-Assisted	45
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Male, Unassisted	45
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Female, Directly-Assisted	45
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Female, Unassisted	45
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Male, Directly-Assisted	45
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Male, Unassisted	45
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Female, Directly-Assisted	45
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Female, Unassisted	45
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Male, Directly-Assisted	45
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Male, Unassisted	45
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Female, Directly-Assisted	45
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Female, Unassisted	45



HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Male, Directly-Assisted	45
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Male, Unassisted	45
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Female, Directly-Assisted	45
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Female, Unassisted	45
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Male, Directly-Assisted	41
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Male, Unassisted	41
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTest Directly-Assisted	626
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTest Unassisted	626
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTestUser Unassisted - Other	203
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTestUser Unassisted - Self	203
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTestUser Unassisted - Sex Partner	220
TB_PREV_DSD	The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period	3,564
TB_PREV_DSD	The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting period).	3,960
TB_PREV_DSD	By Age/Sex (Denominator): <15, Female	120
TB_PREV_DSD	By Age/Sex (Denominator): <15, Male	80
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Female	2,376



TB_PREV_DSD	By Age/Sex (Denominator): 15+, Male	1,384
TB_PREV_DSD	By Age/Sex (Numerator): <15, Female	106
TB_PREV_DSD	By Age/Sex (Numerator): <15, Male	70
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Female	2,140
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Male	1,248
TB_PREV_DSD	TB_PREV_D_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, New, Positive	3,960
TB_PREV_DSD	TB_PREV_N_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, New, Positive	3,564
TX_TB_DSD	Number of ART patients who were screened for TB at least once during the reporting period	21,226
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Female	637
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Male	424
TX_TB_DSD	Denominator: By Aggregated Age/Sex:15+, Female	12,737
TX_TB_DSD	Denominator: By Aggregated Age/Sex:15+, Male	7,428
TX_TB_DSD	Denominator: Number of ART patients who had a specimen sent for bacteriologic diagnosis of active TB disease	850
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Other (No Xpert)	31
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Smear Only	480
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Gene Xpert MTB / R if Assay	339
TX_TB_DSD	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, Already, TB Screen - Negative, Positive	16,488
TX_TB_DSD	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, Already, TB Screen - Positive, Positive	686
TX_TB_DSD	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, New, TB Screen - Negative, Positive	3,887
TX_TB_DSD	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, New, TB Screen - Positive, Positive	162

Implementing Mechanism Details



Mechanism ID: 18268	Mechanism Name: CMMB 1970
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Catholic Medical Mission Board	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 5,200,000	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 5,200,000	
Funding Source	Funding Amount
GHP-State	5,200,000

Cross-Cutting Budget Attribution(s)

Gender: GBV	100,000
Focus Area:	GBV Prevention
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Sub Area:	Operation Research
Focus Area:	Post GBV Care
Sub Area:	Collection and Use of Gender-related Strategic Information
Motor Vehicles: Purchased	36,000

Budget Code Information



Mechanism ID: 18268		
Mechanism Name: CMMB 1970		
Prime Partner Name: Catholic Medical Mission Board		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	1,427,920
Strategic Area	Budget Code	Planned Amount
Care	HVTB	551,280
Strategic Area	Budget Code	Planned Amount
Care	PDCS	240,400
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	983,999
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	280,000
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	1,476,001
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	240,400

Implementing Mechanism Indicator Information

Indicator Number	Label	2019
PMTCT_ART_DSD	Number of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy	487
PMTCT_ART_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received	28,033



	their results)	
PMTCT_ART_DSD	New on ART	283
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	204
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	28,033
PMTCT_STAT_DSD	Number of new ANC and L&D clients	28,033
PMTCT_STAT_DSD	By Age (Denominator): <15-19	1,121
PMTCT_STAT_DSD	By Age (Denominator): 20-24	2,523
PMTCT_STAT_DSD	By Age (Denominator): 50+	3,923
PMTCT_STAT_DSD	By Number of known positives: 15-19	9
PMTCT_STAT_DSD	By Number of known positives: 20-24	21
PMTCT_STAT_DSD	By Number of known positives: 50+	31
PMTCT_STAT_DSD	By Number of new positives: 15-19	12
PMTCT_STAT_DSD	By Number of new positives: 20-24	27
PMTCT_STAT_DSD	By Number of new positives: 50+	39
PMTCT_STAT_DSD	By Number of new negative: 15-19	1,101
PMTCT_STAT_DSD	By Number of new negative: 20-24	2,477
PMTCT_STAT_DSD	By Number of new negative: 50+	3,846
PMTCT_STAT_DSD	By Age (Numerator): 15-19	1,121
PMTCT_STAT_DSD	By Age (Numerator): 20-24	2,523
PMTCT_STAT_DSD	By Age (Numerator): 50+	3,923
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 25-29, Female	5,119
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 30-34, Female	5,118
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 35-39, Female	5,116
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 40-49, Female	5,113
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 25-29, Female, Known at Entry Positive	39
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 25-29, Female, Newly Identified Negative	5,023
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 25-29, Female, Newly Identified Positive	55



PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 30-34, Female, Known at Entry Positive	40
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 30-34, Female, Newly Identified Negative	5,022
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 30-34, Female, Newly Identified Positive	54
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 35-39, Female, Known at Entry Positive	38
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 35-39, Female, Newly Identified Negative	5,022
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 35-39, Female, Newly Identified Positive	55
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 40-49, Female, Known at Entry Positive	41
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 40-49, Female, Newly Identified Negative	5,022
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 40-49, Female, Newly Identified Positive	54
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 25-29, Female	5,119
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 30-34, Female	5,118
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 35-39, Female	5,116
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 40-49, Female	5,113
PrEP_NEW_DSD	Number of individuals who have been newly enrolled on oral antiretroviral pre-exposure prophylaxis (PrEP) in the reporting period to prevent HIV infection	20
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 25-29, Female	3
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 25-29, Male	3
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 30-34, Female	3
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 30-34, Male	3
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 35-39, Female	2
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 35-39, Male	2
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 40-49, Female	2
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 40-49, Male	2



PrEP_NEW_DSD	PrEP_NEW_N_DSD_KeyPopAbr Other Key Populations	20
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	128,325
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Female, Negative	203
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Male, Negative	177
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Male, Positive	9
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Female, Negative	166
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Female, Positive	2
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Male, Negative	44
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Female, Negative	464
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Female, Positive	5
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Male, Negative	180
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Male, Positive	2
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Female, Negative	349
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Female, Positive	13
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Male, Negative	350
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Male, Positive	10
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: <1, Negative	46



HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: <1, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 1-9, Negative	542
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 1-9, Positive	30
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Female, Negative	803
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Female, Positive	19
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative	266
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Male, Positive	4
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Female, Negative	2,388
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Female, Positive	59
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Male, Negative	818
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Male, Positive	20
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Female, Negative	3,344
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Female, Positive	72
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Male, Negative	3,023
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Male, Positive	67
HTC_TST_DSD	Service Delivery Point (Facility) Pediatric : <5 Negative	3,839
HTC_TST_DSD	Service Delivery Point (Facility) Pediatric : <5 Positive	38
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Male, Negative	74
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Male, Positive	9
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Female,	22



	Negative	
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Female, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Male, Negative	12
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Female, Negative	90
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Female, Positive	11
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Male, Negative	33
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Male, Positive	3
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Female, Negative	162
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Female, Positive	21
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Male, Negative	128
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Male, Positive	18
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Female, Negative	441
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Female, Positive	9
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Male, Negative	532
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Male, Positive	9
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Female, Negative	126
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Female, Positive	22
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Male, Negative	58



HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Male, Positive	10
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Female, Negative	434
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Female, Positive	77
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Male, Negative	174
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Male, Positive	32
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Female, Negative	636
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Female, Positive	112
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Male, Negative	527
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Male, Positive	93
HTC_TST_DSD	Service Delivery Point (Facility) Index: <1, Negative	137
HTC_TST_DSD	Service Delivery Point (Facility) Index: <1, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) Index: 1-9, Negative	1,605
HTC_TST_DSD	Service Delivery Point (Facility) Index: 1-9, Positive	31
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 15-19, Negative	1,101
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 15-19, Positive	12
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 20-24, Negative	2,477
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 20-24, Positive	27
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 50+, Negative	3,846
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 50+, Positive	39
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Female, Negative	840
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Female, Positive	22
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Male,	434



	Negative	
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Male, Positive	9
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Female, Negative	3,138
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Female, Positive	80
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Male, Negative	1,254
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Male, Positive	34
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Female, Negative	4,919
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Female, Positive	119
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Male, Negative	3,914
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Male, Positive	93
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Female, Negative	659
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Female, Positive	117
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Male, Negative	365
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Male, Positive	63
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Female, Negative	659
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Female, Positive	117
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Male, Negative	365
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Male, Positive	63



	Male, Positive	
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Female, Negative	659
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Female, Positive	117
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Male, Negative	365
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Male, Positive	63
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Female, Negative	659
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Female, Positive	114
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Male, Negative	376
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Male, Positive	70
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Female, Negative	366
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Female, Positive	9
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Male, Negative	232
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Male, Positive	6
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Female, Negative	366
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Female, Positive	9
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Male, Negative	232
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Male, Positive	6
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39,	366



	Female, Negative	
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Female, Positive	9
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Male, Negative	232
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Male, Positive	6
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Female, Negative	363
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Female, Positive	15
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Male, Negative	231
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Male, Positive	8
HTC_TST_DSD	HTS_TST_N_DSD_MN_Age_Sex_Result <5, Unknown Sex, Negative	478
HTC_TST_DSD	HTS_TST_N_DSD_MN_Age_Sex_Result <5, Unknown Sex, Positive	9
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Female, Negative	3,028
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Female, Positive	70
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Male, Negative	1,832
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Male, Positive	42
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Female, Negative	3,028
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Female, Positive	70
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Male, Negative	1,832
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Male, Positive	42



	Male, Positive	
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Female, Negative	3,028
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Female, Positive	70
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Male, Negative	1,832
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Male, Positive	42
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Female, Negative	3,025
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Female, Positive	68
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Male, Negative	1,838
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Male, Positive	44
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 25-29, Female, Negative	5,023
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 25-29, Female, Positive	55
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 30-34, Female, Negative	5,022
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 30-34, Female, Positive	54
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 35-39, Female, Negative	5,022
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 35-39, Female, Positive	55
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 40-49, Female, Negative	5,022
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 40-49, Female, Positive	54
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29,	157



	Female, Negative	
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Female, Positive	20
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Male, Negative	80
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Male, Positive	11
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Female, Negative	157
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Female, Positive	20
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Male, Negative	80
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Male, Positive	11
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Female, Negative	157
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Female, Positive	20
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Male, Negative	80
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Male, Positive	11
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Female, Negative	153
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Female, Positive	18
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Male, Negative	88
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Male, Positive	13
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Female, Negative	5,392
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Male, Negative	133



	Female, Positive	
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Male, Negative	2,882
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Male, Positive	72
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Female, Negative	5,392
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Female, Positive	133
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Male, Negative	2,882
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Male, Positive	72
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Female, Negative	5,392
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Female, Positive	133
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Male, Negative	2,882
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Male, Positive	72
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Female, Negative	5,391
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Female, Positive	138
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Male, Negative	2,876
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Male, Positive	74
TB_STAT_DSD	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	1,794
TB_STAT_DSD	Total number of registered new and relapsed TB cases, during the reporting period.	1,794
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Numerator: Number of	36



	registered new and relapsed TB cases with documented HIV status, during the reporting period)	
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	629
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	52
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	1,077
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	36
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	629
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	52
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	1,077
GEND_GBV_DSD	Number of people receiving post-GBV care	23
GEND_GBV_DSD	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	4
GEND_GBV_DSD	By type of service: Sexual Violence (Post-Rape Care)	19
GEND_GBV_DSD	By PEP service provision (related to sexual violence services provided)	19
GEND_GBV_DSD	10-14, Female, Physical and/or Emotional Violence	1
GEND_GBV_DSD	10-14, Female, Sexual Violence (Post-Rape Care)	9
GEND_GBV_DSD	10-14, Male, Physical and/or Emotional Violence	1
GEND_GBV_DSD	15-19, Female, Physical and/or Emotional Violence	1
GEND_GBV_DSD	15-19, Female, Sexual Violence (Post-Rape Care)	7



GEND_GBV_DSD	15-19, Male, Physical and/or Emotional Violence	1
GEND_GBV_DSD	20-24, Female, Sexual Violence (Post-Rape Care)	1
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 25-29, Female, Sexual Violence (Post-Rape Care)	2
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	320
TB_ART_DSD	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	6
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	112
TB_ART_DSD	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	10
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	192
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	487
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	391
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	96
PMTCT_EID_DSD	Sum of Infant Age disaggregates	487
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	18,797
TX_CURR_DSD	Age/Sex: 15-19 Male	157
TX_CURR_DSD	Age/Sex: 15-19 Female	354



TX_CURR_DSD	Sum of age/sex disaggregates	511
TX_CURR_DSD	Age/Sex: <1	64
TX_CURR_DSD	Age/Sex: <1-9	728
TX_CURR_DSD	Age/Sex: 10-14 Male	218
TX_CURR_DSD	Age/Sex: 10-14 Female	263
TX_CURR_DSD	Age/Sex: 20-24 Male	451
TX_CURR_DSD	Age/Sex: 50+ Male	1,616
TX_CURR_DSD	Age/Sex: 20-24 Female	1,189
TX_CURR_DSD	Age/Sex: 50+ Female	1,929
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 25-29, Female, Positive	1,891
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 25-29, Male, Positive	1,066
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 30-34, Female, Positive	1,891
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 30-34, Male, Positive	1,066
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 35-39, Female, Positive	1,891
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 35-39, Male, Positive	1,066
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 40-49, Female, Positive	1,891
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 40-49, Male, Positive	1,066
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	4,089
TX_NEW_DSD	By Age/Sex: <1	9
TX_NEW_DSD	By Age/Sex: 1-9	102
TX_NEW_DSD	By Age/Sex: 10-14 Male	27
TX_NEW_DSD	By Age/Sex: 15-19 Male	32
TX_NEW_DSD	By Age/Sex: 20-24 Male	132
TX_NEW_DSD	By Age/Sex: 50+ Male	447



TX_NEW_DSD	By Age/Sex: 10-14 Female	31
TX_NEW_DSD	By Age/Sex: 15-19 Female	93
TX_NEW_DSD	By Age/Sex: 20-24 Female	266
TX_NEW_DSD	By Age/Sex: 50+ Female	326
TX_NEW_DSD	Sum of Age/Sex disaggregates	1,354
TX_NEW_DSD	Pregnancy status	284
TX_NEW_DSD	Breastfeeding status	49
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 25-29, Female, Positive	400
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 25-29, Male, Positive	256
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 30-34, Female, Positive	400
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 30-34, Male, Positive	256
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 35-39, Female, Positive	400
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 35-39, Male, Positive	256
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 40-49, Female, Positive	400
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 40-49, Male, Positive	256
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	16,551
TX_PVLS_DSD	Denominator: Indication: Routine	14,892
TX_PVLS_DSD	Denominator: Indication: Targeted	1,659
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Male Targeted	34
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Male Targeted	582
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Female Targeted	49



TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Female Targeted	994
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Male Routine	298
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine	5,211
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Female Routine	445
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine	8,938
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	4,076
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	4,076
TX_RET_DSD	Numerator by Status: Pregnant	408
TX_RET_DSD	Numerator by Status: Breastfeeding	49
TX_RET_DSD	Denominator by Status: Pregnant	408
TX_RET_DSD	Denominator by Status: Breastfeeding	49
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	81
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,427
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	122
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	2,446
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the	81



	12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,427
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	122
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	2,446
HTS_SELF_DSD	HTS_SELF_N_DSD	1,204
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Female, Directly-Assisted	43
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Female, Unassisted	43
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Male, Directly-Assisted	43
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Male, Unassisted	43
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Female, Directly-Assisted	43
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Female, Unassisted	43
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Male, Directly-Assisted	43
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Male, Unassisted	43



HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Female, Directly-Assisted	43
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Female, Unassisted	43
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Male, Directly-Assisted	43
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Male, Unassisted	43
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Female, Directly-Assisted	43
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Female, Unassisted	43
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Male, Directly-Assisted	43
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Male, Unassisted	43
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Female, Directly-Assisted	43
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Female, Unassisted	43
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Male, Directly-Assisted	43
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Male, Unassisted	43
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Female, Directly-Assisted	43
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Female, Unassisted	43
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Male, Directly-Assisted	43
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Male, Unassisted	43
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Female, Directly-Assisted	43

HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Female, Unassisted	43
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Male, Directly-Assisted	43
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Male, Unassisted	43
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTest Directly-Assisted	602
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTest Unassisted	602
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTestUser Unassisted - Other	194
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTestUser Unassisted - Self	194
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTestUser Unassisted - Sex Partner	214
TB_PREV_DSD	The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period	3,419
TB_PREV_DSD	The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting period).	3,795
TB_PREV_DSD	By Age/Sex (Denominator): <15, Female	114
TB_PREV_DSD	By Age/Sex (Denominator): <15, Male	75
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Female	2,278
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Male	1,328
TB_PREV_DSD	By Age/Sex (Numerator): <15, Female	101
TB_PREV_DSD	By Age/Sex (Numerator): <15, Male	68
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Female	2,052
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Male	1,198
TB_PREV_DSD	TB_PREV_D_DSD_TherapyType_NewExArt_HIV IPT,	3,795



	Life-long ART, New, Positive	
TB_PREV_DSD	TB_PREV_N_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, New, Positive	3,419
TX_TB_DSD	Number of ART patients who were screened for TB at least once during the reporting period	18,695
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Female	562
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Male	374
TX_TB_DSD	Denominator: By Aggregated Age/Sex:15+, Female	11,117
TX_TB_DSD	Denominator: By Aggregated Age/Sex:15+, Male	6,542
TX_TB_DSD	Denominator: Number of ART patients who had a specimen sent for bacteriologic diagnosis of active TB disease	748
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Other (No Xpert)	27
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Smear Only	425
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Gene Xpert MTB / R if Assay	296
TX_TB_DSD	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, Already, TB Screen - Negative, Positive	14,524
TX_TB_DSD	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, Already, TB Screen - Positive, Positive	605
TX_TB_DSD	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, New, TB Screen - Negative, Positive	3,423
TX_TB_DSD	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, New, TB Screen - Positive, Positive	143

Implementing Mechanism Details

Mechanism ID: 18269	Mechanism Name: GHESKIO 1969
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Groupe Haitien d'Etude du Sarcome de Kaposi et des Infections Opportunistes	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	

Approved



G2G: No	Managing Agency:
Total All Funding Sources: 4,600,000	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 4,600,000	
Funding Source	Funding Amount
GHP-State	4,600,000

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	18269	
Mechanism Name:	GHESKIO 1969	
Prime Partner Name:	Groupe Haitien d'Etude du Sarcome de Kaposi et des Infections Opportunistes	
Strategic Area	Budget Code	Planned Amount
Care	HBHC	638,486
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	638,486
Strategic Area	Budget Code	Planned Amount
Care	PDCS	127,697
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0



Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	1,064,142
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	343,429
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount



Treatment	HTXS	1,574,931
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	212,829

Implementing Mechanism Indicator Information

Indicator Number	Label	2019
PMTCT_ART_DSD	Number of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy	359
PMTCT_ART_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	17,671
PMTCT_ART_DSD	New on ART	133
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	226
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	17,671
PMTCT_STAT_DSD	Number of new ANC and L&D clients	17,671
PMTCT_STAT_DSD	By Age (Denominator): <15-19	707
PMTCT_STAT_DSD	By Age (Denominator): 20-24	1,591
PMTCT_STAT_DSD	By Age (Denominator): 50+	2,473
PMTCT_STAT_DSD	By Number of known positives: 15-19	8
PMTCT_STAT_DSD	By Number of known positives: 20-24	19
PMTCT_STAT_DSD	By Number of known positives: 50+	30
PMTCT_STAT_DSD	By Number of new positives: 15-19	5
PMTCT_STAT_DSD	By Number of new positives: 20-24	13
PMTCT_STAT_DSD	By Number of new positives: 50+	22
PMTCT_STAT_DSD	By Number of new negative: 15-19	690
PMTCT_STAT_DSD	By Number of new negative: 20-24	1,557
PMTCT_STAT_DSD	By Number of new negative: 50+	2,415



PMTCT_STAT_DSD	By Age (Numerator): 15-19	707
PMTCT_STAT_DSD	By Age (Numerator): 20-24	1,591
PMTCT_STAT_DSD	By Age (Numerator): 50+	2,473
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 25-29, Female	3,230
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 30-34, Female	3,225
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 35-39, Female	3,223
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 40-49, Female	3,222
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 25-29, Female, Known at Entry Positive	40
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 25-29, Female, Newly Identified Negative	3,156
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 25-29, Female, Newly Identified Positive	28
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 30-34, Female, Known at Entry Positive	39
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 30-34, Female, Newly Identified Negative	3,156
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 30-34, Female, Newly Identified Positive	30
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 35-39, Female, Known at Entry Positive	41
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 35-39, Female, Newly Identified Negative	3,156
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 35-39, Female, Newly Identified Positive	31
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 40-49, Female, Known at Entry Positive	40
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 40-49, Female, Newly Identified Negative	3,156
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 40-49, Female, Newly Identified Positive	32
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 25-29, Female	3,230
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 30-34, Female	3,225



PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 35-39, Female	3,223
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 40-49, Female	3,222
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	76,859
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Female, Negative	118
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Male, Negative	338
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Male, Positive	13
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Female, Negative	43
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Male, Negative	27
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Female, Negative	158
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Female, Positive	2
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Male, Negative	91
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Female, Negative	176
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Female, Positive	3
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Male, Negative	123
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Male, Positive	2
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: <1, Negative	63
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: <1, Positive	3
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 1-9, Negative	616
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 1-9, Positive	33
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19,	68



	Female, Negative	
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative	47
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Female, Negative	284
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Female, Positive	7
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Male, Negative	165
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Male, Positive	4
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Female, Negative	334
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Female, Positive	8
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Male, Negative	236
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Male, Positive	5
HTC_TST_DSD	Service Delivery Point (Facility) Pediatric : <5 Negative	5,381
HTC_TST_DSD	Service Delivery Point (Facility) Pediatric : <5 Positive	54
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Male, Negative	93
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Male, Positive	12
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Female, Negative	32
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Female, Positive	2
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Male, Negative	21
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Male, Positive	2
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Female,	126



	Negative	
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Female, Positive	15
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Male, Negative	74
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Male, Positive	8
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Female, Negative	145
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Female, Positive	22
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Male, Negative	106
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Male, Positive	12
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Female, Negative	709
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Female, Positive	18
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Male, Negative	911
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Male, Positive	14
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Female, Negative	68
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Female, Positive	10
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Male, Negative	46
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Male, Positive	6
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Female, Negative	274
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Female, Positive	48



HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Male, Negative	159
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Male, Positive	28
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Female, Negative	311
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Female, Positive	55
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Male, Negative	221
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Male, Positive	38
HTC_TST_DSD	Service Delivery Point (Facility) Index: <1, Negative	172
HTC_TST_DSD	Service Delivery Point (Facility) Index: <1, Positive	3
HTC_TST_DSD	Service Delivery Point (Facility) Index: 1-9, Negative	1,658
HTC_TST_DSD	Service Delivery Point (Facility) Index: 1-9, Positive	33
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 15-19, Negative	690
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 15-19, Positive	5
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 20-24, Negative	1,557
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 20-24, Positive	13
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 50+, Negative	2,415
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 50+, Positive	22
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Female, Negative	627
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Female, Positive	19
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Male, Negative	410
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Male, Positive	10
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Female, Negative	2,471
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Female, Positive	70



	Positive	
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Male, Negative	1,429
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Male, Positive	40
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Female, Negative	2,743
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Female, Positive	80
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Male, Negative	1,955
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Male, Positive	55
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Female, Negative	449
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Female, Positive	80
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Male, Negative	243
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Male, Positive	44
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Female, Negative	449
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Female, Positive	80
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Male, Negative	243
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Male, Positive	44
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Female, Negative	449
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Female, Positive	80
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Male, Negative	243



	Male, Negative	
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Male, Positive	44
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Female, Negative	447
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Female, Positive	77
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Male, Negative	244
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Male, Positive	39
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Female, Negative	271
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Female, Positive	5
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Male, Negative	146
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Male, Positive	3
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Female, Negative	271
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Female, Positive	5
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Male, Negative	146
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Male, Positive	3
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Female, Negative	271
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Female, Positive	5
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Male, Negative	146
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Male, Positive	3



	Male, Positive	
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Female, Negative	265
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Female, Positive	11
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Male, Negative	145
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Male, Positive	7
HTC_TST_DSD	HTS_TST_N_DSD_MN_Age_Sex_Result <5, Unknown Sex, Negative	667
HTC_TST_DSD	HTS_TST_N_DSD_MN_Age_Sex_Result <5, Unknown Sex, Positive	14
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Female, Negative	466
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Female, Positive	16
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Male, Negative	250
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Male, Positive	5
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Female, Negative	466
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Female, Positive	16
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Male, Negative	250
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Male, Positive	5
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Female, Negative	466
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Female, Positive	16
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Male, Negative	250



	Male, Negative	
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Male, Positive	5
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Female, Negative	466
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Female, Positive	10
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Male, Negative	255
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Male, Positive	14
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 25-29, Female, Negative	3,156
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 25-29, Female, Positive	28
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 30-34, Female, Negative	3,156
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 30-34, Female, Positive	30
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 35-39, Female, Negative	3,156
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 35-39, Female, Positive	31
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 40-49, Female, Negative	3,156
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 40-49, Female, Positive	32
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Female, Negative	206
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Female, Positive	25
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Male, Negative	113
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Male, Positive	13



	Male, Positive	
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Female, Negative	206
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Female, Positive	25
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Male, Negative	113
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Male, Positive	13
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Female, Negative	206
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Female, Positive	25
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Male, Negative	113
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Male, Positive	13
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Female, Negative	204
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Female, Positive	30
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Male, Negative	116
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Male, Positive	20
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Female, Negative	4,032
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Female, Positive	116
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Male, Negative	2,192
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Male, Positive	62
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Male, Positive	4,032



	Female, Negative	
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Female, Positive	116
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Male, Negative	2,192
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Male, Positive	62
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Female, Negative	4,032
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Female, Positive	116
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Male, Negative	2,192
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Male, Positive	62
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Female, Negative	4,037
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Female, Positive	113
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Male, Negative	2,191
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Male, Positive	66
TB_STAT_DSD	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	2,329
TB_STAT_DSD	Total number of registered new and relapsed TB cases, during the reporting period.	2,329
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	46
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	815
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Numerator: Number	70



	of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	1,398
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	46
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	815
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	70
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	1,398
GEND_GBV_DSD	Number of people receiving post-GBV care	51
GEND_GBV_DSD	By type of service: Sexual Violence (Post-Rape Care)	51
GEND_GBV_DSD	By PEP service provision (related to sexual violence services provided)	51
GEND_GBV_DSD	<10, Female, Sexual Violence (Post-Rape Care)	6
GEND_GBV_DSD	10-14, Female, Sexual Violence (Post-Rape Care)	7
GEND_GBV_DSD	15-19, Female, Sexual Violence (Post-Rape Care)	12
GEND_GBV_DSD	20-24, Female, Sexual Violence (Post-Rape Care)	13
GEND_GBV_DSD	20-24, Male, Sexual Violence (Post-Rape Care)	1
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 25-29, Female, Sexual Violence (Post-Rape Care)	2
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 25-29, Male, Sexual Violence (Post-Rape Care)	1
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 30-34, Female, Sexual Violence (Post-Rape Care)	2
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 30-34, Male, Sexual Violence (Post-Rape Care)	1



GEND_GBVDSD	GEND_GBVDSD_Age_Sex_ViolenceType_v3 35-39, Female, Sexual Violence (Post-Rape Care)	2
GEND_GBVDSD	GEND_GBVDSD_Age_Sex_ViolenceType_v3 35-39, Male, Sexual Violence (Post-Rape Care)	1
GEND_GBVDSD	GEND_GBVDSD_Age_Sex_ViolenceType_v3 40-49, Female, Sexual Violence (Post-Rape Care)	2
GEND_GBVDSD	GEND_GBVDSD_Age_Sex_ViolenceType_v3 40-49, Male, Sexual Violence (Post-Rape Care)	1
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	509
TB_ART_DSD	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	9
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	180
TB_ART_DSD	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	15
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	305
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	358
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	287
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	71
PMTCT_EID_DSD	Sum of Infant Age disaggregates	358
TX_CURR_DSD	Number of adults and children receiving antiretroviral	18,561



	therapy (ART)	
TX_CURR_DSD	Age/Sex: 15-19 Male	211
TX_CURR_DSD	Age/Sex: 15-19 Female	312
TX_CURR_DSD	Sum of age/sex disaggregates	523
TX_CURR_DSD	Age/Sex: <1	45
TX_CURR_DSD	Age/Sex: <1-9	446
TX_CURR_DSD	Age/Sex: 10-14 Male	182
TX_CURR_DSD	Age/Sex: 10-14 Female	234
TX_CURR_DSD	Age/Sex: 20-24 Male	718
TX_CURR_DSD	Age/Sex: 50+ Male	1,093
TX_CURR_DSD	Age/Sex: 20-24 Female	1,231
TX_CURR_DSD	Age/Sex: 50+ Female	1,433
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 25-29, Female, Positive	2,032
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 25-29, Male, Positive	1,132
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 30-34, Female, Positive	2,032
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 30-34, Male, Positive	1,132
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 35-39, Female, Positive	2,032
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 35-39, Male, Positive	1,132
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 40-49, Female, Positive	2,032
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 40-49, Male, Positive	1,132
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	2,686
TX_NEW_DSD	By Age/Sex: <1	11
TX_NEW_DSD	By Age/Sex: 1-9	109
TX_NEW_DSD	By Age/Sex: 10-14 Male	45



TX_NEW_DSD	By Age/Sex: 15-19 Male	29
TX_NEW_DSD	By Age/Sex: 20-24 Male	101
TX_NEW_DSD	By Age/Sex: 50+ Male	158
TX_NEW_DSD	By Age/Sex: 10-14 Female	59
TX_NEW_DSD	By Age/Sex: 15-19 Female	45
TX_NEW_DSD	By Age/Sex: 20-24 Female	172
TX_NEW_DSD	By Age/Sex: 50+ Female	197
TX_NEW_DSD	Sum of Age/Sex disaggregates	806
TX_NEW_DSD	Pregnancy status	134
TX_NEW_DSD	Breastfeeding status	30
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 25-29, Female, Positive	283
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 25-29, Male, Positive	157
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 30-34, Female, Positive	283
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 30-34, Male, Positive	157
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 35-39, Female, Positive	283
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 35-39, Male, Positive	157
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 40-49, Female, Positive	283
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 40-49, Male, Positive	157
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	17,700
TX_PVLS_DSD	Denominator: Indication: Routine	15,929
TX_PVLS_DSD	Denominator: Indication: Targeted	1,771
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Male Targeted	37



TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Male Targeted	619
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Female Targeted	54
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Female Targeted	1,061
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Male Routine	319
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine	5,577
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Female Routine	477
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine	9,556
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	2,704
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	2,704
TX_RET_DSD	Numerator by Status: Pregnant	270
TX_RET_DSD	Numerator by Status: Breastfeeding	32
TX_RET_DSD	Denominator by Status: Pregnant	270
TX_RET_DSD	Denominator by Status: Breastfeeding	32
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	54
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	947
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	81
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number	1,622



	of adults and children who are still alive and on treatment at 12 months after initiating ART)	
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	54
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	947
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	81
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,622
HTS_SELF_DSD	HTS_SELF_N_DSD	1,232
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Female, Directly-Assisted	44
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Female, Unassisted	44
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Male, Directly-Assisted	44
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Male, Unassisted	44
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Female, Directly-Assisted	44
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Female, Unassisted	44



HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Male, Directly-Assisted	44
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Male, Unassisted	44
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Female, Directly-Assisted	44
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Female, Unassisted	44
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Male, Directly-Assisted	44
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Male, Unassisted	44
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Female, Directly-Assisted	44
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Female, Unassisted	44
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Male, Directly-Assisted	44
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Male, Unassisted	44
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Female, Directly-Assisted	44
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Female, Unassisted	44
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Male, Directly-Assisted	44
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Male, Unassisted	44
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Female, Directly-Assisted	44
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Female, Unassisted	44
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Male, Directly-Assisted	44



HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Male, Unassisted	44
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Female, Directly-Assisted	44
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Female, Unassisted	44
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Male, Directly-Assisted	44
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Male, Unassisted	44
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTest Directly-Assisted	616
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTest Unassisted	616
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTestUser Unassisted - Other	199
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTestUser Unassisted - Self	199
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTestUser Unassisted - Sex Partner	218
TB_PREV_DSD	The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period	2,186
TB_PREV_DSD	The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting period).	2,428
TB_PREV_DSD	By Age/Sex (Denominator): <15, Female	73
TB_PREV_DSD	By Age/Sex (Denominator): <15, Male	48
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Female	1,458
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Male	849
TB_PREV_DSD	By Age/Sex (Numerator): <15, Female	65



TB_PREV_DSD	By Age/Sex (Numerator): <15, Male	45
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Female	1,311
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Male	765
TB_PREV_DSD	TB_PREV_D_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, New, Positive	2,428
TB_PREV_DSD	TB_PREV_N_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, New, Positive	2,186
TX_TB_DSD	Number of ART patients who were screened for TB at least once during the reporting period	18,953
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Female	570
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Male	381
TX_TB_DSD	Denominator: By Aggregated Age/Sex:15+, Female	11,371
TX_TB_DSD	Denominator: By Aggregated Age/Sex:15+, Male	6,631
TX_TB_DSD	Denominator: Number of ART patients who had a specimen sent for bacteriologic diagnosis of active TB disease	756
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Other (No Xpert)	25
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Smear Only	428
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Gene Xpert MTB / R if Assay	303
TX_TB_DSD	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, Already, TB Screen - Negative, Positive	14,723
TX_TB_DSD	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, Already, TB Screen - Positive, Positive	615
TX_TB_DSD	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, New, TB Screen - Negative, Positive	3,467
TX_TB_DSD	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, New, TB Screen - Positive, Positive	145

Implementing Mechanism Details

Mechanism ID: 18270	Mechanism Name: FOSREF 1925
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement



Prime Partner Name: Foundation for Reproductive Health and Family Education	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 1,700,000	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 1,700,000	
Funding Source	Funding Amount
GHP-State	1,700,000

Cross-Cutting Budget Attribution(s)

Key Populations: MSM and TG	753,124
Focus Area:	Training of health workers and community outreach workers
Focus Area:	Implementation of core HIV prevention interventions for MSM/TG that are consistent with the current PEPFAR technical guidance
Focus Area:	Monitoring and evaluation of MSM/TG programs
Focus Area:	Conducting epidemiologic, social science, and operational research among MSM/TG and their sex partners
Key Populations: FSW	946,876
Focus Area:	Implementation of core HIV prevention interventions for SWs consistent with PEPFAR guidance on sexual prevention
Focus Area:	Training of health workers and community outreach workers
Focus Area:	Collection and use of strategic information on SWs and clients
Focus Area:	Monitoring and evaluation of SW programs



Focus Area:	Conducting epidemiologic, social science, and operational research among SWs, their partners, and clients
Gender: GBV	50,000
Focus Area:	GBV Prevention
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Monitoring and Evaluation

Budget Code Information

Mechanism ID: 18270		
Mechanism Name: FOSREF 1925		
Prime Partner Name: Foundation for Reproductive Health and Family Education		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	301,155
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	86,045
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount



Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	172,088
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	557,279
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	282,279
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	301,154



Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2019
PMTCT_ART_DSD	Number of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy	76
PMTCT_ART_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	2,020
PMTCT_ART_DSD	New on ART	38
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	38
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	2,020
PMTCT_STAT_DSD	Number of new ANC and L&D clients	2,020
PMTCT_STAT_DSD	By Age (Denominator): <15-19	79
PMTCT_STAT_DSD	By Age (Denominator): 20-24	181
PMTCT_STAT_DSD	By Age (Denominator): 50+	283
PMTCT_STAT_DSD	By Number of known positives: 15-19	1
PMTCT_STAT_DSD	By Number of known positives: 20-24	3
PMTCT_STAT_DSD	By Number of known positives: 50+	6
PMTCT_STAT_DSD	By Number of new positives: 15-19	2
PMTCT_STAT_DSD	By Number of new positives: 20-24	2
PMTCT_STAT_DSD	By Number of new positives: 50+	5
PMTCT_STAT_DSD	By Number of new negative: 15-19	77
PMTCT_STAT_DSD	By Number of new negative: 20-24	174
PMTCT_STAT_DSD	By Number of new negative: 50+	271
PMTCT_STAT_DSD	By Age (Numerator): 15-19	79



PMTCT_STAT_DSD	By Age (Numerator): 20-24	181
PMTCT_STAT_DSD	By Age (Numerator): 50+	283
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 25-29, Female	371
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 30-34, Female	370
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 35-39, Female	369
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 40-49, Female	367
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 25-29, Female, Known at Entry Positive	9
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 25-29, Female, Newly Identified Negative	351
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 25-29, Female, Newly Identified Positive	7
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 30-34, Female, Known at Entry Positive	9
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 30-34, Female, Newly Identified Negative	351
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 30-34, Female, Newly Identified Positive	7
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 35-39, Female, Known at Entry Positive	8
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 35-39, Female, Newly Identified Negative	352
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 35-39, Female, Newly Identified Positive	6
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 40-49, Female, Known at Entry Positive	11
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 40-49, Female, Newly Identified Negative	352
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 40-49, Female, Newly Identified Positive	10
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 25-29, Female	371
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 30-34, Female	370
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 35-39, Female	369



PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 40-49, Female	367
PrEP_NEW_DSD	Number of individuals who have been newly enrolled on oral antiretroviral pre-exposure prophylaxis (PrEP) in the reporting period to prevent HIV infection	330
PrEP_NEW_DSD	Male 15-19	8
PrEP_NEW_DSD	Male 20-24	31
PrEP_NEW_DSD	Male 50+	6
PrEP_NEW_DSD	Female 15-19	9
PrEP_NEW_DSD	Female 20-24	32
PrEP_NEW_DSD	Female 50+	7
PrEP_NEW_DSD	FSW	172
PrEP_NEW_DSD	MSM	153
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 25-29, Female	46
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 25-29, Male	47
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 30-34, Female	40
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 30-34, Male	35
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 35-39, Female	23
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 35-39, Male	19
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 40-49, Female	15
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 40-49, Male	12
PrEP_NEW_DSD	PrEP_NEW_N_DSD_KeyPopAbr Other Key Populations	5
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	16,400
PP_PREV_DSD	Age/sex: 10-14 Male	45
PP_PREV_DSD	Age/sex: 15-19 Male	1,085
PP_PREV_DSD	Age/sex: 20-24 Male	4,603
PP_PREV_DSD	Age/sex: 50+ Male	599
PP_PREV_DSD	Sum of Age/Sex disaggregates	6,332
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 25-29, Male	2,517
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 30-34, Male	2,517



PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 35-39, Male	2,517
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 40-49, Male	2,517
KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	32,750
KP_PREV_DSD	By key population type: Men who have sex with men who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	6,800
KP_PREV_DSD	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	25,950
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	27,619
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Female, Negative	19
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Male, Negative	31
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Male, Positive	2
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Female, Negative	5
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Male, Negative	4
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Female, Negative	26
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Male, Negative	16
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Female, Negative	31



HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Male, Negative	21
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: <1, Negative	8
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 1-9, Negative	98
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 1-9, Positive	5
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Female, Negative	22
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative	14
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Female, Negative	89
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Female, Positive	2
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Male, Negative	41
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Female, Negative	131
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Female, Positive	2
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Male, Negative	105
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Male, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) Pediatric : <5 Negative	689
HTC_TST_DSD	Service Delivery Point (Facility) Pediatric : <5 Positive	7
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Female, Negative	81
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Female, Positive	2
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Male, Negative	81
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Male, Positive	2
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Female,	28



	Negative	
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Female, Positive	4
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Male, Negative	14
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Male, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Female, Negative	107
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Female, Positive	20
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Male, Negative	45
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Male, Positive	7
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Female, Negative	166
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Female, Positive	30
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Male, Negative	139
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Male, Positive	25
HTC_TST_DSD	Service Delivery Point (Facility) Index: <1, Negative	23
HTC_TST_DSD	Service Delivery Point (Facility) Index: 1-9, Negative	261
HTC_TST_DSD	Service Delivery Point (Facility) Index: 1-9, Positive	5
HTC_TST_DSD	By Key Population: FSW, Negative	17,586
HTC_TST_DSD	By Key Population: FSW, Positive	601
HTC_TST_DSD	By Key Population: MSM, Negative	5,863
HTC_TST_DSD	By Key Population: MSM, Positive	200
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 15-19, Negative	77
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 15-19, Positive	2
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 20-24, Negative	174



HTC_TST_DSD	Service Delivery Point (Facility) ANC: 20-24, Positive	2
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 50+, Negative	271
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 50+, Positive	5
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Female, Negative	319
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Female, Positive	7
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Male, Negative	175
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Male, Positive	3
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Female, Negative	1,233
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Female, Positive	29
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Male, Negative	479
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Male, Positive	12
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Female, Negative	2,033
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Female, Positive	46
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Male, Negative	1,746
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Male, Positive	40
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Female, Negative	192
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Female, Positive	34
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Male, Negative	105
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Male, Positive	19



	Male, Positive	
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Female, Negative	192
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Female, Positive	34
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Male, Negative	105
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Male, Positive	19
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Female, Negative	192
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Female, Positive	34
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Male, Negative	105
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Male, Positive	19
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Female, Negative	188
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Female, Positive	32
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Male, Negative	106
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Male, Positive	18
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Female, Negative	43
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Male, Negative	22
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Female, Negative	43
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Male, Negative	22
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Female, Negative	43



	Female, Negative	
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Male, Negative	22
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Female, Negative	42
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Female, Positive	3
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Male, Negative	27
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Male, Positive	2
HTC_TST_DSD	HTS_TST_N_DSD_MN_Age_Sex_Result <5, Unknown Sex, Negative	92
HTC_TST_DSD	HTS_TST_N_DSD_MN_Age_Sex_Result <5, Unknown Sex, Positive	2
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Female, Negative	157
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Female, Positive	3
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Male, Negative	86
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Male, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Female, Negative	157
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Female, Positive	3
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Male, Negative	86
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Male, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Female, Negative	157
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Male, Positive	3



	Female, Positive	
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Male, Negative	86
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Male, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Female, Negative	155
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Female, Positive	8
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Male, Negative	84
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Male, Positive	4
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 25-29, Female, Negative	351
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 25-29, Female, Positive	7
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 30-34, Female, Negative	351
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 30-34, Female, Positive	7
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 35-39, Female, Negative	352
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 35-39, Female, Positive	6
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 40-49, Female, Negative	352
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 40-49, Female, Positive	10
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Female, Negative	2,262
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Female, Positive	53
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29,	1,251



	Male, Negative	
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Male, Positive	30
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Female, Negative	2,262
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Female, Positive	53
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Male, Negative	1,251
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Male, Positive	30
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Female, Negative	2,262
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Female, Positive	53
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Male, Negative	1,251
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Male, Positive	30
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Female, Negative	2,259
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Female, Positive	51
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Male, Negative	1,248
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Male, Positive	25
GEND_GBV_DSD	Number of people receiving post-GBV care	10
GEND_GBV_DSD	By type of service: Sexual Violence (Post-Rape Care)	10
GEND_GBV_DSD	By PEP service provision (related to sexual violence services provided)	10
GEND_GBV_DSD	15-19, Female, Sexual Violence (Post-Rape Care)	1
GEND_GBV_DSD	20-24, Female, Sexual Violence (Post-Rape Care)	7
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3	2



	25-29, Female, Sexual Violence (Post-Rape Care)	
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	83
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	66
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	17
PMTCT_EID_DSD	Sum of Infant Age disaggregates	83
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	3,572
TX_CURR_DSD	Age/Sex: 15-19 Male	32
TX_CURR_DSD	Age/Sex: 15-19 Female	59
TX_CURR_DSD	Sum of age/sex disaggregates	91
TX_CURR_DSD	Age/Sex: <1	4
TX_CURR_DSD	Age/Sex: <1-9	44
TX_CURR_DSD	Age/Sex: 10-14 Male	14
TX_CURR_DSD	Age/Sex: 10-14 Female	14
TX_CURR_DSD	Age/Sex: 20-24 Male	100
TX_CURR_DSD	Age/Sex: 50+ Male	267
TX_CURR_DSD	Age/Sex: 20-24 Female	223
TX_CURR_DSD	Age/Sex: 50+ Female	331
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 25-29, Female, Positive	405
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 25-29, Male, Positive	216
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 30-34, Female, Positive	405
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 30-34, Male, Positive	216
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 35-39, Female, Positive	405
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 35-39, Male, Positive	216



TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 40-49, Female, Positive	405
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 40-49, Male, Positive	216
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	992
TX_NEW_DSD	By Age/Sex: <1	1
TX_NEW_DSD	By Age/Sex: 1-9	15
TX_NEW_DSD	By Age/Sex: 10-14 Male	5
TX_NEW_DSD	By Age/Sex: 15-19 Male	7
TX_NEW_DSD	By Age/Sex: 20-24 Male	30
TX_NEW_DSD	By Age/Sex: 50+ Male	79
TX_NEW_DSD	By Age/Sex: 10-14 Female	5
TX_NEW_DSD	By Age/Sex: 15-19 Female	13
TX_NEW_DSD	By Age/Sex: 20-24 Female	66
TX_NEW_DSD	By Age/Sex: 50+ Female	93
TX_NEW_DSD	Sum of Age/Sex disaggregates	298
TX_NEW_DSD	Pregnancy status	38
TX_NEW_DSD	Breastfeeding status	11
TX_NEW_DSD	FSW	394
TX_NEW_DSD	MSM	578
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 25-29, Female, Positive	114
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 25-29, Male, Positive	63
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 30-34, Female, Positive	108
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 30-34, Male, Positive	59
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 35-39, Female, Positive	108
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 35-39, Male, Positive	59



TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 40-49, Female, Positive	108
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 40-49, Male, Positive	59
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	2,995
TX_PVLS_DSD	Denominator: Indication: Routine	2,697
TX_PVLS_DSD	Denominator: Indication: Targeted	298
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Male Targeted	6
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Male Targeted	104
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Female Targeted	9
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Female Targeted	179
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Male Routine	54
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine	944
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Female Routine	81
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine	1,618
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	1,147
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	1,147
TX_RET_DSD	Numerator by Status: Pregnant	116
TX_RET_DSD	Numerator by Status: Breastfeeding	13
TX_RET_DSD	Denominator by Status: Pregnant	116



TX_RET_DSD	Denominator by Status: Breastfeeding	13
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	24
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	401
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	35
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	687
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	24
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	401
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	35
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	687
HTS_SELF_DSD	HTS_SELF_N_DSD	224
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19,	8



	Female, Directly-Assisted	
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Female, Unassisted	8
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Male, Directly-Assisted	8
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Male, Unassisted	8
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Female, Directly-Assisted	8
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Female, Unassisted	8
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Male, Directly-Assisted	8
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Male, Unassisted	8
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Female, Directly-Assisted	8
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Female, Unassisted	8
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Male, Directly-Assisted	8
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Male, Unassisted	8
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Female, Directly-Assisted	8
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Female, Unassisted	8
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Male, Directly-Assisted	8
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Male, Unassisted	8
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Female, Directly-Assisted	8
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Male, Unassisted	8



	Female, Unassisted	
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Male, Directly-Assisted	8
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Male, Unassisted	8
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Female, Directly-Assisted	8
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Female, Unassisted	8
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Male, Directly-Assisted	8
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Male, Unassisted	8
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Female, Directly-Assisted	8
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Female, Unassisted	8
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Male, Directly-Assisted	8
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Male, Unassisted	8
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTest Directly-Assisted	112
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTest Unassisted	112
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTestUser Unassisted - Other	34
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTestUser Unassisted - Self	34
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTestUser Unassisted - Sex Partner	44
TB_PREV_DSD	The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period	986
TB_PREV_DSD	The number of ART patients who were newly started on	1,093



	TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting period).	
TB_PREV_DSD	By Age/Sex (Denominator): <15, Female	32
TB_PREV_DSD	By Age/Sex (Denominator): <15, Male	22
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Female	656
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Male	383
TB_PREV_DSD	By Age/Sex (Numerator): <15, Female	29
TB_PREV_DSD	By Age/Sex (Numerator): <15, Male	20
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Female	591
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Male	346
TB_PREV_DSD	TB_PREV_D_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, New, Positive	1,093
TB_PREV_DSD	TB_PREV_N_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, New, Positive	986
TX_TB_DSD	Number of ART patients who were screened for TB at least once during the reporting period	3,215
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Female	97
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Male	65
TX_TB_DSD	Denominator: By Aggregated Age/Sex:15+, Female	1,927
TX_TB_DSD	Denominator: By Aggregated Age/Sex:15+, Male	1,126
TX_TB_DSD	Denominator: Number of ART patients who had a specimen sent for bacteriologic diagnosis of active TB disease	129
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Other (No Xpert)	5
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Smear Only	72
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Gene Xpert MTB / R if Assay	52
TX_TB_DSD	TX_TB_D_DSD_TBScreen_NewExistingART_HIV	2,499



	Life-long ART, Already, TB Screen - Negative, Positive	
TX_TB_DSD	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, Already, TB Screen - Positive, Positive	105
TX_TB_DSD	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, New, TB Screen - Negative, Positive	586
TX_TB_DSD	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, New, TB Screen - Positive, Positive	24

Implementing Mechanism Details

Mechanism ID: 18425	Mechanism Name: EQUIP
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Right To Care, South Africa	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 2,200,000	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 2,200,000	
Funding Source	Funding Amount
GHP-State	2,200,000

Cross-Cutting Budget Attribution(s)

Key Populations: FSW	8,000
Focus Area:	Training of health workers and community outreach workers
Focus Area:	Monitoring and evaluation of SW programs
Key Populations: MSM and TG	10,000
Focus Area:	Training of health workers and community outreach workers
Focus Area:	Monitoring and evaluation of MSM/TG programs



Human Resources for Health	500,000
----------------------------	---------

Budget Code Information

Mechanism ID: 18425		
Mechanism Name: EQUIP		
Prime Partner Name: Right To Care, South Africa		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	302,500
Strategic Area	Budget Code	Planned Amount
Care	HVTB	127,500
Strategic Area	Budget Code	Planned Amount
Care	PDCS	85,000
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	150,000
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	397,500
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	400,000
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	550,000
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	187,500



Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 18623	Mechanism Name: 4Children
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Catholic Relief Services	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:
Total All Funding Sources: 1,994,831	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 1,994,831	
Funding Source	Funding Amount
GHP-State	1,994,831

Cross-Cutting Budget Attribution(s)

Gender: GBV	682,704
Focus Area:	GBV Prevention
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Focus Area:	Post GBV Care
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Adolescent Girls and Young Women (AGYW)	1,659,573
Education	341,352
Economic Strengthening	682,704



Budget Code Information

Mechanism ID:	18623	
Mechanism Name:	4Children	
Prime Partner Name:	Catholic Relief Services	
Strategic Area	Budget Code	Planned Amount
Care	HKID	1,279,404
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	715,427

Implementing Mechanism Indicator Information

Indicator Number	Label	2019
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	15,545
OVC_SERV_DSD	Age/Sex: 10-14 Male	1,547
OVC_SERV_DSD	Age/Sex: 15-17 Male	967
OVC_SERV_DSD	By: Age/sex: Male 18-24	825
OVC_SERV_DSD	By: Age/sex: Male 25+	1,552
OVC_SERV_DSD	Age/Sex: 10-14 Female	1,584
OVC_SERV_DSD	Age/Sex: 15-17 Female	1,030
OVC_SERV_DSD	By: Age/sex: 18-24 Female	924
OVC_SERV_DSD	By: Age/sex: 25+ Female	2,918
OVC_SERV_DSD	Sum of Age/Sex disaggregates	5,128
OVC_SERV_DSD	Age/Sex: <1	636
OVC_SERV_DSD	Age/Sex: 1-9	3,562
OVC_SERV_DSD	Program Completion: Active	15,079



OVC_SERV_DSD	Program Completion: Graduation	466
OVC_HIVSTAT_DSD	Number of orphans and vulnerable children (<18 years old) whose HIV status is known or unknown by the OVC implementing partner.	9,326
OVC_HIVSTAT_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	15,545

Implementing Mechanism Details

Mechanism ID: 18625	Mechanism Name: Strategic Health Information System (HIS) Program
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: DAI	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 1,000,000	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 1,000,000	
Funding Source	Funding Amount
GHP-State	1,000,000

Cross-Cutting Budget Attribution(s)

Motor Vehicles: Leased	10,000
Human Resources for Health	850,000

Budget Code Information

Mechanism ID: 18625



Mechanism Name: Strategic Health Information System (HIS) Program		
Prime Partner Name: DAI		
Strategic Area	Budget Code	Planned Amount
Care	HVTB	450,000
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	550,000

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 18631	Mechanism Name: Project Sante
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Caris Foundation	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 5,433,710	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 5,433,710	
Funding Source	Funding Amount
GHP-State	5,433,710

Cross-Cutting Budget Attribution(s)

Key Populations: MSM and TG	391,824
Focus Area:	Training of health workers and community outreach workers



Key Populations: FSW	391,824
Gender: GBV	975,470
Focus Area:	Post GBV Care
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Focus Area:	GBV Prevention
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Gender: Gender Equality	391,824
Focus Area:	Changing harmful gender norms and promoting positive gender norms
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Focus Area:	Equity in HIV prevention, care, treatment and support
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Human Resources for Health	1,775,000
Condom programming	1,175,470
Food and Nutrition: Policy, Tools, and Service Delivery	979,559
Water	135,020

Budget Code Information

Mechanism ID: 18631



Mechanism Name: Project Sante		
Prime Partner Name: Caris Foundation		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	674,642
Strategic Area	Budget Code	Planned Amount
Care	HKID	430,098
Strategic Area	Budget Code	Planned Amount
Care	HVTB	352,010
Strategic Area	Budget Code	Planned Amount
Care	PDCS	671,446
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	725,464
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	825,000
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	1,131,030
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	624,020

Implementing Mechanism Indicator Information

Indicator Number	Label	2019
PMTCT_ART_DSD	Number of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy	994



PMTCT_ART_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	68,379
PMTCT_ART_DSD	New on ART	676
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	318
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	68,379
PMTCT_STAT_DSD	Number of new ANC and L&D clients	68,379
PMTCT_STAT_DSD	By Age (Denominator): <15-19	2,733
PMTCT_STAT_DSD	By Age (Denominator): 20-24	6,152
PMTCT_STAT_DSD	By Age (Denominator): 50+	9,570
PMTCT_STAT_DSD	By Number of known positives: 15-19	10
PMTCT_STAT_DSD	By Number of known positives: 20-24	24
PMTCT_STAT_DSD	By Number of known positives: 50+	37
PMTCT_STAT_DSD	By Number of new positives: 15-19	24
PMTCT_STAT_DSD	By Number of new positives: 20-24	59
PMTCT_STAT_DSD	By Number of new positives: 50+	92
PMTCT_STAT_DSD	By Number of new negative: 15-19	2,696
PMTCT_STAT_DSD	By Number of new negative: 20-24	6,066
PMTCT_STAT_DSD	By Number of new negative: 50+	9,430
PMTCT_STAT_DSD	By Age (Numerator): 15-19	2,733
PMTCT_STAT_DSD	By Age (Numerator): 20-24	6,152
PMTCT_STAT_DSD	By Age (Numerator): 50+	9,570
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 25-29, Female	12,485
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 30-34, Female	12,484
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 35-39, Female	12,480
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 40-49, Female	12,475
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 25-29, Female, Known at Entry Positive	55
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 25-29, Female, Newly Identified Negative	12,306
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult	119



	25-29, Female, Newly Identified Positive	
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 30-34, Female, Known at Entry Positive	55
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 30-34, Female, Newly Identified Negative	12,306
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 30-34, Female, Newly Identified Positive	119
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 35-39, Female, Known at Entry Positive	53
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 35-39, Female, Newly Identified Negative	12,306
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 35-39, Female, Newly Identified Positive	117
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 40-49, Female, Known at Entry Positive	55
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 40-49, Female, Newly Identified Negative	12,306
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 40-49, Female, Newly Identified Positive	117
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 25-29, Female	12,485
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 30-34, Female	12,484
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 35-39, Female	12,480
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 40-49, Female	12,475
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	117,424
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Female, Negative	90
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Male, Negative	130
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Male, Positive	2
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Female, Negative	34



HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Male, Negative	11
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Female, Negative	116
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Female, Positive	2
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Male, Negative	35
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Female, Negative	171
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Female, Positive	4
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Male, Negative	164
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Male, Positive	3
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: <1, Negative	29
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 1-9, Negative	326
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 1-9, Positive	17
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Female, Negative	42
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative	19
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Female, Negative	130
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Female, Positive	2
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Male, Negative	32
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Female, Negative	388
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Female, Positive	6
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Male,	296



	Negative	
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Male, Positive	5
HTC_TST_DSD	Service Delivery Point (Facility) Pediatric : <5 Negative	2,408
HTC_TST_DSD	Service Delivery Point (Facility) Pediatric : <5 Positive	25
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Male, Negative	76
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Male, Positive	6
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Female, Negative	22
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Female, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Male, Negative	10
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Female, Negative	90
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Female, Positive	10
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Male, Negative	32
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Male, Positive	3
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Female, Negative	145
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Female, Positive	26
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Male, Negative	110
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Male, Positive	12
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Female, Negative	301
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Female, Positive	6



HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Male, Negative	403
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Male, Positive	2
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Female, Negative	45
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Female, Positive	4
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Male, Negative	17
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Male, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Female, Negative	150
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Female, Positive	28
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Male, Negative	57
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Male, Positive	5
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Female, Negative	278
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Female, Positive	51
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Male, Negative	240
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Male, Positive	42
HTC_TST_DSD	Service Delivery Point (Facility) Index: <1, Negative	91
HTC_TST_DSD	Service Delivery Point (Facility) Index: 1-9, Negative	1,076
HTC_TST_DSD	Service Delivery Point (Facility) Index: 1-9, Positive	17
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 15-19, Negative	2,696
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 15-19, Positive	24
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 20-24, Negative	6,066



HTC_TST_DSD	Service Delivery Point (Facility) ANC: 20-24, Positive	59
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 50+, Negative	9,430
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 50+, Positive	92
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Female, Negative	579
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Female, Positive	12
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Male, Negative	301
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Male, Positive	4
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Female, Negative	1,927
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Female, Positive	40
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Male, Negative	718
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Male, Positive	12
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Female, Negative	3,542
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Female, Positive	77
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Male, Negative	3,085
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Male, Positive	69
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Female, Negative	302
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Female, Positive	52
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Male, Negative	155
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Male, Positive	27



	Male, Positive	
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Female, Negative	302
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Female, Positive	52
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Male, Negative	155
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Male, Positive	27
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Female, Negative	302
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Female, Positive	52
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Male, Negative	155
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Male, Positive	27
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Female, Negative	297
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Female, Positive	57
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Male, Negative	154
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Male, Positive	32
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Female, Negative	207
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Female, Positive	3
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Male, Negative	113
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Male, Positive	2
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34,	207



	Female, Negative	
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Female, Positive	3
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Male, Negative	113
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Male, Positive	2
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Female, Negative	207
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Female, Positive	3
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Male, Negative	113
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Male, Positive	2
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Female, Negative	206
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Female, Positive	11
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Male, Negative	116
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Male, Positive	6
HTC_TST_DSD	HTS_TST_N_DSD_MN_Age_Sex_Result <5, Unknown Sex, Negative	308
HTC_TST_DSD	HTS_TST_N_DSD_MN_Age_Sex_Result <5, Unknown Sex, Positive	3
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Female, Negative	330
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Female, Positive	5
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Male, Negative	175
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Male, Positive	2



	Male, Positive	
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Female, Negative	330
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Female, Positive	5
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Male, Negative	175
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Male, Positive	2
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Female, Negative	330
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Female, Positive	5
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Male, Negative	175
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Male, Positive	2
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Female, Negative	326
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Female, Positive	12
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Male, Negative	180
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Male, Positive	6
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 25-29, Female, Negative	12,306
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 25-29, Female, Positive	119
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 30-34, Female, Negative	12,306
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 30-34, Female, Positive	119
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 35-39, Female, Negative	12,306



	Female, Negative	
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 35-39, Female, Positive	117
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 40-49, Female, Negative	12,306
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 40-49, Female, Positive	117
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Female, Negative	168
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Female, Positive	20
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Male, Negative	83
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Male, Positive	7
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Female, Negative	168
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Female, Positive	20
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Male, Negative	83
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Male, Positive	7
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Female, Negative	168
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Female, Positive	20
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Male, Negative	83
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Male, Positive	7
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Female, Negative	167
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Female, Positive	23



	Female, Positive	
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Male, Negative	105
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Male, Positive	25
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Female, Negative	3,930
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Female, Positive	84
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Male, Negative	1,976
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Male, Positive	43
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Female, Negative	3,930
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Female, Positive	84
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Male, Negative	1,976
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Male, Positive	43
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Female, Negative	3,930
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Female, Positive	84
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Male, Negative	1,976
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Male, Positive	43
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Female, Negative	3,943
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Female, Positive	100
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Male, Negative	1,974



	Male, Negative	
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Male, Positive	49
TB_STAT_DSD	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	1,840
TB_STAT_DSD	Total number of registered new and relapsed TB cases, during the reporting period.	1,840
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	38
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	645
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	52
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	1,105
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	38
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	645
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	52
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	1,105
GEND_GBV_DSD	Number of people receiving post-GBV care	951
GEND_GBV_DSD	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	870



GEND_GBV_DSD	By type of service: Sexual Violence (Post-Rape Care)	81
GEND_GBV_DSD	By PEP service provision (related to sexual violence services provided)	81
GEND_GBV_DSD	<10, Female, Physical and/or Emotional Violence	7
GEND_GBV_DSD	<10, Female, Sexual Violence (Post-Rape Care)	5
GEND_GBV_DSD	<10, Male, Physical and/or Emotional Violence	7
GEND_GBV_DSD	10-14, Female, Physical and/or Emotional Violence	34
GEND_GBV_DSD	10-14, Female, Sexual Violence (Post-Rape Care)	19
GEND_GBV_DSD	10-14, Male, Physical and/or Emotional Violence	14
GEND_GBV_DSD	10-14, Male, Sexual Violence (Post-Rape Care)	1
GEND_GBV_DSD	15-19, Female, Physical and/or Emotional Violence	120
GEND_GBV_DSD	15-19, Female, Sexual Violence (Post-Rape Care)	19
GEND_GBV_DSD	15-19, Male, Physical and/or Emotional Violence	52
GEND_GBV_DSD	15-19, Male, Sexual Violence (Post-Rape Care)	4
GEND_GBV_DSD	20-24, Female, Physical and/or Emotional Violence	296
GEND_GBV_DSD	20-24, Female, Sexual Violence (Post-Rape Care)	16
GEND_GBV_DSD	20-24, Male, Physical and/or Emotional Violence	145
GEND_GBV_DSD	20-24, Male, Sexual Violence (Post-Rape Care)	2
GEND_GBV_DSD	50+, Female, Physical and/or Emotional Violence	12
GEND_GBV_DSD	50+, Female, Sexual Violence (Post-Rape Care)	6
GEND_GBV_DSD	50+, Male, Physical and/or Emotional Violence	12
GEND_GBV_DSD	50+, Male, Sexual Violence (Post-Rape Care)	1
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 25-29, Female, Physical and/or Emotional Violence	26
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 25-29, Female, Sexual Violence (Post-Rape Care)	3
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 25-29, Male, Physical and/or Emotional Violence	20
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 30-34, Female, Physical and/or Emotional Violence	25
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 30-34, Female, Sexual Violence (Post-Rape Care)	2
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3	18



	30-34, Male, Physical and/or Emotional Violence	
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 35-39, Female, Physical and/or Emotional Violence	25
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 35-39, Female, Sexual Violence (Post-Rape Care)	2
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 35-39, Male, Physical and/or Emotional Violence	17
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 40-49, Female, Physical and/or Emotional Violence	24
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 40-49, Female, Sexual Violence (Post-Rape Care)	1
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 40-49, Male, Physical and/or Emotional Violence	16
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	13,667
OVC_SERV_DSD	Age/Sex: 10-14 Male	1,360
OVC_SERV_DSD	Age/Sex: 15-17 Male	848
OVC_SERV_DSD	By: Age/sex: Male 18-24	725
OVC_SERV_DSD	By: Age/sex: Male 25+	1,367
OVC_SERV_DSD	Age/Sex: 10-14 Female	1,392
OVC_SERV_DSD	Age/Sex: 15-17 Female	907
OVC_SERV_DSD	By: Age/sex: 18-24 Female	814
OVC_SERV_DSD	By: Age/sex: 25+ Female	2,560
OVC_SERV_DSD	Sum of Age/Sex disaggregates	4,507
OVC_SERV_DSD	Age/Sex: <1	556
OVC_SERV_DSD	Age/Sex: 1-9	3,138
OVC_SERV_DSD	Program Completion: Active	13,256
OVC_SERV_DSD	Program Completion: Graduation	411
OVC_HIVSTAT_DSD	Number of orphans and vulnerable children (<18 years old) whose HIV status is known or unknown by the OVC implementing partner.	8,201
OVC_HIVSTAT_DSD	Number of active beneficiaries served by PEPFAR	13,667



	OVC programs for children and families affected by HIV/AIDS	
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	273
TB_ART_DSD	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	4
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	98
TB_ART_DSD	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	6
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	165
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	1,007
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	805
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	202
PMTCT_EID_DSD	Sum of Infant Age disaggregates	1,007
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	15,817
TX_CURR_DSD	Age/Sex: 15-19 Male	130
TX_CURR_DSD	Age/Sex: 15-19 Female	244
TX_CURR_DSD	Sum of age/sex disaggregates	374
TX_CURR_DSD	Age/Sex: <1	35



TX_CURR_DSD	Age/Sex: <1-9	422
TX_CURR_DSD	Age/Sex: 10-14 Male	99
TX_CURR_DSD	Age/Sex: 10-14 Female	144
TX_CURR_DSD	Age/Sex: 20-24 Male	332
TX_CURR_DSD	Age/Sex: 50+ Male	1,235
TX_CURR_DSD	Age/Sex: 20-24 Female	878
TX_CURR_DSD	Age/Sex: 50+ Female	1,570
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 25-29, Female, Positive	1,773
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 25-29, Male, Positive	909
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 30-34, Female, Positive	1,773
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 30-34, Male, Positive	909
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 35-39, Female, Positive	1,773
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 35-39, Male, Positive	909
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 40-49, Female, Positive	1,773
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 40-49, Male, Positive	909
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	2,817
TX_NEW_DSD	By Age/Sex: <1	4
TX_NEW_DSD	By Age/Sex: 1-9	73
TX_NEW_DSD	By Age/Sex: 10-14 Male	21
TX_NEW_DSD	By Age/Sex: 15-19 Male	23
TX_NEW_DSD	By Age/Sex: 20-24 Male	60
TX_NEW_DSD	By Age/Sex: 50+ Male	262
TX_NEW_DSD	By Age/Sex: 10-14 Female	25
TX_NEW_DSD	By Age/Sex: 15-19 Female	46



TX_NEW_DSD	By Age/Sex: 20-24 Female	151
TX_NEW_DSD	By Age/Sex: 50+ Female	272
TX_NEW_DSD	Sum of Age/Sex disaggregates	860
TX_NEW_DSD	Pregnancy status	570
TX_NEW_DSD	Breastfeeding status	30
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 25-29, Female, Positive	303
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 25-29, Male, Positive	164
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 30-34, Female, Positive	307
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 30-34, Male, Positive	164
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 35-39, Female, Positive	307
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 35-39, Male, Positive	164
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 40-49, Female, Positive	307
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 40-49, Male, Positive	164
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	14,489
TX_PVLS_DSD	Denominator: Indication: Routine	13,039
TX_PVLS_DSD	Denominator: Indication: Targeted	1,450
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Male Targeted	30
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Male Targeted	509
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Female Targeted	44
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Female Targeted	867

TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Male Routine	255
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine	4,565
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Female Routine	392
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine	7,827
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	2,743
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	2,743
TX_RET_DSD	Numerator by Status: Pregnant	274
TX_RET_DSD	Numerator by Status: Breastfeeding	30
TX_RET_DSD	Denominator by Status: Pregnant	274
TX_RET_DSD	Denominator by Status: Breastfeeding	30
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	56
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	960
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	84
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,643
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have	56



	stopped ART, and those lost to follow-up)	
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	960
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	84
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,643
HTS_SELF_DSD	HTS_SELF_N_DSD	980
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Female, Directly-Assisted	35
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Female, Unassisted	35
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Male, Directly-Assisted	35
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Male, Unassisted	35
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Female, Directly-Assisted	35
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Female, Unassisted	35
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Male, Directly-Assisted	35
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Male, Unassisted	35
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Female, Directly-Assisted	35



HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Female, Unassisted	35
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Male, Directly-Assisted	35
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Male, Unassisted	35
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Female, Directly-Assisted	35
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Female, Unassisted	35
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Male, Directly-Assisted	35
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Male, Unassisted	35
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Female, Directly-Assisted	35
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Female, Unassisted	35
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Male, Directly-Assisted	35
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Male, Unassisted	35
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Female, Directly-Assisted	35
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Female, Unassisted	35
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Male, Directly-Assisted	35
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Male, Unassisted	35
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Female, Directly-Assisted	35
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Female, Unassisted	35



HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Male, Directly-Assisted	35
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Male, Unassisted	35
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTest Directly-Assisted	490
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTest Unassisted	490
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTestUser Unassisted - Other	150
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTestUser Unassisted - Self	150
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTestUser Unassisted - Sex Partner	190
TB_PREV_DSD	The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period	2,271
TB_PREV_DSD	The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting period).	2,525
TB_PREV_DSD	By Age/Sex (Denominator): <15, Female	77
TB_PREV_DSD	By Age/Sex (Denominator): <15, Male	51
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Female	1,516
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Male	881
TB_PREV_DSD	By Age/Sex (Numerator): <15, Female	71
TB_PREV_DSD	By Age/Sex (Numerator): <15, Male	42
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Female	1,364
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Male	794
TB_PREV_DSD	TB_PREV_D_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, New, Positive	2,525
TB_PREV_DSD	TB_PREV_N_DSD_TherapyType_NewExArt_HIV IPT,	2,271



	Life-long ART, New, Positive	
TX_TB_DSD	Number of ART patients who were screened for TB at least once during the reporting period	15,814
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Female	472
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Male	315
TX_TB_DSD	Denominator: By Aggregated Age/Sex:15+, Female	9,488
TX_TB_DSD	Denominator: By Aggregated Age/Sex:15+, Male	5,539
TX_TB_DSD	Denominator: Number of ART patients who had a specimen sent for bacteriologic diagnosis of active TB disease	634
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Other (No Xpert)	19
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Smear Only	359
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Gene Xpert MTB / R if Assay	256
TX_TB_DSD	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, Already, TB Screen - Negative, Positive	12,279
TX_TB_DSD	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, Already, TB Screen - Positive, Positive	511
TX_TB_DSD	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, New, TB Screen - Negative, Positive	2,894
TX_TB_DSD	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, New, TB Screen - Positive, Positive	121

Implementing Mechanism Details

Mechanism ID: 70101	TBD: Yes
REDACTED	

Implementing Mechanism Details

Mechanism ID: 70102	TBD: Yes
REDACTED	



Implementing Mechanism Details

Mechanism ID: 70104	Mechanism Name: GHSC-TA Francophone
Funding Agency: USAID	Procurement Type: Contract
Prime Partner Name: Global Health Supply Chain Program	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: Yes
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:
Total All Funding Sources: 0	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 70104		
Mechanism Name: GHSC-TA Francophone		
Prime Partner Name: Global Health Supply Chain Program		
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0

Implementing Mechanism Indicator Information

(No data provided.)



Implementing Mechanism Details

Mechanism ID: 70105	Mechanism Name: GHSC-RTK
Funding Agency: USAID	Procurement Type: Contract
Prime Partner Name: Global Health Supply Chain Program	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: Yes
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:
Total All Funding Sources: 0	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 70105		
Mechanism Name: GHSC-RTK		
Prime Partner Name: Global Health Supply Chain Program		
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	1,455,051

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Approved



Mechanism ID: 70506	TBD: Yes
REDACTED	



Agency Information - Costs of Doing Business
U.S. Agency for International Development

Agency Cost of Doing Business	GAP	GHP-State	GHP-USAID	Funding Source Total	Applied Pipeline	Total All Funding Sources and Applied Pipeline Amount
Computers/IT Services		205,534		205,534	66,518	272,052
ICASS		460,977		460,977	75,612	536,589
Indirect Costs		104,390		104,390	20,002	124,392
Institutional Contractors		600,000		600,000	0	600,000
Management Meetings/Professional Development		208,099		208,099	0	208,099
Non-ICASS Administrative Costs		183,632		183,632	0	183,632
Staff Program Travel		265,324		265,324	0	265,324
USG Staff Salaries and Benefits - Internationally Recruited		698,348		698,348	0	698,348
USG Staff Salaries and Benefits - Locally		1,059,539		1,059,539	52,025	1,111,564



Recruited						
Total	0	3,785,843	0	3,785,843	214,157	4,000,000

U.S. Department of Health and Human Services/Centers for Disease Control and Prevention

Agency Cost of Doing Business	GAP	GHP-State	GHP-USAID	Funding Source Total	Applied Pipeline	Total All Funding Sources and Applied Pipeline Amount
Capital Security Cost Sharing		484,701		484,701	0	484,701
Computers/IT Services		217,383		217,383	0	217,383
ICASS		920,000		920,000	0	920,000
Institutional Contractors		101,890		101,890	0	101,890
Non-ICASS Administrative Costs		517,363		517,363	0	517,363
Staff Program Travel	0	295,750		295,750	0	295,750
USG Staff Salaries and Benefits - Internationally Recruited	987,500	265,665		1,253,165	0	1,253,165
USG Staff Salaries and Benefits - Locally Recruited	0	2,959,748		2,959,748	0	2,959,748

Approved



Total	987,500	5,762,500	0	6,750,000	0	6,750,000
--------------	----------------	------------------	----------	------------------	----------	------------------

U.S. Department of State

Agency Cost of Doing Business	GAP	GHP-State	GHP-USAID	Funding Source Total	Applied Pipeline	Total All Funding Sources and Applied Pipeline Amount
Staff Program Travel		7,484		7,484	0	7,484
USG Staff Salaries and Benefits - Internationally Recruited		417,516		417,516	0	417,516
USG Staff Salaries and Benefits - Locally Recruited				0	0	0
Total	0	425,000	0	425,000	0	425,000